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Abstract 
Both calpain activation and excessive mitochondrial reactive oxygen species (mtROS) have 
been implicated in the pathogenesis of cardiac diseases. We investigated whether and how 
calpain regulates mtROS generation in mediating cardiac diseases. 
In mouse models of streptozotocin-induced type-1 diabetes and lipopolysaccharides- induced 
sepsis, we show that the protein levels of calpain-1 and calpain activities in mitochondria 
were significantly elevated in diabetic and septic hearts. The elevation of mitochondrial 
calpain-1 correlated with an increase in mtROS generation and oxidative damage. 
Importantly, cardiomyocyte-specific deletion of capns1 disrupted calpain-1 and calpain-2 in 
the heart and prevented mtROS generation in both septic and diabetic mouse hearts. As a 
consequence, cardiomyopathic changes (e.g. cardiac apoptosis, hypertrophy and fibrosis) and 
myocardial dysfunction were attenuated in diabetic or septic capns1 knockout mice 
compared with their wild-type littermates. Mechanistically, we demonstrate that 
mitochondrial calpain-1 directly targeted and cleaved ATP synthase subunit-alpha 
(ATP5A1), leading to a reduction in ATP synthase activity in diabetic hearts and septic 
hearts, and that up-regulation of ATP5A1 restored ATP synthase activity, prevented mtROS 
generation and reduced cardiomyopathic changes in type-1 diabetic mice and in septic mice. 
In addition, selective inhibition of mtROS with mitochondria-targeted antioxidant 
mito-TEMPO prevented mtROS production and intracellular oxidative stress, reduced 
cardiomyopathic changes and improved myocardial function in mouse models of type-1 and 
type-2 diabetes. These in vivo data were recapitulated in cultured cardiomyocytes stimulated 
with diabetic and septic conditions. 
In summary, we have provided strong evidence demonstrating that calpain-1 accumulation in 
mitochondria disrupts ATP synthase through the proteolysis of ATP5A1 and promotes 
mtROS generation, both of which contribute to diabetic cardiomyopathy and septic 
ii 
cardiomyopathy. Given that mitochondrial calpains also increase and contribute to 
myocardial injury in ischemic hearts, our findings suggest that increased mitochondrial 
calpain-1 may be a common mechanism contributing to mtROS generation and myocardial 
injury in the pathogenesis of cardiac diseases. Thus, targeted inhibition of mitochondrial 
calpain may be a potentially effective therapy for cardiac diseases. 
Keywords 
ATP synthase, calpain, cardiac disease, cardiomyopathy, diabetes, mitochondria, reactive 
oxygen species, sepsis 
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1.1 Introduction of cardiovascular disease 
Cardiovascular disease (CVD) includes cardiac disease and vascular disease, referring to 
a range of diseases affecting the circulatory system, such as coronary artery disease, 
congenital heart disease, cardiomyopathy, rheumatic heart disease, atrial fibrillation, 
hypertensive heart disease, aortic aneurysms, endocarditis, peripheral artery disease and 
venous thrombosis [1, 2]. CVD remains the major cause of death globally. Each year, 
more than 17 million people die from CVD which accounts for 30% of all global deaths 
[3]. It is also anticipated that by 2030, CVD-related deaths will increase to more than 23 
million each year [1]. In Canada alone, approximate 70,000 individuals die directly 
associated with CVD every year [4]. There are 1.3 million Canadians with CVD at a 
conservative estimate [5]. Approximately 50,000 new patients [6] are diagnosed with 
heart failure each year and in total about 600,000 Canadians suffering it [7]. Each year, 
the Canadian economy spends almost $20.9 billion on CVD in healthcare system costs, 
decreased productivity and lost wages [8].  
Risk factors for CVD include hypertension, tobacco use, lack of physical activity, obesity, 
high blood cholesterol, poor diet, excessive consumption of alcohol, diabetes and 
inflammation [5] as well as genetic susceptibility [9]. In Canada, about 80% of 
individuals have at least one of these risk factors, and around 10% are exposed to three or 
more [5]. The most above risk factors are preventable. According to the report from 
World Health Organization, for the purpose of disease management, risk factor 
modification is the first recommendation, which can significantly decrease the number of 
people with premature cardiac disease globally [10]. This includes weight loss, quitting 
smoking, more exercise, reductions of lipids, sodium, sugar and alcohol intake, and 
increase of vegetable and fruit consumption. In addition to the lifestyle changes, 
pharmacological therapeutic strategies are available to aid in the risk factors prevention, 
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such as anti-hypertensive therapy and lipid-lowering therapy. Nevertheless, CVD remain 
one of the biggest health challenges in the world. 
Given that diabetes and inflammation are important contributors to cardiac disease, this 
thesis is focused on diabetic cardiomyopathy and septic cardiomyopathy. As such, I 
introduce these two types of cardiac disease in more details as follows.  
1.1.1 Diabetic cardiomyopathy 
1.1.1.1 The definition and characteristics of diabetic 
Cardiomyopathy 
Diabetes represents a major threat to global public health [11]. Globally, the number of 
adults affected with diabetes is estimated to increase from 135 million in 1995 to 300 
million by 2025[12]. Thus, diabetes is projected to become one of the world’s main 
disablers and killers within the next twenty years. The direct costs are extremely high 
because it is a chronic disease with severe complications [13]. Furthermore, total 
financial burden includes indirect costs of lost productivity due to sickness, disability and 
premature retirement of working-age patients [14]. There are two basic types of diabetes 
[15]. Type 1 diabetes is an autoimmune disease in which the body’s immune defense 
system mistakenly attacks and destroys the insulin-producing beta cells of the pancreas, 
which are essential for processing sugar (glucose). Patients with type-1 diabetes require 
exogenous insulin to maintain the blood glucose levels. Approximately, 10 % of patients 
with diabetes are type-1 diabetes [16].  In type-2 diabetes, the more prevalent form, 
patients may produce insulin, but they cannot use it effectively, resulting in high levels of 
glucose in the blood, but low levels of glucose inside cells that need it. Type-2 diabetes is 
associated with several risk factors, including older age, a family history of diabetes, and 
obesity. Both type-1 and type-2 diabetes share the same possible complications, including 
retinopathy, nephropathy, neuropathy, lower limb amputations, sexual dysfunction and 
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cardiovascular disease, particularly heart attack and stroke that can lead to premature 
death [17, 18].   
Cardiovascular complications are the most common cause of morbidity and mortality in 
diabetic patients. Approximately 80% of all diabetic patients die of cardiovascular 
complications [19, 20]. Cardiac complications are mostly due to two pathophysiological 
processes. First, coronary (ischemic) heart disease is increased as a consequence of 
accelerated atherosclerosis associated with risk factors such as visceral obesity, 
hypertension, dyslipidemia, and prothrombotic factors [21-24]. Second, diabetes can 
affect cardiac structure and function in the absence of changes in blood pressure and 
coronary artery disease, a condition called diabetic cardiomyopathy [25].  
Clinical reports in the 1970s first described such patients, who were considered to have a 
diabetic cardiomyopathy [26]. Since then, diabetic cardiomyopathy has been defined as 
ventricular dysfunction that occurs independently of coronary artery disease and 
hypertension [25, 27]. In addition, diabetic cardiomyopathy may be characterized by 
diastolic dysfunction [28, 29], which is more apparent in the presence of myocardial 
ischemia or hypertension [26]. Of far greater epidemiologic importance, however, is the 
risk when diabetes is combined with coronary artery disease and/or hypertension [23]. 
Diabetes patients with acute myocardial infarction have approximately twice the incidence 
of heart failure and death compared to non-diabetic patients [30-32]. The development of 
heart failure in patients with diabetes is a problem of major clinical and epidemiologic 
importance [33]. Diabetic cardiomyopathy is patho-physiologically characterized by the 
loss of cardiomyocytes, cardiac hypertrophy, fibrosis and inflammation [34-37]. The 
pathogenesis of diabetic cardiomyopathy has not been fully understood (Figure 1-1) but 
seems multifactorial, which includes, but not limited to, autonomic dysfunction, 
metabolic disorders, alteration in structural proteins, disturbance of ion homeostasis, 
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myocardial hypertrophy and interstitial fibrosis [38, 39]. In addition, increased glycation 
of interstitial proteins such as collagen resulting from sustained hyperglycemia promotes 
myocardial stiffness and impairs contractility [40-42]. At present, therapeutic approaches 
are limited. 
1.1.1.2 The underlying mechanisms of diabetic cardiomyopathy 
1.1.1.2.1 Metabolic dysfunction in cardiomyocytes  
1.1.1.2.1.1 Hyperglycemia 
Hyperglycemia reduces glucose clearance, increases gluconeogenesis, and plays an 
important role in the pathogenesis of diabetic cardiomyopathy (Figure 1-1). Chronic 
hyperglycemia impairs myocardial cells, as well as fibroblasts and endothelial cells, in 
which multiple mechanisms have been proposed. Hyperglycemia increases the 
production of reactive oxygen species (ROS) in the heart [43-46]. ROS activates poly 
ADP-ribose polymerase (PARP) which increases glycosylation and inhibits 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and therefore, the glycolysis 
process turns into a biochemical cascade of myocardial injury [29, 47]. This includes 
elevated advanced glycation end products (AGEs), activations of the hexosamine 
biosynthesis pathway and the polyol pathway, as well as increased production of protein 
kinases (PKC) [48]. AGEs induce excessive collagen expression and accumulation, and 
promote collagen cross-linking, leading to myocardial fibrosis and consequently 
decreased myocardial compliance [49]. Under hyperglycemic state, the glucose 
transporter-4 activity is decreased, causing reduced transmembrane transportation of 
glucose to the cardiomyocytes, leading to decreased glucose uptake of myocardial cells, 
which then affects the energy metabolism of cardiomyocytes [50]. Increase of ROS, 
PARP, AGEs and aldehyde reductase by hyperglycemia are directly associated with 
myocardial apoptosis. Hyperglycemia also affects the structure and function of the  
6 
 
Figure 1-1. Schematic of mechanisms contributing to diabetic cardiomyopathy 
The proposed mechanisms and their downstream consequences are summarized: 
hyperglycemia-induced glucotoxicity, hyperlipidemia-induced lipotoxicity and Insulin 
resistance-induced mitochondrial dysfunction and metabolic disorder contribute to ROS 
production, RAAS activation, calcium disorder, etc. all of which promote cardiac 
apoptosis, hypertrophy, fibrosis and inflammation, leading to cardiomyopathy in diabetes. 
ROS, reactive oxygen species; RAAS, renin-angiotensin-aldosterone system.  
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myocardium by post-translational modifications [51]. For example, hyperglycemia 
induces structural changes in the extracellular matrix, as well as expression and function 
of ryanodine receptors and sarcoplasmic reticulum calcium ATPase (SERCA), leading to 
the myocardial systolic and diastolic dysfunction [29].  
Hyperglycemia can introduce a number of changes in metabolism, particularly substrate 
utilization that could be an underlying mechanism leading to cardiomyopathy [52]. 
Although the normal heart is able to derive energy from multiple substrates including 
ketones, amino acids, carbohydrates and fatty acids, approximately 70% of adenosine 
triphosphate (ATP) generation occurs via fatty acid oxidation and the remaining 30% is 
provided by glucose and lactate [53]. The diabetic myocardium however, uses fatty acid 
oxidation almost exclusively for energy production.   
1.1.1.2.1.2 Increased free fatty acids 
Free fatty acids (FFAs) are important energy substances for the heart. Approximately 
two-thirds of the energy production comes from fatty acid oxidation in the normal heart. 
In diabetic patients, glucose utilization is significantly decreased and fatty acid 
β-oxidation increased in cardiomyocytes, while fatty acid synthesis is increased in 
hepatocytes, and fatty acid catabolism is elevated in adipocytes, leading to high levels of 
triglyceride glycerol and FFAs in the circulation [54, 55]. Meanwhile, hyperinsulinemia 
and hyperlipidemia induce accumulation of fatty acids in cardiomyocytes exceeding the 
cellular fatty acid oxidation capacity, leading to cardiac lipotoxicity [56] (Figure 1-1). 
Excessive intake and oxidization of fatty acids cause the accumulation of metabolic 
intermediate products of fatty acids in myocardial cells [57, 58], increase the oxygen 
demand and elevate mitochondrial membrane potential, resulting in increased ROS 
generation, decreased ATP synthesis, mitochondrial dysfunction and finally apoptosis in 
cardiomyocytes [59-61]. Increased oxidized fatty acids also induce production of 
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ceramide which is a sphingomyelin that can induce cardiomyocyte apoptosis by 
inhibition of mitochondrial respiratory chain [62, 63].   
1.1.1.2.1.3 Disorder of calcium homeostasis  
Precise regulation of calcium homeostasis in cardiomyocytes is the core link to ensure 
cardiac function. In diabetic hearts, increased intracellular fatty acid levels cause 
potassium channels opening, leading to shortening of action potential duration and L-type 
calcium channel opening, which eventually affects the calcium storage of sarcoplasmic 
reticulum, contributing to the disturbance of calcium homeostasis [64-66]. In addition, 
ROS-induced endoplasmic reticulum stress causes intracellular calcium accumulation 
leading to reduced myocardial cell contraction [67]. ROS also modulates L-type calcium 
channel to inhibit Ca2+ influx and suppresses SERCA activation [68]. Activities of 
SERCA and its inhibitor phospholamban (PLB) play important roles in maintaining 
calcium homeostasis in cardiomyocytes [69].  PLB is a key regulator of SERCA activity 
and cardiac contractility by modulating sarcoplasmic reticulum calcium sequestration. 
Study has shown that in diabetic rat hearts, the messenger RNA (mRNA) and protein 
levels of PLB were significantly increased while SERCA activity and sarcoplasmic 
reticulum calcium concentration were decreased, leading to cytoplasmic calcium 
overload, impaired ventricular relaxation and cardiac diastolic dysfunction [68]. 
Overexpression of SERCA2a in cardiomyocytes improved calcium homeostasis and 
myocardial contraction in diabetic rats [70]. 
1.1.1.2.1.4 Insulin resistance 
Insulin resistance (IR) is an important risk factor for diabetic cardiovascular 
complications [71] (Figure 1-1). Cell insulin signals have two key signaling pathways. 
One is the insulin receptor substrate-1 (IRS-1) pathway, which is the upstream signal of 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, responsible for the major metabolic 
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response. The other is mitogen-activated protein kinase (MAPK) signaling pathway, 
which is related to vascular remodeling, cardiac hypertrophy, myocardial fibrosis, and 
cardiomyocyte apoptosis [72]. IR may accumulate fatty acids, inhibit IRS and Akt, thus 
reducing insulin-mediated uptake of glucose. Studies have shown that endothelial 
dysfunction caused by tumor necrosis factor-alpha (TNF-α) and excessive generation of 
ROS is an important mechanism of IR [73].  IR not only disturbs myocardial energy 
mechanism, but also directly impairs left ventricular structure and function [74]. IR and 
hyperinsulinemia have been shown to aggravate systemic metabolic disorders, activate 
the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), 
and induce oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress and 
calcium homeostasis disturbance, all of which contribute to myocardial fibrosis, cardiac 
hypertrophy, cardiomyocyte apoptosis, and coronary microcirculation dysfunction, 
eventually leading to heart failure [73].  
1.1.1.2.2 Myocardial fibrosis and hypertrophy 
1.1.1.2.2.1 RAAS system 
The RAAS is well-known in the development of heart failure caused by various stress 
including diabetes [75, 76]. Studies have shown that RAAS system activation in diabetic 
patients is closely related to cardiac hypertrophy and fibrosis [77]. Angiotensin II 
activates angiotensin receptor-1 which is located on cardiomyocytes and cardiac 
fibroblasts, and induces increased collagen synthesis and reduced collagen decomposition, 
leading to cardiac hypertrophy and fibrosis which eventually result in decreased 
ventricular compliance and cardiac dysfunction [78]. At present, RAAS inhibitors such as 
angiotensin receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitor 
have been widely used to mitigate diabetic cardiac complications in clinical settings. 
Both are effective in decreasing morbidity and mortality in diabetic patients with cardiac 
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complications [79].  
1.1.1.2.2.2 Matrix metalloproteinases (MMPs) 
The homeostasis of myocardial extracellular matrix is dependent on collagen synthesis 
and degradation.  It is well known that MMPs promote collagen degradation, whereas 
tissue inhibitor of metalloproteinase (TIMPs) inhibit MMPs and consequently prevent 
collagen degradation [80]. Thus, the balance between MMPs and TIMPs is important in 
maintaining collagen homeostasis and subsequent extracellular matrix homeostasis. In 
fact, up-regulation of MMP-2 and MMP-9 has been shown to play an important role in 
atherosclerosis, cardiomyopathy and congestive heart failure [81, 82]. Interestingly, 
studies have found that myocardial expression of MMP-2 is decreased in streptozotocin 
(STZ)-induced diabetic mice, causing reduced collagen degradation and promoting 
myocardial fibrosis [83]. It has also been found that in diabetic rat hearts, increased 
production of ROS interacts with cytoplasmic glutathione leading to activation of 
MMP-2 which cleaves PARP [84] and then induces apoptosis in cardiomyocytes through 
a mitochondrial pathway. The long-term high glucose stimulation induces an unbalance 
between MMPs and TIMPs, which disturbs homeostasis of extracellular matrix collagen 
synthesis and degradation, leading to myocardial fibrosis and finally ventricular systolic 
and diastolic dysfunction [80]. 
1.1.1.2.2.3 Cardiomyocyte apoptosis 
Apoptosis is an evolutionarily conserved suicide process that plays critical roles in 
embryonic development and in the homeostasis, remodeling, surveillance, and host 
defenses of postnatal tissues [85]. Apoptosis is mediated mainly through two central 
pathways: the extrinsic (or death receptor) pathway and the intrinsic (or mitochondrial) 
pathway, which converge via activation of intracellular enzymes called 'caspases'. The 
caspase cascade eventually leads to the activation of the effector caspases, in particular, 
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caspase-3. These effector caspases are responsible for the typical morphological changes 
observed in cells undergoing apoptosis [86].  
Cardiac myocyte apoptosis has been observed in the hearts of diabetic patients and mouse 
models of diabetes and is believed to promote diabetic cardiomyopathy [35, 37, 46, 
87-89]. The diabetic heart may in fact be more susceptible to cardiac myocyte apoptosis 
as reports show that death from myocardial infarction is twice higher in diabetic patients 
than in non-diabetic patients [30-32]. Further studies have shown that hearts of diabetic 
patients with dilated cardiomyopathy had a pronounced increase in apoptotic cells than 
non-diabetic patients.  
Zhang et al found that high glucose activated caspase-8 and caspase-9, the key promoters 
of cardiomyocyte exogenous and endogenous apoptotic pathways followed by activation 
of downstream apoptotic executioner caspase-3 and induced apoptosis in cultured 
neonatal mouse cardiomyocytes [90]. Studies from our lab also showed an increase in 
cardiac apoptosis in cultured cardiomyocytes and mouse hearts under diabetic conditions 
[91, 92]. In addition, studies have shown that endoplasmic reticulum stress is another 
mechanism of apoptosis in cardiomyocytes. Li et al found that in STZ-induced diabetic 
rats, glucose regulated protein78 (GRP78) expression was up-regulated, caspase-12 and 
CCAAT/enhancer-binding protein homologous protein (CHOP) were activated, which 
mediated endoplasmic reticulum stress and further induced apoptosis, and eventually 
leading to diabetic cardiomyopathy [93]. Cardiomyocyte death causes a loss of 
contractile tissue, directly leading to myocardial dysfunction. The loss of cardiomyocytes 
induces hypertrophy of the remaining cells, characteristic changes in diabetic 
cardiomyopathy. Thus, inhibition of cardiomyocyte apoptosis results in a significant 
prevention of the development of diabetic cardiomyopathy in animal models [94, 95]. 
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1.1.1.2.2.4 Microvascular disease 
Diabetic cardiomyopathy has been associated with myocardial microvascular 
abnormalities [96]. Diabetes impaired the stability of myocardial microvascular vessels in 
both diabetic human myocardial explants and experimental diabetes, and microvascular 
endothelial dysfunction was observed in pre-diabetes, which may explain the increased 
risk of complications of microvascular origin in pre-diabetes and early type-2 diabetes 
[97]. Of note, coronary microvascular rarefaction frequently occurs in diabetic hearts and 
contributes to diabetic cardiac complications [98]. Myocardial microvascular rarefaction 
compromises coronary circulation, which can directly impair myocardial function in 
diabetes. On the other hand, compromised coronary circulation may induce a condition of 
sub-ischemia in hearts, which initiates cardiomyocyte death and subsequent myocardial 
remodeling, characteristic changes in diabetic cardiomyopathy [99]. Thus, prevention of 
coronary microvascular rarefaction may be a useful strategy to reduce diabetic cardiac 
complications. However, the mechanism of diabetic microvascular disease in diabetic 
hearts has not been clear. Hyperglycemia, lipid metabolism disorder, oxidative stress, 
inflammatory response, reduced nitric oxide (NO) synthesis, endothelial damage, PPAR 
over-expression, platelet dysfunction and coagulation abnormalities can cause vascular 
endothelial cell damage or functional disorder, leading to increased vascular endothelial 
permeability and basement membrane thickening, which ultimately contribute to the 
development of diabetic cardiomyopathy [100]. Activation of PKC seems an important 
down-stream signaling mechanism, contributing to decreased nitric oxide (NO) 
production in the vascular endothelium and increased prostaglandin synthesis, both of 
which contribute to endothelial dysfunction. In addition, PKC regulates other protein 
kinase activity, such as PI3K/Akt and MAPK, causing vascular endothelial dysfunction 
and vasoconstriction [101]. Imbalance of vasoactive hormones causes endothelial damage 
and the capillary basement membrane thickening, and further leads to myocardial fibrosis 
13 
and reduced blood flow which contribute to early diastolic dysfunction and late 
contraction abnormality in the heart [102, 103].  
1.1.1.2.2.5 Nrf2-ARE pathway 
Nuclear erythroid-related factor 2 (Nrf2) - antioxidant response element (ARE) pathway 
is an antioxidant defense system [104]. The activated Nrf2 dissociates from Kelch ECH 
associating protein 1 (KEAP1) into the nucleus, binds to the ARE sequence, and further 
activates the ARE-regulated gene transcription. Currently studies have shown that 
Nrf2-ARE pathway is involved in progress of tumor, stress, apoptosis and inflammatory 
response. Nrf2 as a redox-sensitive transcription factor regulates the transcription of 
antioxidant enzymes and plays an important role in inflammatory response, apoptosis, 
mitochondrial metabolism and stem cell regulation [105]. Meanwhile, Nrf2 inhibits high 
glucose-induced nuclear factor-κB (NF-кB) activation, improves cardiac diastolic and 
systolic function, prevents left ventricular end-diastolic pressure increase and ventricular 
dilatation, and reduces cardiomyocytes apoptosis and interstitial fibrosis. In the diabetic 
mouse model, sulforaphane restored the expression levels of Nrf2 and Nrf2-dependent 
antioxidant genes in the aorta, which prevented diabetes-induced ventricular wall 
thickening, myocardial lipid accumulation, fibrosis, inflammation and apoptosis [106]. In 
addition, Nrf2 decreases ROS production, prevents oxidative stress - induced insulin 
resistance, and reduces oxidative stress - induced islet beta cell apoptosis. It has been 
found that in the heart of diabetic patients, Nrf2 protein was significantly decreased and 
ROS production was increased. He et al found that high glucose injured cardiomyocytes 
and induced diabetic cardiomyopathy by ROS [107]. They have also shown that in Nrf2 
gene knockout mice, even slightly elevation of blood glucose level caused diabetic 
myocardial injury in a short period. Therefore, this suggests that Nrf2-ARE pathway may 
be involved in the development of diabetic cardiomyopathy. 
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1.1.1.2.2.6 Inflammatory response 
In recent years, studies have found that abnormalities in energy metabolism are closely 
associated with the occurrence of chronic inflammation, which is induced by 
proinflammatory cytokines and chemokines, and which is believed to be one of the 
important pathogenesis of diabetic cardiomyopathy [108, 109]. Increased concentrations 
of inflammatory cytokines such as TNF-α and interleukin-6 in serum of patients with 
diabetes suggest that chronic inflammation may be associated with cardiac complications 
[110]. TNF-α induces inflammation and cell apoptosis leading to myocardial fibrosis 
[111]. In diabetic rats, inhibition of TNF-α reduced myocardial fibrosis and improved 
cardiac function [112]. NF-кB, as a transcription factor of various inflammatory factors, 
regulates the expression of proinflammatory, fibrosis and hypertrophy-related genes. In 
Diabetic patients, non-enzymatic glycation reaction of excessive blood glucose with 
proteins produces AGEs, which bind the specific receptors on the cell membrane, leading 
to the release of a large amount of ROS. The ROS activates NF-кB, which further 
promotes transcriptions of TNF-α, interleukin-6 and other inflammatory factors, and 
eventually induces vascular endothelial cell injury and fibroblast proliferation, leading to 
the onset of diabetic cardiomyopathy [113]. In macrophages, NF-κB activation 
up-regulates the expression of nucleotide-binding oligomerization domain-like receptor 
protein 3 (NLRP3), which interacts with ASC (apoptosis-associated speck-like protein 
containing a caspase recruitment domain) and pro-caspase-1 leading to the formation of 
an inflammasome. The inflammasome promotes self-cleavage of pro-caspase-1 to form 
active caspase-1 (p10 / p20), which induces the maturation and secretion of interleukin 1 
beta (IL-1β) and IL-18. Luo et al found that both NLRP3 inflammasome and IL-1β were 
increased in diabetic hearts, leading to the development of diabetic cardiomyopathy, and 
silencing of NLRP3 gene prevented diabetic heart remodeling and improved cardiac 
function [114]. Thus, NLRP3 inflammasome has been suggested as a potential target for 
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clinical treatment of diabetic cardiomyopathy. 
1.1.1.3 Treatments of diabetic cardiomyopathy 
Metabolic disorders, myocardial fibrosis, cardiomyocyte apoptosis, microvascular disease, 
oxidative stress, inflammatory response, mitochondrial structure and function changes are 
all involved in the development of diabetic cardiomyopathy. At present, there is no 
specific treatment for diabetic cardiomyopathy, and the main treatments include lifestyle 
Interventions, blood sugar regulation and clinical medications.  
1.1.1.3.1 Lifestyle Interventions  
Diet and exercise are beneficial for the treatment of diabetic cardiomyopathy and also 
helpful for blood sugar control, weight control, improving insulin sensitivity, and 
reducing heart burden [73].  
1.1.1.3.2 Blood sugar regulation  
Control of blood sugar limits glucose toxicity caused by hyperglycemia, and therefore 
prevents diabetes cardiomyopathy. Metformin, an oral hypoglycemic which is a 
medication that lowers blood sugar, is believed to activate adenosine 
monophosphate-activated protein kinase (AMPK) which plays an important role in 
cardiac energy metabolism [115]. Thus, metformin treatment may improve diabetic 
cardiomyopathy. Incretin mimetics, such as glucagon-like peptide-1 (GLP-1) receptor 
agonists, which are innovative and effective medications to improve blood glucose 
control, have been shown to have cardioprotective effects [116, 117].  
1.1.1.3.3 β-blockers 
These drugs can improve autonomic nervous system function in diabetes, restore cardiac 
remodeling and reduce the incidence of sudden death [118].  
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1.1.1.3.4 Statins 
Statins, a class of lipid-lowering medications, have effect of inhibiting cholesterol 
synthesis, inflammatory and oxidative stress. Studies have shown that statins improve left 
ventricular function and inhibit myocardial fibrosis [119]. Large-scale clinical trials 
confirmed that statins have a protective effect on cardiovascular disease [120]. 
1.1.1.3.5 RAAS blockers 
Studies have shown that RAAS blockers not only lower blood pressure, but also reduce 
insulin resistance and improve myocardial diastolic function [121, 122].  
1.1.1.3.6 Calcium antagonists 
Calcium antagonists or calcium channel blockers have antihypertensive effects and also 
play roles in decrease of excitation-contraction coupling, inhibition of oxidative stress 
and regulation of vascular smooth muscle proliferation and so on [123]. Cardiomyocyte 
calcium retention in diabetic patients is associated with depletion of high-energy 
phosphate compound and ultrastructural disorders, which can be corrected by calcium 
antagonists [124]. 
1.1.1.3.7 Insulin and thiazolidinedione derivatives 
Insulin and thiazolidinedione derivatives [125] improve endothelial function, reduce 
vascular smooth muscle hyperplasia, and have protective effects on left ventricular 
function in diabetic cardiomyopathy patients [126].  
1.1.2 Septic cardiomyopathy 
1.1.2.1 The definition and characteristics of septic cardiomyopathy 
Sepsis, or infection-induced systemic inflammatory response syndrome (SIRS), is a 
common complication after infection, shock, severe trauma and major surgery, and the 
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most common cause of death in critically ill patients [127]. According to statistics, about 
15,000 patients die from sepsis and its complications every day in the world [128]. The 
cardiovascular system is usually compromised by sepsis and septic shock. Myocardial 
injury is a common complication during sepsis, the incidence of which is up to 40% [129]. 
Meanwhile, myocardial dysfunction also aggravates the sepsis condition, and is an 
important factor affecting the prognosis of sepsis [130, 131]. Sepsis combined with 
myocardial dysfunction intensifies the evolution of the disease, increasing the risk of 
multiple organ failure and death [132], and its mortality rate is as high as 70-90% 
compared to 40-60% in septic shock patients without myocardial dysfunction [133, 134]. 
In 1951, Waisbren [135] was the first to report that sepsis could lead to myocardial 
depression characterized by impaired systolic function, enlarged heart, decreased ejection 
fraction, poor ventricular contractility in preload and decreased peak systolic 
pressure/end-systolic volume ratio, and so on [136-138]. Currently, sepsis complicated 
with cardiac dysfunction is commonly referred to as septic cardiomyopathy.  
1.1.2.2 The underlying mechanisms of septic cardiomyopathy 
1.1.2.2.1 Myocardial depressant factor (MDF) 
As early as the 1960s, many studies have demonstrated the presence of MDF in septic 
shock [139, 140]. During sepsis, endotoxins or lipopolysaccharides (LPS) of 
Gram-negative bacteria are important pathogens responsible for myocardial dysfunction 
[130, 141, 142]. LPS activates mononuclear macrophages, neutrophils, lymphocytes and 
other immune cells, leading to the release of various myocardial inhibitory factors in the 
blood [143]. Among myocardial inhibitory factors, TNF-α, IL-1β, and IL-6 have been 
well addressed to cause cardiac insufficiency. TNF-α has been found to induce 
myocardial injury by causing cardiomyocyte apoptosis and calcium mishandling [144]. 
IL-1β is another important MDF, which is generated by monocytes, macrophages and 
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neutrophils after stimulation by TNF-α. IL-1β has been shown to inhibit myocardial 
contractility, and has a synergistic effect with TNF-α [145]. Studies have shown that IL-6 
is also involved in myocardial injury in acute sepsis. Increased IL-6 expression in 
monocytes in patients with meningococcal sepsis is associated with cardiac dysfunction 
[146]. However, the disappointing clinical trials using anti-TNF-α approaches suggest the 
complexity of and involvement of potential multiple-mechanisms in septic 
cardiomyopathy [144].  
1.1.2.2.2 Mitochondrial dysfunction and ROS generation 
Mitochondrion is the major site of myocardial energy metabolism. Sepsis induces 
myocardial mitochondrial respiratory chain disorders which disturb oxidative 
phosphorylation and decrease ATP synthesis leading to cardiac dysfunction [143, 147, 
148]. In septic animal models and patients, it has been shown that myocardial 
mitochondria were decreased associate with ultrastructure abnormalities and autophagy 
[149-151]. Meanwhile, mitochondrial dysfunction caused myocardial energy metabolism 
disorders and impaired electron transport chain resulting in generation of a large amount 
of ROS [152]. Mitochondrial ROS production and oxidant damage occur in cultured 
cardiomyocytes under septic conditions. Mitochondrial ROS production is also increased 
in septic hearts [153, 154].  
An excessive ROS is generated by mitochondria under pathological conditions, leading to 
mitochondrial oxidative damage, which impairs mitochondrial function and induces cell 
death via apoptosis and necrosis [155, 156]. ROS production by mitochondria has also 
been shown to trigger the redox dependent intracellular signaling, leading to 
pro-inflammatory response [157]. Thus, selective inhibition of mitochondrial ROS 
prevents proinflammatory cytokine expression in cardiomyocytes under septic conditions 
and reduces myocardial dysfunction in septic animals, underscoring an important role of 
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mitochondrial ROS in septic cardiomyopathy.  
1.1.2.2.3 Caspase-3 activation and apoptosis 
In experimental endotoxemia/sepsis, numerous studies have evaluated the role of 
apoptotic pathway program activation [158, 159]. In cultured adult cardiomyocytes, LPS 
directly activates caspase-3 and induces apoptosis [160]. A recent study demonstrated that 
septic serum also induces caspase-3 activation and apoptosis in cultured human 
cardiomyocytes [161]. In vivo studies have confirmed that caspase-3 activation is 
significantly increased and apoptosis occurs in the heart in animal models of sepsis and 
septic patients, which is associated with multiple heart caspase activation and cytochrome 
c release from mitochondria in sepsis [162, 163]. Although cardiac caspase-3 activity is 
dramatically increased in these models, the levels of apoptotic cell death in septic heart 
are very low and may be insufficient to explain the dramatic progression of myocardial 
dysfunction in sepsis [151]. Interestingly, studies have promisingly shown that either 
blocking caspase-3 activation by targeting mitochondria-dependent apoptotic pathway or 
direct inhibition of caspase-3 activity significantly attenuates myocardial dysfunction and 
improves the survival rate in sepsis [160, 162, 164, 165]. These results suggest that 
nuclear apoptosis independent pathways are also involved in caspase-3-mediated 
myocardial dysfunction in sepsis. Indeed, activated-caspase-3 may also directly impair 
myocardial function via changes in calcium handling and cleavage of sarcomeric 
myofilaments including α-actin, α-actinin, troponin-T, and myosin light chain cleavage, 
independent of their modulation of nuclear apoptosis [166].  
1.1.2.2.4 Calcium homeostasis and imbalance 
Calcium is an important second messenger during cardiac contraction. It participates in 
cardiac excitation-contraction coupling. The homeostasis of intracellular and extracellular 
calcium concentration in cardiomyocytes is the basis of maintaining myocardial function 
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[167]. Sepsis induces considerable inflammatory factors release and ROS production, 
which may impair calcium regulatory machinery in sarcoplasmic reticulum, leading to 
calcium leakage and subsequent damage of mitochondrial membrane calcium transport 
systems [168]. In cardiomyocytes, excessive uptake and accumulation of calcium inside 
the mitochondria exceed the tolerance range of calcium, leading to the formation of 
"calcium overload" and finally resulting in irreversible mitochondrial damage and cell 
death [169]. Calcium overload may also induce excessive ROS production in 
mitochondria, which signals expression of pro-inflammatory factors. 
1.1.2.2.5 Activation of the RAAS 
In recent years, increased attention has been drawn on the role of RAAS in 
sepsis-induced cardiomyopathy [170]. During sepsis, cardiac RAAS is highly activated 
and myocardial ACE activity increases, which up-regulates expression of renin and 
angiotensin [171]. It is well known that activation of the RAAS promotes myocardial 
injury under pathological conditions, e.g. ischemic heart disease [172]. It has been found 
that animal model administrated with ACE inhibitors and angiotensin II receptor blockers 
in early phase of sepsis showed improved cardiovascular function. This may be 
associated with RAAS antagonists-induced hemodynamic changes, including shunt 
reduction, attenuation of sepsis-induced microcirculation dysfunction, tissue edema 
alleviation, etc., which prevent myocardial damage and reduce mortality [173]. 
1.1.2.3 Treatments of septic cardiomyopathy 
1.1.2.3.1 Fluid resuscitation 
In patients with severe infections or septic shock have relative or absolute hypovolemia, 
rapid and effective fluid resuscitation works well [174]. However, in patients with septic 
cardiomyopathy, the effect of liquid resuscitation is limited. Normal fluid resuscitation 
cannot restore left ventricular function, and the fluid overload or hypervolemia is also 
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harmful for the body. It has been controversial that which kind of fluid should be used for 
resuscitation in septic cardiomyopathy. Study has shown that in early phase of sepsis, 
colloid fluid resuscitation improved cardiac perfusion, cardiac output and systolic 
function [175].  
1.1.2.3.2 Levosimendan 
Levosimendan, marketed under the trade name Simdax, is a calcium sensitizer. It effects 
independently of the beta-adrenergic receptor and is used as treatment of decompensated 
heart failure. Prospective randomized controlled study has found that in patients with 
septic cardiomyopathy, administration of levosimendan increased cardiac output and left 
ventricular ejection fraction, reduced pulmonary arterial pressure, lowered blood lactate 
levels and improved systemic and local tissue perfusion [176]. In patients with severe 
heart failure, levosimendan significantly reduced the levels of inflammatory mediators in 
the blood, lowered the blood brain natriuretic peptide (BNP) level and improved the 
hemodynamic status [177]. 
1.1.2.3.3 Beta blockers 
Beta-adrenergic hyperactivity is an important factor in the pathogenesis of septic 
cardiomyopathy, and the administration of beta-blockers may benefit [178]. However, the 
use of β-blockers is controversial, as it may reduce myocardial contractility. Therefore, 
although β-blockers have been used in sepsis studies for nearly 50 years, they cannot be 
included in sepsis guidelines. At present, there is still controversy about the use of 
β-blockers in the treatment of septic cardiomyopathy [179]. 
1.1.2.3.4 Mechanical assist devices 
In the United States, the intra-aortic balloon pump (IABP), a cardiac assist device, has 
been approved by the U.S. Food and Drug Administration for adjuvant treatment of septic 
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shock. In a canine model of severe septic shock with a low cardiac index, Solomon et al 
[180] have reported that IABP prolonged survival and reduced the dose of 
antihypertensive drugs. Clinical studies have also shown that in patients with septic shock, 
IABP significantly restored blood pressure, improved cardiac function index, increased 
urine output and reduced the 30-day mortality [181]. 
Extracorporeal membrane oxygenation (ECMO) is an extracorporeal assist device that 
temporarily circulates blood through an artificial lung to take over the function of the 
lungs, providing prolonged cardiac and respiratory support in patients with acute 
respiratory failure [182, 183]. ECMO could reduce mortality of severe myocardial 
depression caused by septic shock [184]. However, there are only few case reports using 
ECMO to treat sepsis cardiomyopathy.  
To date mechanical assist devices such as IABP and ECMO do not appear to be the 
standard treatment for septic cardiomyopathy, but may be the last resort when serious 
infections lead to severe myocardial depression, while all else therapies have failed. The 
administration of IABP or ECMO in the treatment of septic cardiomyopathy still requires 
more and larger clinical studies for their efficacies. 
1.2 ROS and cardiac disease 
1.2.1 Oxidative stress in cardiac disease 
Numerous studies have demonstrated that increased ROS contributes to cardiac disease 
progression, such as coronary artery disease, cardiomyopathy, myocardial infarction, 
ischemia/reperfusion injury, and heart failure [185]. The enhanced generation of ROS and 
following oxidative stress is evidently a common phenomenon during cardiac disease 
[186]. Oxidative stress refers to a pathological condition in which toxic effects induced 
by ROS damage all components of the cell due to an imbalance between ROS production 
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and antioxidant defense mechanisms [187]. Increased biochemical markers of oxidative 
stress, such as 8-iso-prostaglandin F2α or lipid peroxides, have been observed both 
systemically in the plasma and locally in the pericardial fluid or myocardium in patients 
and animal models with heart failure and also directly correlated with the severity of 
myocardial injury [188-190]. This notion suggests that ROS are important mediators in 
cardiac remodeling. In fact, inhibition of ROS-generating oxidases or antioxidant 
treatment has been shown to be effective to prevent cardiac remodeling [191]. In mice, 
for example, dimethyl thiourea alleviated oxidative stress and inhibited cardiac 
remodeling and heart failure after myocardial infarction [192], and the antioxidant 
N-2-mercaptopropionyl glycine mitigated hypertrophic remodeling in pressure overload 
model of transverse aortic constriction [193].  
1.2.2 Reactive oxygen species (ROS) in cardiac cells  
ROS are various highly reactive compounds with unpaired electrons in the outer valence 
shell [194]. Major intracellular ROS in heart tissues include superoxide radical (•O2
−), 
hydrogen peroxide (H2O2), and hydroxyl radical (
•OH) [185] (Figure 1-2). As a primary 
radical, •O2
− is formed from one-electron reduction of oxygen molecular. •O2
− is very 
unstable and its half-life is very short. Its dismutation happens in a few seconds after its 
formation, and it is finally converted to H2O2 either spontaneously or by superoxide 
dismutase (SOD) [195] (Figure 1-2). As a membrane-impermeant molecule, •O2
− 
diffusion capacity is limited, and therefore it mostly induces intracellular compartments 
damage, such as disassembly of iron-sulphur clusters. In contrast, H2O2 is less reactive 
than •O2
−, but is more stable and more lipophilic, allowing it to permeate membranes and 
act at remote sites from its original location. H2O2 can be dismutated by catalase, or 
reduced by glutathione peroxidase (GPX) to H2O (Figure 1-2). In addition, H2O2 could be 
reduced to •OH and hydroxide anion (OH−) in the presence of transition metal ions such 
as Fe2+ or Cu+ via the Fenton reaction [195] (Figure 1-2).  The •OH can also be formed 
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Figure 1-2. Schematic diagram of formation and elimination of ROS 
The superoxide (•O2
−) is formed from one-electron reduction of oxygen molecular (O2) 
and can be dismutated to hydrogen peroxide (H2O2) by superoxide dismutase (SOD). The 
H2O2 can be converted to 2H2O by glutathione peroxidase (GPX) or to O2 + H2O by 
catalase. The •OH can be formed from H2O2 via the Fenton reaction and the Harber-Weiss 
reaction.  
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from electron exchange between H2O2 and 
•O2
− by means of the Harber-Weiss reaction 
(Figure 1-2). As the most reactive oxidant free radical species, •OH is primarily 
responsible for oxidative stress-associated cellular injury in cardiac disease. It is normally 
generated in trace amounts, but in pathologic conditions such as ischemia/reperfusion 
injury, its formation is markedly increased [196].  Due to its non-diffusible characteristic 
and extremely short half-life of 10−9 s, •OH causes non-specific damage to all cellular 
macromolecules within a small radius from the site of its generation, including but not 
limited to protein and deoxyribonucleic acid (DNA) modification, and lipid peroxidation 
[197]. 
1.2.3 Sources of ROS in cardiac cells 
Cellular ROS are generated from various sources including mitochondrial respiratory 
chain, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, 
NO synthases, peroxidases, cytochrome P450, lipoxygenase, and other hemoproteins 
[198]. Three major cell types in the heart (cardiomyocytes, fibroblasts and endothelial 
cells) express all these enzymes and are capable of generating ROS. Although the exact 
proportions of ROS production from individual source are not known, it has been 
suggested that the predominant sources of ROS in heart tissues are NADPH oxidase, 
mitochondria and xanthine oxidase, all of which have been demonstrated to play 
important roles the pathogenesis of cardiac disease. These three major ROS sources in 
heart are described below: 
1.2.3.1 NADPH oxidase (NOX) 
NOX is a multi-component enzyme system that catalyzes the NADPH-dependent 
reduction of oxygen to the •O2
−, which is the precursor of the other ROS [199]. This O2
- 
producing system is well characterized in neutrophils where it plays an important role in 
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bacteria killing. The enzyme complex comprises two membrane subunits (gp91phox and 
p22phox, which form flavocytochrome b558), at least three cytosolic proteins (p40phox, 
p47phox and p67phox, which form the cytosolic complex) and the small GTPase Rac1 or 
Rac2 [200-203]. The catalytic core of NADPH oxidase is the membrane-integrated 
flavocytochrome b558 [204]. NADPH is a highly regulated enzyme. In resting cells, the 
cytosolic complex is separated from the membrane-bound catalytic core. Upon 
stimulation, NADPH oxidase activation appears to be triggered by the phosphorylation of 
the cytosolic phox proteins and their translocation with Rac to the membrane-bound 
flavocytochrome b558 to assemble into an active oxidase [204, 205].  
Several homologs of gp91phox (also termed Nox2)—Nox1, Nox3, Nox4, and Nox5—have 
been identified in nonphagocytic cells [206]. In the heart, recent studies showed that the 
phagocyte-type of NADPH oxidase is expressed in adult cardiomyocytes and is a major 
source of O2
- during pathophysiological conditions [207]. In addition, NOX has been 
demonstrated to significantly contribute to ROS generation in vascular cells (such as 
adventitia, medial smooth muscle, and endothelium) [208]. It has been shown to be 
activated and generate excessive •O2
− in vascular tissue contributing to the pathogenesis 
of angiotensin II - induced endothelial dysfunction and vascular hypertrophy [209].  
1.2.3.2 Mitochondria 
The heart is the highest oxygen consuming organ which uptakes about 0.1ml O2/g/min at 
basal conditions [210]. Therefore, cardiomyocytes have the highest volume density of 
mitochondria within human body, to fulfill the demand for generation of the energy 
source ATP via oxidative phosphorylation reactions. The enzymatic components of 
oxidative phosphorlyation are consistent in all eukaryotic cells. These components 
include: NADH-ubiquinone oxidoreductase (complex I), succinate-ubiquinone 
oxidoreductase (complex II), ubiquinol - ferricytochrome c oxidoreductase (complex III), 
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ferricytochrome c-oxygen oxidoreductase (complex IV), and F1F0 ATP synthase 
(complex V). During the process of ATP production, electrons transfer through these 
multimeric complexes, termed as electron transport chain (ETC). Briefly, in 
mitochondrial ETC, electrons donated from nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) are transferred by complex I and II respectively, 
to complex III via ubiquinone (Coenzyme Q10) [211]. Electrons are then delivered by 
cytochrome c to complex IV, and finally passed to O2, converting to water. During the 
transfer of electrons, protons are translocated from the mitochondrial matrix to the 
intermembrane space by complex I, III and IV, and thereby the proton gradient and the 
mitochondrial membrane potential are formed. At last, complex V via the use of the 
energy stored in this proton gradient across the inner mitochondrial membrane produces 
ATP.  Complex V using the ETC - driven membrane potential is termed oxidative 
phosphorlyation. However, not all of the oxygen acts as the terminal electron acceptor. 
Small amount of oxygen is partially reduced by electrons leaked from the ETC and 
transformed into •O2
−. Hence, a little oxidative species is generated as byproducts. The 
complexes I and III are believed as the major sites for electron leakage [211]. Of note, an 
impairment of complex V not only reduces ATP production but also contributes to 
mitochondrial ROS generation.  
Under normal conditions, mitochondria are capable to eliminate these toxic by-products 
of ROS by mitochondrial antioxidant systems. These antioxidant enzymes include 
catalase, SOD and GPX, and several low-molecular-weight antioxidants such as 
ascorbate, α-tocopherols and thiols and ubiquinol [212]. •O2
− can be converted to H2O2 by 
manganese SOD (MnSOD) in mitochondrial matrix or copper-zinc SOD (CuZnSOD) in 
the intermembrane space. Then, H2O2 can be readily reduced to water by catalase or 
GPX, which utilize H2O2 to oxidize reduced glutathione (GSH) to oxidized glutathione 
(GSSG). Meanwhile, GSSG can be converted back to GSH by glutathione reductase 
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(GR). Under pathological conditions, the ETC is blocked, leading to substantial electrons 
inappropriately transferring directly to O2 to form 
•O2
−, which is beyond the ability of 
mitochondrial antioxidant systems to scavenge, and thereby a large amount of ROS is 
produced [213]. However, it remains incompletely understood how mitochondrial ROS 
generation is regulated in cardiomyocytes under pathological conditions. 
1.2.3.3 Xanthine oxidase (XO) 
XO plays an important role in purine metabolism pathway under normal physiological 
conditions [214]. The enzyme generates ROS as a byproduct in the catalytic process of 
final product uric acid by oxidation of hypoxanthine and xanthine [215]. It has been 
suggested that the level of XO may be low in the heart and it was even not found in 
human cardiomyocytes. XO is normally present in the small intestinal mucosa and the 
liver [216, 217]. However, in disease conditions such as cardiomyopathies or under stress 
such as inflammation or increased oxidative stress by prolonged hypoxia, it is activated 
and released into serum [218]. The released XO may subsequently reach to target tissues 
like heart via circulating system and gather more than thousand-fold at the interstitial 
matrix of the vasculature or binding to surface of endothelial cells. XO-derived ROS has 
been implied to contribute to myocardial ischemia/reperfusion injury by many 
experimental data [219]. It has been shown that XO is highly activated and produces 
excessive superoxide in mesenteric tissue leading to intensified vascular tone in an 
essential hypertensive model[220]. Increased activity of XO has also been observed in 
end-stage failing human heart. It has been suggested that inhibition of XO is a potential 
therapeutic method to improve cardiovascular injury [221, 222]. For example, treatment 
with allopurinol, an inhibitor of XO, has been proved to effectively decrease the level of 
lipid peroxidation and aid postoperative recovery [223]. 
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1.2.4 Oxidative damage in cardiac cells 
ROS can induce massive peroxidative damage to phospholipids, proteins and DNA. ROS 
also lead to protein modifications, such as nitration and carbonylation, and generation of 
lipid peroxidation adducts (e.g. 4-hydroxynonenal [HNE]) [224]. ROS-mediated protein 
modifications (carbonylation and nitration) and HNE adduct change or impair protein 
function and stability [225]. As a consequence, ROS directly influences cellular structure 
and function, and has been suggested as the integral signaling molecules in myocardial 
remodeling and failure, leading to cardiomyocyte apoptosis, inflammation, hypertrophy 
and interstitial fibrosis in the development of heart failure [226, 227].  
1.2.4.1 Oxidative damage to proteins  
Superoxide induces the release of ferrous iron from Fe-S clusters. Ferrous iron then 
readily binds polypeptides. Thus, the Fenton reaction results in the formation of •OH, 
which damages proteins at sites [212]. Protein oxidation is assessed by measuring the 
contents of carbonyls, which can be easily quantified [228]. In addition to 
sulfur-containing residues, most amino acids are irreversibly oxidized, and thus the 
oxidatively-modified protein is likely degraded through the proteolysis. Given that 
hydroxyl radicals readily react with, and H2O2 can directly oxidize cysteine and 
methionine, both residues are targeted by the hydroxyl radical resulting from the Fenton 
chemistry more than other amino acid residues [212, 229]. However, H2O2
− mediated 
cysteine and methionine oxidation is very slow and thus, H2O2 at physiological 
concentrations is unlikely to induce direct oxidation of amino acids [230, 231]. Particular 
mitochondrial proteins such as aconitase have been shown to be inactivated by H2O2 
[232]. In aconitase, superoxide is highly reactive with the [4Fe-S] cluster [233]. Citrate 
synthase is another target of mitochondrial ROS, and in fact SOD2 mutant mice display a 
reduction of citrate synthase activity in the heart [234]. 
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1.2.4.2 Oxidative damage to lipids 
ROS can cause oxidation of lipids which is one of major mechanisms contributing to 
lipid peroxidation (LPO). Others include enzymatic oxidation and non-enzymatic 
oxidation such as ozone. Thus, LPO product can be measured as an indicator of oxidative 
damage to lipids.  
Superoxide itself may not directly oxidize lipids. However, it reacts with NO to form 
peroxynitrite (ONOO−), which can initiate lipid peroxidation [235]. Superoxide may also 
induce conversion of Fe3+ to Fe2+, which reacts with H2O2 and subsequently generates 
hydroxyl radicals in the vicinity of lipids, contributing to LPO. 
The reaction of ROS with lipids can be detrimental or beneficial to the cell depending on 
their products. Lipid peroxidation can disturb bio-membrane and modify proteins and 
DNAs, but products of lipid peroxidation may also regulate gene expression and redox 
signaling, leading to oxidative stress tolerance. In addition, lipid oxidation results in lipid 
hydroperoxides, which in turn become DNA-adducting electrophiles, leading to 
propagation of ROS damage [236, 237]. 
1.2.4.3 Oxidative damage to nucleic acids 
As mentioned above, superoxide can release Fe2+ from Fe-S clusters, which can damage 
DNA. H2O2 directly oxidizes Fe
2+ in the Fenton reaction thus generating the extremely 
reactive •OH [238, 239]. Although •OH reacts readily with all biomolecules, such 
reactions are limited because •OH only affects them near the site of its production. Thus, 
when •OH production is present at the site of a ferrous iron-DNA complex, DNA can be 
damaged [212]. •OH can attack any bases in DNA, with guanine being the particular 
target [240]. Since 8-hydroxyguanine (8-oxoG) is the major product formed in an 
•OH-DNA reaction, it has used as an indicator of DNA oxidative damage [241]. In 
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addition to nuclear DNA, mitochondrial DNA (mtDNA) is particularly susceptible to 
oxygen radicals because of its close proximity to the locations of superoxide generation 
by the ETC and its lack of histone protection. In fact, studies have shown more mtDNA 
damage than nuclear DNA damage in cells treated with H2O2 at concentrations at 200 μM 
or less [242-245], indicating the increased ROS vulnerability of mtDNA compared to 
nuclear DNA. 
1.2.5 Mitochondrial ROS and cardiac disease 
For a long time, people have been focusing on antioxidant therapies for cardiovascular 
disease like vitamin E and CoQ based on promising experiments [246, 247]. 
Unfortunately, clinical trials showed disappointing outcomes. Recently, it has been 
recognized that such therapies need to be more targeted towards mitochondria and the 
respiratory chain because they are the main sources of ROS in cardiomyocytes [248]. 
Indeed, mitochondrial ROS production is increased and oxidative stress occurs in a 
variety of cardiac diseases [249]. Sustained high levels of ROS in the mitochondria 
directly damage mitochondrial components [250], including permanent inactivation of 
mitochondrial proteins, destruction of mitochondrial DNA and phospholipid bilayer of 
mitochondrial membrane, inhibition of mitochondrial respiratory chain function, and 
down-regulation of mitochondrial DNA replication, which further accelerate free radicals 
generation leading to forming a vicious cycle: free radical generation → mitochondrial 
structure destruction → more free radical generation. As a consequence, excessive 
mitochondrial ROS compromises energy production and induces cell death. 
Mitochondrial ROS may also serve as a signaling molecule, leading to pro-inflammatory 
cytokines expression resulting in inflammation and fibrosis as well as myocardial 
hypertrophy [251]. All of these changes contribute to cardiac injury, remodeling and 
heart failure. Thus, targeted inhibition of mitochondrial ROS has been shown to reduce 
cardiac injury and prevent myocardial remodeling and heart failure in a variety of animal 
32 
models [252, 253]. Thus, mitochondrial ROS may represent an excellent target for 
therapy. Indeed, a number of mitochondrial-targeted anti-oxidants have been 
commercially developed including mito-E, mito-TEMPO, mitoQ10, SS31 
(6’-dimethyltyrosine-Lys-Phe-NH2), etc. with some being under clinical trials for various 
diseases [254].  
1.2.5.1 Mitochondrial ROS and ischemic heart disease 
Mitochondria are not only the main targets of oxidative stress but also the major sites of 
ROS production. Under physiological conditions, about 0.2% -2.0% of molecular oxygen 
is transformed to superoxide by acquiring electron from complex I and complex III of the 
electron transport chain in cardiomyocytes [211]. During myocardial ischemia, numerous 
studies have shown that a small amount of ROS is generated in mitochondria, which may 
disrupt the electron transport chain [195]. After onset of reperfusion, the immediate 
restoration of oxygen levels and inefficient oxidative phosphorylation promote a large 
amount of mitochondrial ROS production and subsequent oxidative stress [255]. 
Excessive mitochondrial ROS induces cell death and promotes proinflammatory cytokine 
expression in ischemic heart tissues, leading to the infiltration of inflammatory cells 
which enhances ischemic heart injury [256]. Thus, targeted inhibition of mitochondrial 
ROS reduced ischemia/reperfusion (I/R) injury in in vitro cardiomyocytes and in vivo 
hearts. 
1.2.5.2 Mitochondrial ROS and hypertensive cardiomyopathy 
Hypertension is a highly prevalent human disease that imposes a major risk for 
development of wide spectrum of cardiac and vascular diseases including atherosclerosis, 
cardiomyopathy, stroke and kidney diseases. Meanwhile, mitochondrial ROS and 
oxidative stress are increased in heart tissues in response to hypertension and implicated 
in the development of hypertensive cardiomyopathy [257]. Increased mitochondrial ROS 
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in cardiomyocytes induces mitochondrial protein oxidative damage and mitochondrial 
DNA deletions, contributing to the development of cardiac hypertrophy, fibrosis and 
failure. In an angiotensin II-induced mouse model, Dai et al reported that mitochondrial 
ROS and oxidative stress were induced in cardiomyocytes and over-expression of 
catalase targeted to mitochondria prevented myocardial hypertrophy, fibrosis and 
mitochondrial damage in mice [257]. Over-expression of catalase targeted to 
mitochondria also prevented heart failure induced by over-expression of Gαq in mice 
[258]. Similarly, administration of mitochondrial targeted antioxidant peptide SS31 
reduced mitochondrial oxidative damage, prevented apoptosis, and ameliorated cardiac 
hypertrophy, diastolic dysfunction, and fibrosis induced by angiotensin-II in mice without 
changing blood pressure. The SS31 administration also partially rescued the heart failure 
phenotype of Gαq overexpressing mice [259]. The protective effects of SS31 were 
reproduced by McLachlan et al in stroke-prone spontaneously hypertensive rats using 
another mitochondrial-targeted antioxidant mitoQ10 [260]. These findings suggest the 
potential clinical application of mitochondrial-targeted antioxidants in treating 
hypertensive cardiomyopathy. 
1.2.5.3 Mitochondrial ROS and metabolic cardiomyopathy 
Mitochondrial ROS and consequent oxidative stress are associated with metabolic heart 
disease [36, 261]. Many studies have shown that elevated glucose and free fatty acids 
levels present in the diabetic state drive the formation of ROS [262, 263]. It is believed 
that enhanced substrate flux through the mitochondria enhances electron leak and 
subsequently ROS formation [264]. Oxidative stress occurs when ROS are generated in 
excess through the reduction of oxygen and inadequate antioxidant defense [187]. In this 
regard, studies have shown that anti-oxidant defense system was usually impaired in 
diabetic hearts [265-267]. Furthermore, analysis of cardiac biopsy on patients diagnosed 
with diabetes complicated with heart failure revealed mitochondrial swelling and ROS 
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production in cardiomyocytes. Lastly, restoration of mitochondrial anti-oxidant defense 
function by over-expression of thioredoxin-2 effectively prevented mitochondrial 
oxidative stress and consequently attenuated myocardial hypertrophy in mouse models of 
type-1 diabetes. However, further investigation is needed to determine whether 
therapeutic scavenging mitochondrial ROS using mitochondrial-targeted anti-oxidants 
reduces diabetic cardiomyopathy in animal models of both type-1 and type-2 diabetes. 
Under other metabolic stress, pooled neutral fatty acids within the mitochondria due to 
the inability to utilize efficiently are more susceptible to oxidative damage [268]. 
Sverdlov Al et al observed oxidative posttranslational modifications of cardiac 
mitochondrial proteins in mice fed a high-fat high-sucrose diet [269, 270]. This 
mitochondrial oxidative stress in the heart was associated with cardiac diastolic and 
mitochondrial dysfunction as well hypertrophy. Importantly, transgenic over-expression 
of catalase in mitochondria ameliorated cardiac mitochondrial dysfunction, hypertrophy 
and diastolic dysfunction in mice fed a high-fat high-sucrose diet [271, 272]. Thus, 
increased myocardial mitochondrial ROS generation is an important factor promoting the 
development of metabolic cardiomyopathy and may represent an important target for 
therapy. 
1.2.5.4 Mitochondrial ROS and septic cardiomyopathy 
Mitochondrial ROS production and oxidant damage occur in cultured cardiomyocytes 
under septic conditions [273]. Mitochondrial ROS production is also increased in septic 
hearts [274]. It has been demonstrated that excessive mitochondrial ROS induced 
caspase-3 activation and apoptosis in cardiomyocytes during sepsis, which compromises 
myocardial function [143]. Interestingly, mitochondrial ROS also serves as a signaling 
molecule, which induces expression of pro-inflammatory mediators and subsequent 
infiltration of inflammatory cells, leading to myocardial injury and depression in sepsis 
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[275, 276]. Our lab demonstrated that mitochondrial ROS increased and mediated TNF-α 
expression in cardiomyocytes in response to LPS [277]. In a rat model of a 
pneumonia-related sepsis, Zhang et al reported that mitochondria-targeted vitamin E, 
another mtROS specific antioxidant, improved cardiac performance and attenuated 
inflammation [278]. Yao et al further demonstrated that sepsis-induced mitochondrial 
ROS damage mtDNA, leading to the release of free mtDNA and the activation of a toll 
like receptor 9 pathway, which contributes to the development of cardiac failure after 
sepsis [273]. Thus, targeting mitochondrial ROS by mitochondria-targeted antioxidants 
represents a promising therapeutic approach to protect the heart in sepsis.  
1.3 The Calpain family 
1.3.1 General information 
Calpains belong to a family of calcium-dependent thiol-proteases [279, 280]. The first 
calpain discovered and purified was calpain-1 in 1964 by Guroff [281]. A total of 15 
isoforms of calpain (14 large subunit members and one small subunit) and one 
endogenous inhibitor (calpastatin) have been discovered in mammals. Among them, 
calpains 1,2,4, 5, 7, 9 and 10 are ubiquitously expressed members. Calpain-3 (skeletal 
muscle and retina), calpain-6 (placenta), calpain-8 (smooth muscle), calpain-11 (testes), 
calpain-12 (skin) and calpain-13 (testes and lung) are tissue specific isoforms [282]. 
Based on domain IV structure, calpains can be divided into two groups: the typical and 
atypical calpains. Nine of calpain isoforms (1, 2, 3, 8, 9, 11, 12, 13 and 14) containing a 
penta-EF hand in domain IV are classified as typical. The penta-EF domain can bind 
calpastatin, Ca2+ or the calpain small subunit (only calpains 1, 2 and 9 have been shown 
to bind). In contrast, other five isoforms (calpains 5, 6, 7, 10 and 15) are classified as 
atypical as they do not have a penta-EF hand in domain IV and thus, they are unable to 
bind calpastatin or the calpain small subunit [283, 284]. (Figure 1-3).   
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Figure 1-3. Schematic structures of calpain family members in mammals 
The main structural domains and localization of the mammalian calpain protein family 
and their endogenous inhibitor calpastatin are shown. Figure is adapted from Margaret C. 
Frame, et al. Nature Reviews Molecular Cell Biology, 2002 Apr;3(4): 233-245 
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Most calpains have four structural domains: I, II, III and IV (Figure 1-3). Upon Ca2+ 
activation (autolysis), domain I is cleaved in calpains 1, 2 and 9 [280]. However, it is 
unknown if other typical calpains have autolysis of domain I. In atypical calpains, 
domain I is not cleaved and their function remains largely unknown, except in calpain-10 
where a mitochondrial targeting sequence is identified within domain I [285]. The calpain 
active site resides in domain II, which has a catalytic triad of cysteine, asparagine and 
histidine. This catalytic triad is present in the entire family except calpain-6, which does 
not have proteolytic activity [286]. In addition to the catalytic triad, domain II can also 
have binding sites for Ca2+ which assists in calpain activation [287]. There are two 
Ca2+-binding spots and one C2-like motif which binds phospholipid in domain III [288]. 
These Ca2+-binding and phospholipid binding residues are conserved in the calpain 
family except calpain-10. Domain III is important in regulation of calpain activity by 
management of specific electrostatic interactions and in recognition of their substrates 
[287]. Domain IV has the penta-EF hand to bind Ca2+, calpastatin or domain VI of the 
small subunit (calpain 4). These penta-EF hands are important for calpain activation since 
they contain the most Ca2+ binding spots [289].  
Calpain-4, also known as a small calpain subunit, is a 28 kDa protein that forms 
heterodimers with typical calpains, encoded by capn4 or (capns1) gene [280]. It only 
contains domain V and VI (Figure 1-3). The function for domain V is known to bind the 
C-terminus region of domain IV in large calpain subunits [290]. Both domain VI and IV 
have a penta-EF hand for Ca2+-binding and heterodimer formation [291]. Calpain small 
subunit 2 (CSS2) was recently discovered and it dimerizes with calpain-2 [292]. However, 
CSS2 may not redundant with calpain-4 because global deletion of calpain-4 is 
embryonic lethal [293]. 
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1.3.2 Calpastatin 
Calpastatin is an endogenous protein that specifically inhibits calpains (e.g. calpain-1 and 
calpain-2), but not any other proteases. Calpastatin has 8 splice variants, ranging from 
18.7-85 kDa [294, 295]. Calpastatin has six domains (XL, L, I, II, III and IV) [280]. 
Domains I-IV are similar and contain inhibitory subdomains A, B and C. None of the 
subdomains can inhibit calpains when assayed alone, but when subdomains A and B or B 
and C are assayed together calpain activity is reduced. When subdomains A and C are 
assayed together there is no inhibition. Subdomains A and C have been shown to bind to 
domain IV and VI, respectively, in a Ca2+-dependent manner (Figure 1-4), while 
subdomain B binds domain II in a Ca2+-independent manner. Of the four domains the 
order of inhibition effectiveness is: domain I>domain IV>domain III>domain II [296]. 
Little is known about the XL domain other than it contains three PKA phosphorylation 
sites [297]. The function of domain L is still unknown. 
1.3.3 Calpain activation 
Calpains require Ca2+ concentrations at physiological pH and ionic strength (Figure 1-4). 
Although calpains 1 and 2 share identical 28 kDa small subunits, their 80 kDa large 
subunits are different. This discrepancy in structures presumably accounts for the 
differential Ca2+ requirement for activation between them. Calpains 1 and 2 require 
micromolar and millimolar of Ca2+ for their half-maximal activation, respectively [280].  
Activation of typical calpains involves a series of conformational changes, which engage 
the interactions between various domains. In the absence of Ca2+, the interaction between 
the N-terminal anchor helix and Domain VI of the small subunit imposes constraints on 
the protease core (Domains I and II) and makes these two Domains (I and II) separate in 
an inactive conformation [298, 299]. This prevents the active site Cys residue located in 
Domain I from forming the catalytic triad with His and Asn in Domain II because the Cys  
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Figure 1-4. Schematic diagram of calpain activation and regulation 
Calpain requires Ca2+ for activation. Calpain activity can also be regulated by other 
factors, such as ERK1/2 and PIPs. Calpastatin represents the negative regulator of calpain 
activity, which is also in a Ca2+-dependent manner. ERK1/2, extracellular 
signal-regulated kinase-1/2; PIPs, phosphatidylinositol phosphates. 
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is far away from the His (about 10 Å) [300]. Also, the wedge (tryptophan 288) between 
Domains I and II also blocks the formation of the catalytic triad. In the presence of 
sufficient Ca2+, calpain undergoes a series of conformational changes that lift the 
restraints on the protease core, which includes freeing the anchor helix from its contact 
with the small subunit. As a consequence, the catalytic triad containing the active site Cys 
residue located in Domain I and His and Asn in Domain II is formed in a proteolytically 
active conformation [300-302]. This activating process is reversible because abrogation 
of Ca2+ by adding excess EDTA pushes this reaction back to an inactive form of calpain.  
In addition to Ca2+, several other factors have been shown to affect calpain activation 
(Figure 1-4). For example, phosphorylation of calpain may lower the Ca2+ requirement 
for its activation. It was reported that phosphorylation of calpain-2 by ERK1/2 can 
directly induce its activation without increasing Ca2+ [303-305]. Calpain-2 activation is 
also regulated by its binding to phosphatidylinositol 4,5-bisphosphate [306, 307]. This 
may explain why calpain-2 can be activated in cells where there is no way that Ca2+ can 
reaches the millimolar levels. 
1.4 Calpain and cardiac disease 
Activated calpain cleaves its substrates through limited enzymatic cleavage. Its substrates 
are numerous, including a variety of regulatory and receptor proteins, cytoskeletal 
proteins, myofibrillar proteins and protein kinases [308], which are involved in many 
pathophysiological functions. Thus, calpain activation has been implicated in cardiac 
apoptosis, hypertrophy, fibrosis and inflammation in the development of cardiac disease.  
1.4.1 Calpain and cardiac remodeling 
1.4.1.1 Calpain and cardiac apoptosis 
Apoptosis is a highly-regulated, energy-dependent form of programmed cell death known 
41 
to play an important role in the development and progression of cardiovascular disease 
[309]. One mechanism by which apoptosis is induced in cardiomyocytes is via calpain 
activity [310-314]. 
Calpain has been proved to directly cleave pro-caspase 3, 7, 8, 9 and as such has been 
implicated in apoptosis [315, 316]. Additionally, apoptosis resulting from alterations in 
intracellular calpain concentrations may include calpain-2 mediated caspases-12 cleavage 
and activation [317]. Moreover, calpain has been shown to cleave Bcl-xL, an apoptotic 
inhibitor [318]. The protease is also implicated in ischaemia-reperfusion induced 
apoptosis and has been shown to participate in TNF-alpha mediated apoptosis in 
cardiomyocytes [312]. A recent study demonstrated that cardiac over-expression of 
calpain-1 is sufficient to cause heart failure in transgenic mice [319]. Our lab recently 
showed that hyperglycemia-induced calpain-1 activation, mediated through an NADPH 
oxidase-dependent pathway, can lead to apoptosis through down-regulation of (Na, 
K)-ATPase activity in cardiomyocytes and in vivo diabetic hearts [311]. Calpain 
inhibition via calpastatin over-expression imparted an anti-apoptotic effect on 
cardiomyocytes. In this study we also demonstrated that the pro-apoptotic role of calpain 
is mediated through caspase-3 activation. During high glucose stimulation calpain 
inhibition via pharmacological calpain inhibitors, calpain-1 siRNA and calpastatin 
overexpression was able to block calpain activation and consequently prevent apoptosis 
in cardiomyocytes and hyperglycemic hearts [320]. 
Calpain inhibition has been found to be protective in ischaemia injury models as well 
[321-324]. ROS production and the resulting oxidative stress is a key feature of I/R injury 
[325]. Our lab has shown that in high glucose treatment, ROS mediate calpain activation 
in cardiomyocytes. Calpain activation may be the outcome of increased intracellular 
calcium in cardiomyocytes after oxidative activation of L-type calcium channels and 
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ryanodine receptor by ROS leads to calcium release [311]. This is consistent with reports 
that calcium is increased under I/R stimulation and high glucose conditions [326-328]. 
The pro-apoptotic effects of calpain were also on display as once calpain activity was 
inhibited by calpastatin overexpression, cardiomyocyte apoptosis and necrosis were 
diminished in diabetic and non-diabetic hearts after I/R and encouraged myocardial 
functional recovery [329]. Mani and colleagues used a mouse model of myocardial 
infarction to demonstrate that active caspase-3 increased after myocardial infarction (MI) 
in the border zone but calpeptin, a calpain inhibitor and caused a decrease in calpain 
activity that reduced chamber dilation and protected left ventricular pump function and 
reduced cardiomyocyte loss in the border zone [330]. This was further supported by our 
recent report in a mouse model of MI [331]. All these previous studies have demonstrated 
an important role of calpain activation in cardiac apoptosis under stress.  
1.4.1.2 Calpain and cardiac hypertrophy 
Hypertrophy is an important feature of cardiac remodeling. It is characterized by the 
individual cardiomyocyte size increase. Pathological cardiac hypertrophy is initiated by 
biomechanical, stretch-sensitive (mechanical deformation) or neurohumoral mechanisms 
(release of endothelin-1, catecholamines, angiotensin II, chemokines, cytokines, and 
growth factors) [72]. Proteins involved in these intracellular signaling pathways would be 
the targets of calpains [332].  
Although the exact mechanism is unclear, calcium is believed to play some role in 
promoting cardiac hypertrophy [333] Alteration in calcium handling is a common 
occurrence in some models of cardiac hypertrophy [334]. The clear increase in 
intracellular calcium may serve as an avenue facilitating the morphological and 
biochemical changes that lead to a hypertrophic state. One way in which this occurs may 
be through the action of calcium-activated calpain [335]. Despite limited understanding 
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of its role in cardiac hypertrophy, elevated calpain activity is an established feature of the 
diabetic myocardium [336]. In one study, calpain-like activity was increased in the 
myocardium concurrent with cardiac mass after injection with isoproterenol to stimulate 
beta-agonist induced hypertrophy [337].  
A proposed method by which calpain indirectly promotes hypertrophy is through the 
activation of calcineurin, a Ca2+/calmodulin dependent protein phosphatase [338]. 
Proteolysis of calcineurin by calpain involves removal of the autoinhibitory domain 
which causes calcineurin to assume its active conformation, no longer requiring calcium 
and calmodulin for activation [339]. Calpain can also cleave an endogenous inhibitor of 
calcineurin, cain/cabin 1 [340]. On its way to promoting hypertrophy, calcineurin 
activates nuclear factor of activated T-cells (NF-AT), a transcription factor that 
translocates into the nucleus and initiates pro-hypertrophic gene expression [341]. 
Another transcription factor implicated in hypertrophy is NF-κB [342]. When inactive, 
NF-κB is complexed to its inhibitor, inhibitor-κB (IκB) and is thus prevented from entering 
the nucleus [343].  Calpain has been shown to degrade IκB but under normal 
circumstances activation of IκB kinase (IKK) by extracellular signals initiates the 
degradation of IκB [344-346]. Phosphorylation of two serine residues of the IκB structure 
by IKK leads to ubiquitination and subsequent digestion by the proteasome. NF-κB 
becomes free to translocate into the nucleus and transcribe its associated genes [343].  
Specifically, NF-κB is responsible for the activation of pro-inflammatory cytokines some 
of which, such as TNF-α, are elevated in the diabetic heart [347, 348]. Pro-inflammatory 
cytokines can subsequently induce expression of other cytokines to enhance cell injury. 
Our lab used a cardiac-specific capn4 knockout model and both an STZ and OVE26 
mouse model with calpastatin overexpression to investigate the role of calpain in the 
hyperglycemic myocardium. We demonstrated that impeding calpain function can reverse 
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hypertrophy and concurrently found that elevated calpain also increased NF-AT and 
NF-κB activity [336]. This finding supports the suggestion that calpain plays an 
important role in the activity of NF-κB and calcineurin, both key activators of 
hypertrophic pathways. We also observed that limiting calpain activity through capn4 
knockout also decreases TNF-α and TGF-ß1 expression in the diabetic heart [336]. 
Similarly, in a mouse model of ischemic heart disease using cardiac-specific capn4 
knockout mice, our lab reported that disruption of calpain reduces hypertrophy. Again, 
this anti-hypertrophic effect of calpain disruption was associated with inhibition of 
NF-κB activation and subsequent reduction of TNF-α expression in ischemic hearts [331]. 
Nevertheless, the signaling mechanisms by which calpain promotes hypertrophy in 
diseased hearts have not been fully understood.   
1.4.1.3 Calpain and cardiac fibrosis 
Myocardial fibrosis is a maladaptive response to stress characterized by excess collagen 
accumulation and is believed to occur independently of organ hypertrophy [349]. In the 
heart, myocytes are bounded by the extracellular matrix (ECM) which is primarily 
composed of collagen with smaller amounts of elastin, laminin and proteoglycans among 
others [350]. Collagen is vital to the maintenance of cardiac architecture [351]. Although 
studies indicate that only 2-4% of the myocardium is collagen, even slight changes in 
collagen concentration can have substantial effects on the mechanical properties of the 
heart [352]. The dominant collagens are type I, accounting anywhere from 50-80%, and 
type III collagen, comprising around 10% of the ECM; the other collagens are present but 
to a much lesser degree [353]. Collagen I is characterized by tensile strength whereas 
collagen III has greater elastic potential and for this reason, ratios between collagen types 
are significant [354]. Collagen may also be involved in the transmission of force generated 
by cardiac muscle and therefore has a substantial impact on the diastolic and systolic 
function of the heart. 
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Increased ventricular stiffness resulting from elevated levels of collagens can inhibit 
myocyte recoil during cardiac relaxation resulting in aberrant ventricular filling and 
consequently stroke volume. Increases in collagen content impair sarcomere extension 
and compromise the heart’s ability to generate adequate pressure for systemic perfusion 
[355]. Taken together, it is clear that fibrosis greatly jeopardizes the heart’s ability to 
function and not surprisingly, fibrosis is a leading cause of heart failure. 
We have shown that myocardial collagen deposition is increased in mouse models of 
Type I diabetes such as the STZ and OVE26 mouse. In these models, cardiac-specific 
capn4 knockout or calpastatin overexpression reduced both collagen deposition and gene 
expression of collagens I and III. Clearly as calpain over-activity is restrained, the amount 
of total collagen accumulation in the hyperglycemic heart is diminished and the relative 
amounts of collagens I and III are brought back to homeostatic levels [349]. In a mouse 
model of myocardial infarction, we similarly demonstrated that cardiac-specific capn4 
knockout attenuated both collagen deposition and gene expression of collagens I and III 
[331].     
Fibrosis is believed to be mediated by fibroblasts [356]. Having established a correlation 
between calpain activity and collagen content in the myocardium, we isolated and 
cultured cardiac fibroblast cells. The study aimed to identify fibroblasts as targets of 
calpain hyperactivity and examine the mechanisms that relate calpain to fibroblast 
stimulation in the diabetic heart [336]. The precise manner in which hyperglycemia 
stimulates increased collagen deposition by fibroblasts in cardiac tissue is not clearly 
understood. Transforming growth factor- beta 1 (TGF-β1) has gained notoriety as a 
potent fibrogenic cytokine [357]. TGF-ß1 is a key regulator of inflammation and wound 
healing; it’s released at wound sites where it recruits neutrophils, monocytes and 
fibroblasts to initiate tissue repair [358]. It also plays a central role in the maintenance of 
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the ECM and can induce the expression of ECM proteins including collagen from 
fibroblasts [359]. But further research into the mechanisms behind fibrosis has 
highlighted its ability to promote excess and unnecessary secretion of collagen from 
fibroblasts. One possibility is that high glucose up-regulates TGF-β1 expression leading 
to increased fibroblast proliferation. TGF-ß1 knockout models show reduced fibrosis in 
ageing hearts while TGF-ß1 overexpression in mice caused interstitial fibrosis [360].  
TGF-β1 has also been demonstrated to induce differentiation of fibroblasts to 
myofibroblasts [360]. Although in their resting state, fibroblasts are considered to be 
sessile they migrate and proliferate upon activation. During the reparative process, tissue 
needs to be contracted and as a result a subpopulation of the fibroblasts will gain 
contractile properties that resemble those belonging to smooth muscle cells and this 
modulation allows the cell, now called a myofibroblast, to secrete greater amounts of 
collagen [361]. Over the course of their development, myofibroblasts irreversibly acquire 
proteins, one of which is alpha-smooth muscle actin (α-SMA), a well-accepted marker of 
myofibroblast differentiation. Calpastatin overexpression imparts an anti-fibrotic 
advantage to the myocardium as our study showed that α-SMA is elevated in the diabetic 
heart but diabetic capn4 knockout hearts showed a significant decrease in α-SMA 
expression [336].       
Maintenance and degradation of the extracellular matrix in the myocardium is regulated 
by MMPs which are regulated in turn by their inhibitors, TIMPs. Modifications in the 
activities of either MMPs or TIMPs have marked effects on the architecture of the ECM 
in the myocardium [362]. In the event of impaired MMP regulation an imbalance in 
collagen synthesis versus collagen degradation leads to the accumulation of fibrillar 
collagen and the appearance of myocardial fibrosis [363]. The diabetic heart has been 
shown to have up-regulated MMP-9 activity [364] and down-regulated MMP-2 activity 
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[83]. In our lab we found an increase in total MMP activity in fibroblasts in vitro and 
diabetic hearts in vivo, calpain inhibition reduced MMP activity in both cases suggesting 
MMP inhibition may protect the diabetic heart against fibrosis [336].  
Further, in angiotensin-II induced cardiac remodelling, Letavernier and colleagues 
demonstrated using microscopy and immunohistochemical analysis of collagen type I 
that fibrosis can be reduced around the aorta and tissue arteries by inhibiting calpain 
[365]. An accompanying decrease in MMP activity was also observed suggesting that 
stimulation by calpain is not limited only to the fibroblast, whether directly or indirectly 
through fibrogenic factors, but also to the remodelling machinery in the ECM.  
1.4.1.4 Calpain and cardiac inflammation 
Inflammation occurs frequently in the heart under stress [366]. After an initial injury of 
the myocardium, the endogenous stress protein levels are up-regulated, such as HSP10 
(heat shock protein 10), HSP60, and HSP70. These stress proteins, known as ‘alarmins’, 
are ligands for toll like receptors (TLRs) which are expressed on the surface of 
inflammatory/ immune cells and cardiac cells. Binding of HSPs to TLRs induces the 
expression of pro-inflammatory factors including cell adhesion molecules, chemokines, 
and chemokine receptors, promoting both the recruitment and the activation of a series of 
inflammatory cells, such as neutrophils and monocytes. These cells release cytotoxic 
substance, inducing damage to endothelial cells and cardiomyocytes, which in turn, 
amplify alarmin expression [367]. The expression of proinflammatory factors are 
regulated by various transcriptional factors with NF- κB being the most important. At rest 
state, iκB binds and inhibits NF-κB in cytosol. Upon activation, iκB is degraded and 
NF-κB translocated into nucleus for activation [368]. Calpain has been shown to target 
and cleave iκB and thus, promotes NF-κB activation in inducing the expression of 
proinflammatory factors and inflammation [369]. Using calpastatin transgenic mouse 
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model, our lab demonstrated that inhibition of calpain by calpastatin over-expression or 
pharmacological inhibitor of calpain significantly reduced inflammatory cytokine TNF-α 
expression in cardiomyocytes and hearts [336]. We further reported that cardiac-specific 
knockout capn4 restored the protein levels of IκB, prevented NF-κB activation and 
attenuated TNF-α expression in hearts after myocardial infarction [331]. Clearly, calpain 
activation promotes inflammation in the heart under stress. In addition, in animal mouse 
model of angiotensin II-mediated cardiovascular remodeling, over-expression of 
calpastatin disturbed and delayed the ability to recruit inflammatory cells in mice [365]. 
Similarly, decreased endothelium adhesiveness to circulating leucocytes has been shown 
in angiotensin II infusion model with calpastatin overexpressing or calpain-1 deficiency 
[370]. Thus, calpain is involved in the occurrence of inflammation in cardiovascular 
system under diseased conditions. 
1.4.2 Calpain in cardiac disease 
1.4.2.1 Calpain and ischemia-reperfusion 
Calpain has been implicated in ischemia/ reperfusion (I/R)-induced injury in the heart 
[371]. Activation of calpains induced by Ca2+ overload during IR, leads to the proteolysis 
of the cytoskeletal protein fodrin rendering the membrane fragile [372]. IR increases 
cytosolic calpains activities leading to cardiac injury by cleaving Bid to truncated Bid 
[373], Ca2+ - ATPase [374, 375], Na, K - ATPase [376] and troponin T [372].  
Pharmacological inhibitors of calpain decreased myocardial infarction size in I/R models 
and attenuated the progression of heart failure after MI [330]. The protective effects of 
calpain inhibitors were then confirmed by over-expression of calpastatin in global whole 
I/R model and a mouse model of ischemia/reperfusion injury [324, 329]. In addition, 
cardiac-specific capn4 knockout reduced myocardial infarct size and remodeling, and 
improved myocardial dysfunction in a mouse model of myocardial infarction [331]. 
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These promising findings suggest that calpain may be a therapeutic target to limit 
myocardial ischemia/reperfusion injury. However, further investigation is warranted to 
understand the underlying mechanisms. 
1.4.2.2 Calpain and diabetic cardiomyopathy 
Diabetic cardiomyopathy is a serious clinical condition. It is a tremendous personal 
struggle for Canadians and a significant financial burden for our health care system [4]. 
However, the mechanisms by which this occurs remain incompletely understood and no 
cure is available for this disease. In recent years, our lab has been investigating calpain 
activation in diabetic cardiomyopathy. In cultured cardiomyocytes, our lab reported that 
incubation with high glucose or high palmitate increased calpain activation and inhibition 
of calpain with pharmacological inhibitor, siRNAs or over-expression of calpastatin 
prevented high glucose or palmitate-induced apoptosis [91, 377]. Further studies showed 
that selective silencing of calpain-1 but not calpain-2 prevented high glucose or 
palmitate-induced apoptosis in cardiomyocytes [91, 377]. In mouse models of 
STZ-induced and genetic type-1 diabetes, our lab reported that transgenic 
over-expression of calpastatin or cardiac-specific capn4 knockout attenuated cardiac 
apoptosis, hypertrophy and fibrosis, which are associated with an improvement of 
myocardial function [336]. These findings provide strong evidence in support of the role 
of calpain in type-1 diabetes-related cardiomyopathy. In db/db mice, calpain activity was 
increased in the heart and correlated with myocardial remodeling and dysfunction, which 
were attenuated by over-expression of calpastatin [378]. This data underlies a role of 
calpain in type-2 diabetes-related cardiomyopathy. More recently, our lab demonstrated 
that cardiac-specific capn4 knockout prevented cardiac apoptosis, reduced hypertrophy 
and fibrosis, and improved myocardial function in mice fed a high fatty diet, a model of 
pre-diabetes with impairment of glucose tolerance and insulin resistance [377]. This 
provides further evidence to support the role of calpain in type-2 related cardiomyopathy. 
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Mechanistically, our lab showed that calpain might induce ER stress and subsequent 
apoptosis in diabetic cardiomyopathy [377]. Taken together, calpain may represent a new 
therapeutic target for diabetic cardiac complications. 
1.4.2.3 Calpain and septic cardiomyopathy 
As described above, both caspase-3 activation and apoptosis are important in the 
development of myocardial dysfunction during sepsis [158-160, 162, 164, 165]. Studies 
have suggested that calpain is an important player in cell death signaling. Partial cleavage 
of pro- or anti-apoptotic proteins by calpain might activate or inactivate, respectively, 
putative substrates including caspase-3, caspase-7, -8, and -9 [158, 159], caspase-12 
[317], Bcl-2 [318], Bcl-xl [318], Bid [373], Bax [379], and inhibitor of NF-κB [344]. Our 
lab reported that calpain was activated in cardiomyocytes and hearts under septic 
conditions. Inhibition of calpain by its pharmacological inhibitors or over-expression of 
calpastatin protected cardiomyocytes against sepsis-induced apoptosis both in vitro and in 
vivo, which was associated with improved myocardial dysfunction. Silencing of 
individual calpain isoforms revealed that calpain-1 but not calpain-2 contributed to 
sepsis-related apoptosis in cardiomyocytes [320]. Furthermore, a recent study showed 
that calpain inhibition might be associated with activation of Akt/ GSK-3β (glycogen 
synthase kinase-3 beta) signaling in preventing cardiac apoptosis during sepsis [380]. 
Meanwhile, calpain activation was associated with NF-κB activation via degradation of 
IκB, leading to expression of pro-inflammatory mediates, which in turn elicited 
myocardial depression in sepsis [381]. Thus, transgenic over-expression of calpastatin or 
cardiac-specific capn4 knockout inhibited calpain activation and prevented 
pro-inflammatory cytokine expression in septic hearts. 
1.5 Mitochondrial calpain and cardiac disease 
Although calpains have been considered cytoplasmic enzymes [280, 382], studies have 
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demonstrated that calpain-1, calpain-2 and calpain-10 are also present in mitochondria 
[285, 314, 383-390]. Further studies reveal that calpain-1 has a mitochondrial targeted 
signal peptide which induces its translocation to mitochondria [391]. A previous study 
showed that homocysteine (Hcy) induced the translocation of active calpain from cytosol 
to mitochondria, leading to matrix MMP-9 activation in cultured rat heart microvascular 
endothelial cells [392]. In isolated hearts, Chen Q et al showed that a global 
ischemia/reperfusion induced calpain-1 activation within mitochondrial intermembrane 
space, leading to the cleavage of apoptosis-inducing factor (AIF) and subsequent 
apoptosis [313]. Using the same model, Chen Q et al further demonstrated that global 
ischemia/reperfusion increased calpain activation in mitochondrial matrix and disrupted 
complex-I activity [393]. The increased calpain-2 activity in mitochondrial matrix was 
also reported in a rat model of ischemia/reperfusion injury by a different lab and 
contributed to disruption of complex-I activity [394]. These studies suggest that 
increased mitochondrial calpain activity may be implicated in ischemic heart disease. In 
fact, several key mitochondrial proteins have been suggested to be substrates of calpain 
including AIF [313, 314, 383, 395], optic atrophy-1 (Opa-1) [396], Na+/Ca2+ exchanger 
[397] and ATP synthase-α [398], etc. Proteolysis of these proteins will compromise 
mitochondrial function and subsequent cardiac injuries following ischemia/reperfusion. 
However, it remains to be determined whether mitochondrial calpain is also increased in 
other pathological conditions. Given that mitochondria are major source of ROS in 
cardiomyocytes, mitochondrial dysfunction elicits ROS generation which may induce cell 
death and also serve as a signaling molecule promoting cardiac hypertrophy, fibrosis and 
inflammation, all of which contribute to cardiac disease and heart failure. Thus, it is 
highly possible that increased mitochondrial calpain induces ROS generation and cardiac 
disease under pathological conditions. 
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1.6 Rationales 
CVD are arguably the number-one health problem in the world. Constant prevalence of 
CVD and its high morbidity and mortality indicate that there are huge gaps in 
understanding of the underlying mechanisms and that better therapy strategies are 
urgently needed to control CVD and its clinical manifestations. Amongst various 
proposed mechanisms, oxidative damage induced by ROS has been critical in this 
disease. As a major source of ROS in cardiomyocyte, mitochondria are important players 
in pathogenesis of cardiac disease, while it has been increasingly recognized that calpain 
activation contributes to cardiac disease [399]. However, it has never been reported 
whether calpain activation can modulate mitochondrial ROS generation in cardiac 
disease. A previous study showed that mitochondrial calpains are increased in isolated 
hearts following global ischemia/reperfusion, leading to apoptosis via cleavage and 
release of AIF [313]. However, it remains unknown whether increased mitochondrial 
calpain is a common mechanism contributing to cardiac disease and if yes, how 
mitochondrial calpain mediates cardiac disease. Since both diabetes and inflammation are 
critically important factors in promoting cardiac disease, in this thesis, I used diabetic 
cardiomyopathy and septic cardiomyopathy as disease models to address the above 
questions.  
1.7 Hypotheses 
In this work, the following four hypotheses were investigated: 
1. Calpain is increased in mitochondria in cardiomyocytes under diabetic and septic 
conditions;  
2. Increased mitochondrial calpain contributes to mitochondrial ROS generation in 
cardiomyocytes under diabetic and septic conditions;  
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3. Increased mitochondrial calpain disrupts ATP synthase via cleavage of ATP5A1 
leading to excessive mitochondrial ROS generation in cardiomyocytes under 
diabetic and septic conditions; 
4. Administration of mitochondrial-targeted antioxidant reduces diabetic adverse 
cardiac changes and improves myocardial function in diabetes.  
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Chapter 2 
2 Deletion of capn4 protects the heart against 
endotoxemic injury by preventing ATP synthase 
disruption and inhibiting mitochondrial superoxide 
generation2 
 
 
 
 
 
 
 
 
 
 
 
                               
2 This chapter has been published in the following manuscript: 
 Ni R, Zheng D, Wang Q, Yu Y, Chen R, Sun T, Wang W, Fan GC, Greer PA, Gardiner RB, 
and Peng T. (2015) Deletion of capn4 Protects the Heart Against Endotoxemic Injury by 
Preventing ATP Synthase Disruption and Inhibiting Mitochondrial Superoxide Generation, 
Circ Heart Fail 8, 988-996. 
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2.1 Introduction  
Sepsis is the leading cause of death among the critically ill [1]. Among the general 
population, sepsis accounts for 215, 000 deaths per year [2], making it the 10th most 
common cause of death in the United States [3]. Myocardial dysfunction is a key 
manifestation contributing to morbidity and mortality among septic patients in intensive 
care units [4], and 40-50% of patients with prolonged septic shock develop myocardial 
depression [5]. Estimates of mortality due to sepsis range from 20-30% [6, 7], however, 
mortality increases to 70-90% when there is accompanying myocardial dysfunction [7]. 
Thus, myocardial dysfunction is a decisive factor in determining survival or death in 
sepsis. Lipopolysaccharides (LPS) of gram-negative bacteria are important pathogens 
responsible for myocardial dysfunction during sepsis [8, 9]. LPS-induced 
pro-inflammatory cytokines, in particular, tumour necrosis factor-alpha (TNF-α), play a 
critical role in myocardial dysfunction in animal models of sepsis [8, 10, 11]. However, 
the mechanisms underlying LPS-induced pro-inflammatory response in septic hearts 
remain not fully understood and no cure is available to correct this life-threatening 
condition. 
Calpains belong to a family of calcium-dependent thiol-proteases [12, 13]. Fifteen gene 
products of the calpain family are reported in mammals. Among them, calpain-1 and 
calpain-2 are ubiquitously expressed, while other calpain family members have more 
limited tissue distribution. Both calpain-1 and calpain-2 are heterodimers. They consist of 
distinct large 80-kDa catalytic subunits encoded by capn1 and capn2, respectively, and a 
common small 28-kDa regulatory subunit encoded by capn4. The regulatory subunit is 
indispensable for calpain-1 and calpain-2 activities. These two calpain isoforms are 
regulated by the endogenous calpain inhibitor, calpastatin. Our recent study demonstrated 
that over-expression of calpastatin reduced cardiac TNF-α expression and attenuated 
91 
myocardial dysfunction in calpastatin transgenic mice (Tg-CAST) in response to LPS 
[14]. However, the underlying mechanisms by which calpain participates in the 
regulation of pro-inflammatory response remain to be defined. Moreover, tissue-specific 
gene deletion of calpain is generally considered to be more conclusive to clarify the 
contribution of cardiac calpain since inhibition of systemic inflammation could not be 
excluded to confer cardiac protection in endotoxemia in Tg-CAST mice. 
Although calpain-1 and calpain-2 have been considered mainly cytoplasmic enzymes, 
recent studies have found that they are also present in mitochondria [15, 16]. 
Mitochondrial calpains have been shown to play important roles in pathophysiological 
conditions [16]. However, it has never been shown whether calpains are altered in 
mitochondria and whether mitochondrial calpains contribute to pro-inflammatory 
response in septic hearts. Activation of mitochondrial calpains may be involved in 
mitochondrial dysfunction because several mitochondrial proteins have been suggested to 
be potential substrates of calpain, including, but not limited to, ATP5A1 [17], optic 
atrophy-1 (Opa-1) [18], apoptosis-inducing factor [19], and Na+/Ca2+ exchanger-1 
(NCX-1) [20]. Proteolysis of these mitochondrial proteins will compromise 
mitochondrial function and may lead to excessive ROS generation. Thus, calpain may 
regulate mitochondrial ROS production. Our recent study has demonstrated that LPS 
increases mitochondrial ROS and selectively blocking mitochondrial ROS inhibits TNF-α 
expression in cardiomyocytes [21]. Taken together, these studies raise an intriguing 
hypothesis that calpain activation may induce excessive mitochondrial ROS generation, 
leading to cardiac pro-inflammatory response and myocardial dysfunction in sepsis. 
In the present study, we employed cardiomyocyte-specific capn4 knockout mice to 
investigate whether and how calpain activation disrupts ATP synthase and induces 
mitochondrial ROS generation in cultured cardiomyocytes and hearts during LPS 
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stimulation. 
2.2 Methods 
2.2.1 Animals 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). 
All experimental procedures were approved by the Animal Use Subcommittee at the 
University of Western Ontario, Canada. Breeding pairs of C57BL/6 mice were purchased 
from the Jackson Laboratory. Tg-CAST mice were generously provided by Dr. Laurent 
Baud (the Institut National de la Santé et de la Recherche Médicale, Paris, France) 
through the European Mouse Mutant Archive [22]. Mice with cardiomyocyte-specific 
disruption of capn4 (capn4-ko) were generated as described previously [23]. All of the 
mice used in this study, including controls, were littermates of the same generation. Adult 
male mice (aged 2 months, 8-15 mice in each group) were injected with LPS (4 mg/kg, 
i.p.) or saline as a control. 
2.2.2 Echocardiography  
Animals were lightly anaesthetized with inhalant isoflurane (1%) and imaged using a 
40-MHz linear array transducer attached to a preclinical ultrasound system (Vevo 2100, 
Visual Sonics, Canada) with nominal in-plane spatial resolution of 40 μm (axial)  80 μm 
(lateral). M-mode and 2-D parasternal short-axis scans (133 frames/second) at the level 
of the papillary muscles were used to assess changes in left ventricle (LV) end-systolic 
inner diameter (LVIDs), LV end-diastolic inner diameter (LVIDd), LV posterior wall 
thickness in end-diastole (LVPW;d) and end-systole (LVPW;s), and fractional shortening 
(FS%). LV end-systolic volume (LV Vol;s) and end-diastolic volume (LV Vol;d) were 
acquired by 7/(2.4+LVIDs) × LVIDs3 and 7/(2.4+LVIDd) × LVIDd3 , respectively. 
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2.2.3 Delivery of recombinant adenovirus into mice  
Mice were anaesthetized with inhaled isofluorane (1%). With the guide of 
echocardiography, adenovirus containing human ATP5A1 gene (Ad-ATP5A1, 2×109 PFU 
in 100 μL, SignaGen Laboratories) or containing GFP (Ad-GFP, SignaGen Laboratories) 
was injected into mouse left ventricle. 
2.2.4 Isolation and culture of adult mouse cardiomyocytes  
Adult mouse ventricle cardiomyocytes were isolated from Tg-CAST and wild-type mice 
(C57BL/6), and cultured as described in our recent study [24]. 
2.2.5 Adenoviral infection of cardiomyocytes  
Cardiomyocytes were infected with Ad-ATP5A1, adenoviral vector containing 
mitochondria-targeted rat calpastatin (Ad-mtCAST, SignaGen Laboratories), or beta-gal 
(Ad-gal, Vector Biolabs) as a control at a multiplicity of infection of 100 PFU/cell as we 
previously described [25]. 
2.2.6 Measurement of mitochondrial superoxide generation  
Superoxide flashes in single mitochondrion were measured to determine mitochondrial 
superoxide generation in living cardiomyocytes as described previously [26]. Briefly, 
cardiomyocytes were infected with an adenoviral vector expressing mt-cpYFP 
(Ad-mt-cpYFP). Ad-mt-cpYFP expresses a circularly permuted yellow fluorescent 
protein (cpYFP) in the mitochondrial matrix of cells using the cytochrome C oxidase 
subunit IV targeting sequence (mt-cpYFP). Twenty-four hours after infection, confocal 
imaging was recorded using the Olympus FV 1000 laser-scanning microscope equipped 
with a 63x, 1.3NA oil immersion objective and a sampling rate of 0.7s/frame. 
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2.2.7 Construction of plasmid with mitochondrial targeted capn1 
expression and transfection in cardiomyocyte-like H9c2 Cells  
The full coding region of human capn1 cNDA was recovered from pCMV6-XL5 
containing human capn1 (Origene) and inserted into pCMV/myc/mito following 
mitochondrial signal peptide (Life Technologies Inc.). The resulting plasmid 
pCMV/myc/mito-capn1 expresses myc-tagged capn1 selectively in mitochondria. 
Rat cardiomyocyte-like H9c2 cells were cultured and transfected with 
pCMV/myc/mito-capn1 or pCMV/myc/mito as a control using the jetPRIMETM DNA 
transfection reagent (VWR International) according to the manufacturer’s instructions. 
2.2.8 Calpain activity  
Calpain activity was determined by using a fluorescence substrate 
N-succinyl-LLVY-AMC (Cedarlane Laboratories) as previously described [14]. 
2.2.9 Real-time reverse-transcriptase polymerase chain reaction 
(RT-PCR)  
Total RNA was extracted from heart tissues using the Trizol Reagent (Life Technologies 
Inc.) following the manufacturer's instruction. Real-time RT-PCR was performed to 
analyze mRNA expression for TNF-α, ATP5A1 and GAPDH as described previously 
[27]. 
2.2.10 Western blot analysis  
The protein levels of calpain-1, calpain-2, mitochondrial voltage-dependent anion 
channel (VDAC1), cytochrome c, cyclophidin D, complex Va, ATP synthase-alpha 
(ATP5A1) and beta subunits, Opa-1, calreticulin, and GAPDH were determined by 
western blot analysis using respective specific antibodies (Cell Signaling and Santa Cruz 
Biotechnology). 
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2.2.11 Measurement of ROS generation in isolated mitochondria  
Interfibrillar Mitochondria were isolated from the freshly harvested heart as described 
previously [28], with minor modifications as follows. Instead of Nagarse, trypsin (5 mg/g 
wet weight of tissues) was used and after homogenizing and centrifuging, trypsin 
inhibitor (0.5 mg/ml) was added to the supernatant. The isolated mitochondria were 
further purified using Percoll density gradient centrifugation [29]. Mitochondrial ROS 
generation was determined on addition of pyruvate/malate or succinate by using Amplex 
Red and horseradish peroxidase according to the manufacturer’s instruction. 
2.2.12 Immuno-fluorescence staining and confocal microscopy 
Mitochondrial smears were prepared on slides and fixed with freshly prepared 4% 
paraformaldehyde. After incubation with appropriate primary antibodies (calpain-1 and 
VDAC-1) and secondary antibodies conjugated with different fluorescences (Alexa Fluor 
488 Donkey anti-mouse IgG and Alexa Fluor 594 Goat anti-rabbit IgG), signals were 
obtained with an Olympus FluoViewTM FV1000 confocal microscope equipped with the 
IX81 motorized inverted system as described in our recent report [30]. 
2.2.13 Immuno-electron microscopy  
The sections of heart tissues were incubated with primary antibodies against calpain-1 
(Cell Signaling), and then labeled with second antibodies tagging with colloidal gold 
(10nm, Cedarlane Laboratories). Gold particles were identified in mitochondria and 
quantified as the number of gold particles in given mitochondrial areas. 
2.2.14 Co-immunoprecipitation (co-IP) and native gel electrophoresis  
Co-IP and non-denaturing polyacrylamide gel electrophoresis were carried out to analyze 
protein–protein interactions. Briefly, calpain-1 and its interacting proteins were pulled 
down using Immunoprecipitation kit - dynabeads protein G (Life Technologies Inc.), and 
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ATP synthase complex was isolated using ATP synthase immunocapture kit (Abcam Inc.) 
in isolated mitochondria according to the manufacturer’s instructions. Both calpain-1/its 
interacting proteins and ATP synthase complex were subjected to SDS-polyacrylamide 
gel electrophoresis for separation, followed by western blot analysis for ATP5A1 and 
calpain-1 using their specific antibodies, respectively. 
2.2.15 ATP synthase activity  
ATP synthase activity was measured using an assay coupled with pyruvate kinase, which 
converts ADP to ATP and produces pyruvate from phosphoenolpyruvate, as described 
previously [31]. 
2.2.16 Statistical Analysis 
All data were presented as mean ± SD. Statistical comparisons between only two groups 
were done using an unpaired Student’s t-test. For comparisons of more than two groups, 
one-way analysis of variance (ANOVA) or two-way ANOVA was performed as 
appropriate. Post hoc comparisons were performed using Newman-Keuls or Bonferroni 
comparison analysis in one-way ANOVA or two-way ANOVA, respectively. One-way 
repeated-measures ANOVA was performed for time course and dose response studies on 
mitochondrial superoxide flashes. A value of P < 0.05 was considered statistically 
significant. 
2.3 Results 
2.3.1 Deletion of Capn4 Reduces Pro-Inflammatory Response and 
Attenuates Myocardial Dysfunction in Endotoxemic Mice 
To determine whether cardiomyocyte-specific deletion of capn4 provides beneficial 
effects in septic hearts, we injected capn4-ko and their wild-type mice with LPS or saline. 
As previously reported [14], LPS induced TNF-α expression and decreased myocardial 
97 
function in wild-type mice; however, deficiency of capn4 significantly attenuated TNF-α 
expression and myocardial dysfunction in endotoxemic capn4-ko mice (Figure 2-1A and 
B, and Table 2-1). Thus, cardiomyocyte-specific deletion of capn4 protects the heart 
against LPS-induced injury.  
2.3.2 Genetic Inhibition of Calpain Prevents Mitochondrial 
Superoxide Generation in Hearts and Cultured 
Cardiomyocytes during LPS Stimulation 
Our recent study has shown that mitochondrial ROS contributes to LPS-induced 
pro-inflammatory response in cardiomyocytes [32]. In this study, we examined whether 
there is a link between calpain and mitochondrial ROS generation in endotoxemia. We 
determined ROS generation in isolated mitochondria of mouse hearts at 4 hours after LPS 
stimulation. LPS treatment increased ROS generation in mitochondria using either 
pyruvate/malate or succinate as substrates (Figure 2-1C and D). Capn4 deletion 
significantly reduced ROS generation in mitochondria from LPS-stimulated capn4-ko 
mice (Figure 2-1C and D). However, the anti-oxidant capacity slightly increased in 
response to LPS and there was no difference between wild-type and capn4-ko mice (data 
not shown). These results suggest that calpain induces mitochondrial ROS generation in 
response to LPS and the increase in mitochondrial ROS production is not due to the 
disruption of anti-oxidant defence system.
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Figure 2-1. Mitochondrial ROS generation, TNF-α expression and dysmyocardial 
function in capn4-ko mice and their wild-type littermates  
Mice were injected with LPS or saline (6-7 mice in each group). Four hours later, 
myocardial function was assessed (B) and the mRNA levels of TNF-α measured (A). 
Mitochondrial ROS generation was determined following addition of pyruvate/malate (C) 
or succinate (D) using Amplex Red. Data are mean ± SD, n = 4-7. *P < 0.05 versus saline 
in WT and †P < 0.05 versus LPS in WT. 
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Table 2-1. Myocardial function in Capn4-KO mice during endotoxemia 
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To confirm the role of calpain in mitochondrial ROS generation, we isolated and cultured 
cardiomyocytes from adult Tg-CAST and wild-type mice. Cardiomyocytes were infected 
with Ad-mt-cpYFP [26] and followed by incubation with LPS (0.1-5 μg/ml) or saline for 
up to 4 hours. Although cpYFP is also sensitive to the pH, our recent study showed that 
mt-cpYFP flash events reflect a burst in electron transport chain-dependent superoxide 
production that is coincident with a modest increase in matrix pH in cardiomyocytes [33]. 
Thus, we used cpYFP as a probe to analyze mitochondrial superoxide flashes in 
cardiomyocytes (Figure 2-2A). Mitochondrial superoxide flashes in cardiomyocytes were 
inhibited by mitochondria-targeted superoxide dismutase mimetics, mito-TEMPO (Fig. 
2B). LPS increased mitochondrial superoxide generation in wild-type cardiomyocytes in 
a time- and dose-dependent manner (Figure 2-2C and D). However, the increase in 
mitochondrial superoxide generation by LPS was abrogated in Tg-CAST cardiomyocytes 
(Figure 2-2E). These results demonstrate that calpain is important in mitochondrial 
superoxide generation in cardiomyocytes induced by LPS stimulation. 
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Figure 2-2. Measurement of single mitochondrial superoxide flashes in 
cardiomyocytes  
Adult mouse cardiomyocytes were isolated from Tg-CAST mice and their wild-type (WT) 
littermates. After incubation with LPS or saline for 0-4 hours, mitochondrial superoxide 
generation was determined. (A1-4) Representative pictures for mitochondrial superoxide 
flashes in cardiomyocytes. Individual mitochondria display green color in 
cardiomyocytes. Inside of yellow boxes, the green color increases from 0 to 10 sec and 
decreases after 15 sec, indicating one superoxide flash in one box. (B) Mitochondrial 
superoxide flashes were inhibited by mito-TEMPO in cardiomyocytes. (C) 
Cardiomyocytes were incubated with LPS (1 μg/ml) for up to 240 minutes. Mitochondrial 
superoxide flashes were measured. (D) Cardiomyocytes were incubated with LPS (0, 0.1, 
1 and 5 μg/ml) for 4 hours. Mitochondrial superoxide flashes were quantified. (E) 
Mitochondrial superoxide flashes in WT and Tg-CAST cardiomyocytes. Data are mean ± 
SD from 4-7 different cultures. *P < 0.05 versus 0, saline + WT or saline + vehicle, and 
#P < 0.05 versus LPS + WT or LPS + vehicle. 
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2.3.3 LPS Induces Calpain-1 Accumulation in Mitochondria 
To determine whether calpains were altered in mitochondria of LPS-treated mouse hearts, 
we prepared mitochondrial and cytosolic fractions from sham and LPS-stimulated mouse 
hearts. An intact set of mitochondrial proteins (VDAC1, cytochrome c, cyclophilin D, 
complex Va and ATP5A1) was detected in the mitochondrial fraction, whereas GAPDH 
and calreticulin appeared in cytosolic but not mitochondrial fraction, validating the purity 
and integrity of isolated mitochondria (Figure 2-3A). The protein levels and activities of 
calpain-1 and calpain-2 were significantly elevated in mitochondria from LPS- compared 
with saline-treated hearts (Figure 2-4A-D). LPS also increased calpain activities in 
cytosol of the heart (Figure 2-3B). However, LPS did not change the protein levels of 
calpain-10, an isoform widely recognised as a mitochondrial calpain (data not shown). 
Since our recent study have implicated calpain-1 but not calpain-2 in LPS-induced TNF-α 
expression in cardiomyocytes [14], we focused on investigating calpain-1 for the 
following studies.  
To provide further evidence in support of calpain-1 accumulation in mitochondria, we 
determined calpain-1 and VDAC1 proteins in isolated mitochondria of LPS-treated 
mouse hearts by dual immunofluorescent confocal microscopy. Confocal microscopic 
analysis demonstrated that VDAC1 was detected in mitochondrial membrane (red) and 
calpain-1 was present inside of mitochondria (green), and percentages of 
calpain-1-labelled mitochondria were much greater in LPS-treated versus sham mouse 
hearts (Figure 2-4E). Immune-electron microscopy confirmed the localization of 
calpain-1 in mitochondria (Figure 2-4F and G). Consistently, there were much more 
calpain-1 signals in mitochondria of LPS-treated hearts than those of sham mouse hearts 
whereas calpain-1 signals in cytosol remained comparable between sham and LPS-treated 
hearts (Figure 2-4G and Figure 2-5B). As a negative control for primary antibodies, no 
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signal was observed when calpain-1 antibody was replaced by a negative IgG isotype 
(Figure 2-5A). These results demonstrate that LPS induces calpain-1 accumulation in 
mitochondria of the heart. However, inhibition of calpain activity prevented LPS-induced 
calpain-1 accumulation in mitochondria of mouse hearts (Figure 2-6), suggesting that 
calpain-1 may re-locate to mitochondria after activation in response to LPS. 
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Figure 2-3. (A) Confirmation of isolated mitochondria  
Mitochondria were isolated and purified from heart tissues. Western blot analysis was 
performed to detect a set of mitochondrial proteins, GAPDH and calreticulin in 
mitochondrial (Mt) and cytosolic fractions (Cyt).  
(B) Calpain activities in the cytosol 
The cytosol was isolated from heart tissues of sham and LPS-injected mice and calpain 
activities were measured. Data are mean ± SD, n = 5. *P<0.05. 
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Figure 2-4. Calpain accumulation in mitochondria 
Mitochondrial fractions were prepared from mice treated with saline or LPS (6 mice in 
each group). (A) A representative western blot for calpain-1, calpain-2, and VDAC1 in 
mitochondrial fraction from 2 out of 6 different hearts in each group. (B)  Quantification 
of capn1/VDAC1 in mitochondria. (C) Quantification of capn2/VDAC1. (D) Calpain 
activity in mitochondrial fraction. Data are mean ± SD, n = 6. *P < 0.05 versus saline. (E) 
Mitochondria were isolated from sham and LPS-treated mice. Dual immunofluorescent 
staining for VDAC1 and calpain-1 was performed in isolated mitochondria. 
Representative microphotographs of confocal microscopy for VDAC1 and calpain-1 
shows membrane staining of VDAC1 in mitochondria (Red) and that calpain-1 is located 
in mitochondria (Green). (F) Representative microphotographs of immune-electron 
microscopy for calpain-1 in mitochondria (black dots). (G) Quantification of calpain-1 
signals in mitochondria and cytosol. Data are mean ± SD from 3 different heart tissues in 
each group. *P < 0.05 versus saline + mitochondria. 
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Figure 2-5. (A) Specificity of capn1 staining by immune-electron microscopy  
Representative microphotographs of immune-electron microscopy for capn1 (black dots).  
(B) Relative distribution of capn1 signals in mitochondria versus cytosol  
Data are mean ± SD, n = 3 hearts in each group. * p < 0.05 vs mitochondria in Sham.
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Figure 2-6. The protein levels of capn1 in mitochondria 
Mice were injected with LPS or saline in combination with calpain inhibitor-III (CI-III) 
or vehicle. Four hours later, mitochondria were isolated from the heart and the protein 
levels of capn1 and VDAC1 were determined by western blot analysis. The 
representative western blot for capn1 and VDAC1 in mitochondria from 2 out of 6 
different hearts in each group is shown. 
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2.3.4 Targeted Over-expression of Calpastatin in Mitochondria 
Inhibits Superoxide Generation in Cardiomyocytes during LPS 
Stimulation  
To investigate the role of mitochondrial calpain, we infected cultured cardiomyocytes 
with adenoviral vector containing mitochondria-targeted calpastatin (Ad-mtCAST) and 
then incubated them with LPS for 4 hours. Selective over-expression of calpastatin in 
mitochondria prevented mitochondrial superoxide flashes induced by LPS (Figure 2-7). 
This result describes a crucial role of mitochondrial calpain in superoxide generation in 
cardiomyocytes during LPS stimulation.  
2.3.5 Up-regulation of Calpain-1 Selectively in Mitochondria Induces 
Superoxide Generation and Pro-inflammatory Response in 
Cardiomyocytes 
To provide direct evidence to support our hypothesis that the accumulation of calpain-1 in 
mitochondria contributes to superoxide generation and subsequent pro-inflammatory 
response, we transfected cardiomyocyte-like H9c2 cells with pCMV/myc/mito-capn1, a 
plasmid expressing mitochondrial targeted capn1. Twenty-four hours later, mitochondrial 
and cytosolic fractions were isolated from cardiomyocyte-like H9c2 cells. 
Over-expressed capn1 was confirmed as myc-tagged protein in mitochondrial but not in 
cytosolic fractions (Figure 2-8). Intriguingly, over-expression of capn1 restricted to 
mitochondria significantly increased mitochondrial superoxide generation and induced 
TNF-α expression in cardiomyocyte-like H9c2 cells, both of which were inhibited by 
mito-TEMPO (Figure 2-9A and B). These results strongly implicate mitochondrial 
calpain-1 in ROS production and pro-inflammatory response.  
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Figure 2-7. Effects of mitochondria-targeted calpastatin over-expression on 
mitochondrial superoxide flashes and ATP synthase activity in LPS-stimulated 
cardiomyocytes 
(A)  A representative western blot confirms myc-tagged CAST is expressed selectively 
in mitochondria of H9c2 cells after infection with adenoviral vector containing 
mitochondria-targeted calpastatin (Ad-mtCAST) or Ad-gal as a control. (B and C) After 
infection with Ad-mtCAST, adult cardiomyocytes were exposed to LPS or saline for 4 
hours, mitochondrial superoxide generation (B) and ATP synthase activity (C) were 
determined. Data are mean ± SD from 6 different cultures. *P < 0.05 versus saline + 
Ad-gal, and # P < 0.05 versus LPS + Ad-gal. 
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Figure 2-8. Plasmid expressing mitochondria-targeted capn1 
(A) Schematic map of the plasmid expressing mitochondrial targeted capn1 
(pCMV/myc/mito-capn1). (B) H9c2 cells were transfected with pCMV/myc/mito-capn1 
or an empty plasmid (pCMV/myc/mito) as a control. Twenty-four hours later, 
mitochondrial and cytosolic fractions were prepared, and myc, GAPDH and VDAC1 
were detected by western blot analysis. A representative western blot confirms 
myc-tagged calpain-1 is expressed selectively in mitochondria.  
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Figure 2-9. Effects of mitochondrial targeted capn1 on superoxide generation and 
TNF-α expression in H9c2 cells 
After transfection with pCMV/myc/mito-capn1, H9c2 cells were incubated with 
mito-TEMPO or vehicle for 24 hours. (A) Mitochondrial superoxide flashes were 
assessed. (B) TNF-α mRNA was analyzed. Data are mean ± SD from 4-6 different 
cultures. *P < 0.05 versus pCMV/myc/mito + vehicle, and #P < 0.05 versus 
pCMV/myc/mito-capn1 + vehicle. 
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2.3.6 ATP5A1 Is a Direct Target of Calpain-1 in Mitochondria in 
Response to LPS 
To explore the potential targets of calpain-1 in mitochondria, we pulled down the 
calpain-1 and its interacting proteins from isolated mitochondria of LPS-treated mouse 
hearts. Western blot analyses for a number of mitochondrial proteins (VDAC1, 
cytochrome c, cyclophidin D, NCX1, ATP5A1, ATP synthase-β and Opa-1) revealed that 
only ATP5A1 was pulled down with calpain-1 (Figure 2-10A1). Likewise, calpain-1 was 
detected in immune-captured ATP synthase complex (Figure 2-10A2). These results 
demonstrate a physical interaction between calpain-1 and ATP5A1 in mitochondria. 
Furthermore, ATP5A1 is a direct substrate of calpain-1 since co-incubation of active 
calpain-1 with recombinant ATP5A1 protein in vitro resulted in multiple cleavages of 
ATP5A1 (Figure 2-11).   
We therefore reasoned that calpain-1 cleaved ATP5A1 and disrupted ATP synthase 
activity in mitochondria of LPS-treated mouse hearts. Accordingly, LPS reduced ATP 
synthase activity in mitochondria, which is consistent with previous reports [34, 35]. 
However, the reduction in ATP synthase activity was prevented by capn4 deletion (Figure 
2-10B). In line with the reduction of ATP synthase activity, the protein levels of 
ATP5A1were markedly decreased in mitochondria from LPS-treated wild-type hearts 
(Figure 2-10C) and restored in capn4-ko mice after LPS stimulation (Figure 2-10D). 
However, the mRNA levels of ATP5A1 remained comparable among those groups (data 
not shown). In cultured cardiomyocytes, selective over-expression of calpastatin in 
mitochondria by infection with Ad-mtCAST significantly attenuated LPS-induced 
reduction in ATP synthase activity (Figure 2-7C).  
115 
 
116 
 
 
 
 
Figure 2-10. Role of calpain in ATP5A1 expression and ATP synthase disruption in 
endotoxemic mouse hearts 
(A1) A representative western blot shows that ATP5A1 is detected in calpain1 interacting 
proteins. (A2) A representative western blot shows that calpain-1 is detected in captured 
ATP synthase complex. (B-D) Myocardial mitochondria were isolated from capn4-ko and 
their wild-type (WT) mice treated with saline or LPS. (B) ATP synthase activity was 
measured in mitochondria. (C and D) The upper panels are the representative western 
blot for ATP5A1 protein from 2 out of 4 hearts in each group and the lower panels are the 
quantification of ATP5A1 protein relative to VDAC1 in mitochondria. Data are means ± 
SD, n = 4-6. *P < 0.05 versus saline, saline + WT or LPS+WT and #P < 0.05 versus LPS 
+ WT.  
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Figure 2-11. Calpain-1 dependent cleavages of ATP5A1  
Recombinant protein ATP5A1 was incubated with active calpain-1 in a reaction buffer 
containing 50 μmol/L of Ca2+ at room temperature for 15 minutes. A representative 
SDS-PAGE gel after coomassie blue staining shows ATP5A1 protein and its multiple 
cleaved fragments. 
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2.3.7 Over-expression of ATP5A1 Reduces Mitochondrial 
Superoxide Generation and TNF-α Expression and Attenuates 
Myocardial Dysfunction in Endotoxemic Mice  
To investigate whether up-regulation of ATP5A1 provides cardiac protection, we 
delivered Ad-ATP5A1 into mice. Ad-GFP served as a control. Forty-eight hours later, 
mice received LPS (4 mg/kg, i.p.) or saline. Four hours later, delivery of Ad-ATP51 
significantly increased ATP5A1 protein in both sham and LPS-treated hearts (Figure 
2-12A and B) and ATP synthase activity in LPS-treated hearts (Figure 2-12C), suggesting 
that ectopic expression of ATP5A1 integrates into the complex of ATP synthase. 
Up-regulation of ATP5A1 reduced mitochondrial ROS generation (Figure 2-12D) and 
TNF-α expression in mouse hearts after LPS stimulation (Figure 2-12E), and improved 
myocardial function in endotoxemic mice (Figure 2-12F and Table 2-2). 
In cultured cardiomyocytes, incubation with ATP synthase inhibitor oligomycin A 
increased mitochondrial superoxide flash generation (Figure 2-13). To provide direct 
evidence to support the role of ATP5A1, we infected cardiomyocytes with Ad-ATP5A1 or 
Ad-gal as a control, and then incubated them with LPS for 4 hours. Up-regulation of 
ATP5A1 increased ATP synthase activity (Figure 2-14A) and reduced mitochondrial 
superoxide generation induced by LPS (Figure 2-14B). Similarly, infection with 
Ad-ATP5A1 attenuated mitochondrial superoxide generation and TNF-α expression 
induced by mitochondrial-targeted calpain-1 in cardiomyocytes (Figure 2-14C and D). 
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Figure 2-12. Effects of ATP5A1 over-expression in endotoxemic mouse hearts  
Adult mice were injected with Ad-ATP5A1 or Ad-GFP and then treated with LPS. Four 
hours later, mitochondria were isolated. (A) A representative western blot from 2 out of 
4-6 different hearts for ATP5A1 and VDAC1. (B) Quantification of ATP5A1/VDAC1 
protein ratio. (C) ATP synthase activity. (D) Mitochondrial ROS generation was assessed 
following addition of succinate. (E) TNF-α mRNA was analyzed in heart tissues by 
real-time RT-PCR. (F) Myocardial function was assessed by echocardiography. Data are 
means ± SD, n = 4-7. *P < 0.05 versus saline+Ad-GFP, and #P < 0.05 versus 
LPS+Ad-GFP.
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Table 2-2. Effect of Ad-ATP5A1 on myocardial function in endotoxemic mice 
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Figure 2-13. Effect of oligomycin A on mitochondrial superoxide flashes in adult 
cardiomyocytes 
Adult mouse cardiomyocytes were incubated with oligomycin A in the presence or 
absence of mito-TEMPPO. At different time points after addition of oligomycin A, 
mitochondrial superoxide flashes were determined. Data are MEAN ± SD from 3 
different cultures. *P < 0.05 versus control and # P < 0.05 versus control, oligomycin 30 
min, or 20 min. 
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Figure 2-14. Role of ATP5A1 in mitochondrial superoxide generation and TNF-α 
expression  
(A and B) Adult mouse cardiomyocytes were infected with Ad-ATP5A1 or Ad-gal. 
Twenty-four hours later, the cells were incubated with LPS or saline for 4 hours. 
Mitochondrial superoxide generation (A) and ATP synthase activity (B) were determined. 
(C and D) After transfection with pCMV/myc/mito-capn1, H9c2 cells were infected with 
Ad-ATP5A1 or Ad-gal for 24 hours. Mitochondrial superoxide flashes (C) and TNF-α 
mRNA (D) were analyzed. Data are mean ± SD from 4-6 different experiments. *P < 
0.05 versus Ad-gal + saline or Ad-gal + pCMV/myc/mito, and #P < 0.05 versus Ad-gal + 
LPS or pCMV/myc/mito-capn1 + Ad-gal. 
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2.4 Discussion 
In this study, we demonstrate that LPS treatment increases calpain-1/-2 in mitochondria and the 
accumulation of calpain in mitochondria correlates with mitochondrial ROS generation in the 
heart. Deletion of capn4 reduces mitochondrial ROS production in cardiomyocytes and the hearts 
in response to LPS. Selective up-regulation of calpain-1 in mitochondria sufficiently induces 
superoxide generation and TNF-α expression in cardiomyocytes. Furthermore, calpain-1 in 
mitochondria disrupts ATP synthase through proteolysis of ATP5A1 in response to LPS 
stimulation. Up-regulation of ATP5A1 inhibits mitochondrial superoxide generation in 
cardiomyocytes, and attenuates TNF-α expression, leading to the improvement of myocardial 
function in endotoxemic mice. To our knowledge, this is the first study demonstrating a novel role 
of calpain-1 in disrupting ATP synthase and promoting mitochondrial superoxide generation in 
endotoxemic hearts. 
In a rat model of endotoxemia, the role of calpain in myocardial dysfunction was suggested by 
using pharmacological inhibitors of calpain [36]. Further evidence came from our demonstration 
that over-expression of calpastatin attenuated myocardial dysfunction in Tg-CAST mice during 
LPS stimulation [14]. In the present study using tissue-specific capn4 knockout mice, we show 
that deletion of capn4 decreases myocardial TNF-α expression, reduces mitochondrial ROS 
production and attenuates myocardial dysfunction in endotoxemic mice. These findings verify the 
view that cardiac calpain plays a direct role in myocardial dysfunction in sepsis and may 
represent an important therapeutic target for sepsis. 
Calpains have been shown to relocate to the membrane and nucleus in the heart under 
stress [37, 38]. They are also present in mitochondria [16, 39, 40]. A recent study has 
demonstrated that calpain-1 activity is increased in cardiac mitochondria during 
ischemia-reperfusion [41]. In the present study, we demonstrate that LPS induces the 
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accumulation of calpain-1 in mitochondria of the heart. Although it is currently unknown 
whether the accumulation of calpain-1 in mitochondria results from an increase in its 
translocation into mitochondria or a decrease in their degradation in mitochondria, our 
previous study showed that the protein levels of calpain-1 in whole heart lysates were not 
altered after LPS stimulation [14], suggesting that LPS may induce the translocation of 
calpain-1 into mitochondria. It is worthwhile to mention that immune-electron 
microscopic analysis shows no significant change in calpain-1 in cytoplasm upon LPS 
stimulation. Given that interfibrillar mitochondria constitute about 15-20% of cellular 
volume in cardiomyocytes, we believe that a small portion of calpain-1 protein relocates 
to mitochondria while the majority of calpain-1 remains in cytoplasm. Thus, relocation of 
a small portion of calpain-1 may not significantly affect the protein levels of calpain-1 in 
cytoplasm upon LPS stimulation. Furthermore, the re-location of calpain-1 in 
mitochondria is dependent on its activation in response to LPS as inhibition of calpain 
prevents calpain-1 accumulation in mitochondria. Active calpain-1 mitochondrial 
translocation has been also shown in homocysteine-stimulated microvascular endothelial 
cells [42]. A recent study has identified a mitochondrial targeting sequence in the 
N-terminal region of capn1, which provides a molecular basis for calpain-1 
mitochondrial translocation [43]. It is currently unknown what causes the translocation of 
active calpain-1 from cytosol to mitochondria in the setting of septic cardiomyopathy. A 
recent study demonstrated that calpain translocation to sarcolemmal was dependent on 
Ca2+ entry through Na+/Ca2+ exchanger in cardiomyocytes [44]. Given that mitochondrial 
Ca2+ is altered in septic cardiomyocytes [45], it is possible that mitochondrial Na+/Ca2+ 
exchanger may facilitate the translocation of calpain-1 from cytosol to mitochondria in 
cardiomyocytes in response to LPS stimulation, which merits further investigation. 
An important finding of this study is that calpain-1 accumulation in mitochondria 
mediates ROS generation in endotoxemic mouse hearts. Importantly, targeted 
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over-expression of capn1 in mitochondria mimics the effect of LPS on mitochondrial 
superoxide generation in cardiomyocytes. Thus, this study provides a novel mechanism 
that mitochondrial superoxide is induced by calpain-1 in cardiomyocytes during LPS 
stimulation. Given the importance of mitochondrial ROS in cardiac pathophysiological 
processes [46], further investigations are needed to clarify whether mitochondrial 
calpain-1 activation is a common mechanism for mitochondrial superoxide generation in 
other pathological conditions. Mitochondrial ROS induces the damage to mitochondria 
which may promote more ROS production in mitochondria, forming the vicious circle, 
finally leading to mitochondrial dysfunction [47]. Mitochondrial ROS is also an 
important signaling mechanism in mediating gene expression. In this regard, we have 
recently demonstrated that mitochondrial ROS mediates TNF-α expression in cultured 
cardiomyocytes during LPS stimulation [32]. The present study further demonstrates that 
selective over-expression of capn1 in mitochondria induces TNF-α expression in 
cardiomyocytes, which is inhibited by mito-TEMPO, providing direct evidence in support 
of the view that mitochondrial calpain-1 mediates pro-inflammatory response through 
superoxide generation. 
In an effort to explore the mechanisms by which calpain-1 induces superoxide generation 
in mitochondria, we demonstrate that ATP5A1 co-localizes with calpain-1 in LPS-treated 
mouse hearts. We further show that calpain-1 may cleave ATP5A1, substantiating the 
finding from a recent report that ATP5A1 is a potential substrate of calpain [17]. 
Disruption of ATP synthase inhibits ATP production, directly contributing to myocardial 
dysfunction. In septic hearts, ATP synthase activity and ATP production are decreased [34, 
35]. Our observations are consistent with a model whereby calpain-1 accumulation in 
mitochondria compromises ATP synthase in LPS-treated mouse hearts. In fact, we show a 
significant reduction of ATP5A1 protein and of its activity in mitochondria from 
LPS-treated mouse hearts, which are prevented by capn4 deletion. On the other hand, 
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disruption of ATP synthase within complex V results in excess electron “backup” in the 
individual electron transfer complexes [47], in particular complexes I and III, promoting 
mitochondrial superoxide generation. In support of this view, inhibition of ATP synthase 
activity directly increases mitochondrial superoxide generation in cardiomyocytes, and 
up-regulation of ATP5A1 attenuates mitochondrial superoxide generation and TNF-α 
expression in cardiomyocytes induced by LPS and mitochondrial-targeted calpain-1.  
Furthermore, we show that up-regulation of ATP5A1 increases ATP synthase activity, 
reduces mitochondrial ROS generation and TNF-α expression, and attenuates myocardial 
dysfunction in endotoxemic mice. Taken together, our observation argues that calpain-1 
mediates mitochondrial superoxide generation, at least partly by disrupting ATP synthase, 
leading to LPS-induced pro-inflammatory response in the heart. It is worthwhile to 
mention that over-expression of ATP5A1 did not abrogate TNF-α expression in 
cardiomyocytes. This suggests that other targets of calpain-1 in mitochondria may exist in 
regulation of TNF-α expression, which merits further investigation. In fact, a recent study 
demonstrated that calpain also targets and cleaves apoptosis inducing factor in 
mitochondria of the heart [41], leading to ischemia/reperfusion injury. Thus, it is possible 
that calpain-mediated cleavage of apoptosis inducing factor may also contribute to septic 
cardiomyopathy, which needs further investigation for clarification. 
In summary, the present study has provided convincing evidence that calpain activation 
directly contributes to myocardial pro-inflammatory response to LPS by promoting 
mitochondrial calpain-1 translocation and ROS generation. ATP5A1 may represent an 
important target of calpain-1 in mitochondria and its proteolysis disrupts ATP synthase, 
leading to mitochondrial superoxide generation in endotoxemia. Our study suggests that 
calpain and mitochondrial ROS may be potential therapeutic targets for myocardial 
dysfunction in sepsis. 
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Chapter 3 
3 Mitochondrial calpain-1 disrupts ATP synthase and 
induces superoxide generation in type-1 diabetic hearts: 
a novel mechanism contributing to diabetic 
cardiomyopathy3 
 
 
 
 
 
 
 
 
 
 
 
                               
3 This chapter has been published in the following manuscript: 
 Ni R, Zheng D, Xiong S, Hill DJ, Sun T, Gardiner RB, Fan GC, Lu Y, Abel ED, Greer PA, 
and Peng T. (2016) Mitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide 
Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic 
Cardiomyopathy, Diabetes 65, 255-268. 
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3.1  Introduction 
Diabetes is a global metabolic disease and will affect nearly 400 million people by 2030 
[1]. Cardiovascular complications are the most common cause of morbidity and mortality 
in diabetic patients, and approximately 80% of all diabetic patients will die of 
cardiovascular diseases [2, 3]. Both type-1 and type-2 diabetes can directly affect cardiac 
structure and function in the absence of changes in blood pressure and coronary artery 
disease, a condition described as diabetic cardiomyopathy. Diabetic cardiomyopathy may 
present with diastolic dysfunction in the early stages and may subsequently proceed to 
systolic dysfunction [4]. The pathogenesis of diabetic cardiomyopathy is incompletely 
understood and limited treatment options exist.  
Calpains belong to a family of calcium-dependent thiol-proteases [5]. Fifteen gene 
products of the calpain family are reported in mammals. Among them, calpain-1 and 
calpain-2 are ubiquitously expressed and well-studied. Both calpain-1 and calpain-2 
consist of distinct large 80-kDa catalytic subunits encoded by capn1 and capn2, 
respectively, and a common small 28-kDa regulatory subunit encoded by capn4. The 
regulatory subunit is indispensable for calpain-1 and calpain-2 activities. Calpain-1 and 
calpain-2 are regulated by the endogenous calpain inhibitor, calpastatin. We have recently 
reported that genetic inhibition of calpain by over-expression of calpastatin or deletion of 
capn4 prevented cardiomyocyte apoptosis and reduced cardiomyopathic changes in 
mouse models of streptozotocin (STZ)-induced type-1 diabetes [6, 7], highlighting a 
critical role of calpain in diabetic cardiomyopathy. However, the underlying mechanisms 
remain to be determined. 
Although calpain-1 and calpain-2 have been considered as mainly cytoplasmic enzymes, 
they are also present in mitochondria [8, 9]. It was reported that hyperhomocysteinemia 
135 
induced the translocation of active calpain-1 from cytosol to mitochondria, which was 
associated with intra-mitochondrial oxidative stress in cultured rat heart microvascular 
endothelial cells [10], suggesting that calpain may regulate mitochondrial ROS 
generation. This was supported by our recent study, which demonstrated that inhibition of 
calpain prevented mitochondrial ROS generation in endothelial cells upon high glucose 
stimulation [11]. It has been suggested that calpains may target some important proteins 
in mitochondria, including, but not limited to, ATP synthase-alpha (ATP5A1) [12], optic 
atrophy-1 (Opa-1) [13], apoptosis-inducing factor [14], and Na+/Ca2+ exchanger-1 
(NCX-1) [15]. In diabetic hearts, studies have shown that the protein levels of ATP5A1 
are reduced and ATP synthase activity decreases [16, 17]. Disruption of these 
mitochondrial proteins may compromise mitochondrial function, resulting in excessive 
ROS generation. In fact, mitochondrial ROS production is increased in hearts of type-1 
and type-2 diabetic models [17-20]. Although mitochondrial superoxide generation is not 
increased in the heart of some T1D animals [21, 22], selective inhibition of mitochondrial 
ROS reduces cardiomyopathic changes in T1D [23, 24]. These studies raise an intriguing 
hypothesis that calpain activation may lead to excessive mitochondrial ROS generation in 
diabetic hearts, which contributes to diabetic cardiomyopathy. 
In this study, we demonstrate that diabetes induces calpain-1 accumulation in 
mitochondria of the heart. Increased calpain-1 in mitochondria is associated with ATP 
synthase disruption, which stimulates mitochondrial ROS generation and thus, promotes 
diabetic cardiomyopathy in a mouse model of STZ-induced T1D. 
3.2 Research design and methods 
3.2.1 Animals 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). 
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All experimental procedures were approved by the Animal Use Subcommittee at the 
University of Western Ontario, Canada in accordance with the guidelines of the Canadian 
Council for Animal Care. Breeding pairs of C57BL/6 mice and db+/- mice were 
purchased from the Jackson Laboratory (CA, USA). Transgenic mice with 
over-expression of calpastatin (Tg-CAST, C57BL/6 background) were generously 
provided by Dr. Laurent Baud (The Institut National de la Santé et de la Recherche 
Médicale, Paris, France) through the European Mouse Mutant Archive [25]. Mice with 
cardiomyocyte-specific disruption of capn4 (capn4-ko) were generated as described in 
our recent reports [7]. All of the mice used in this study, including controls, were 
littermates of the same generation.  
3.2.2 Experimental protocol 
Type-1 diabetes was induced in adult male mice (2-month old) by consecutive peritoneal 
injection of STZ (50 mg/kg/day) for 5 days [7]. Seventy-two hours after the last injection 
of STZ, whole blood was obtained from the mouse tail-vein and random glucose levels 
were measured using the OneTouch Ultra 2 blood glucose monitoring system (Life Scan, 
Inc. CA, USA). Mice were considered diabetic and used for the study only if they had 
hyperglycemia ( 15 mM) 72 h after STZ injection. Citrate buffer-treated mice were used 
as a non-diabetic control (blood glucose < 12 mM). Two months after induction of 
diabetes, mice (n=8-12 in each group) were subjected to the following experiments.  
3.2.3 Echocardiography 
Animals were lightly anaesthetized with inhalant isoflurane (1%) and imaged using a 
40-MHz linear array transducer attached to a preclinical ultrasound system (Vevo 2100, 
FUJIFILM VisualSonics, Canada) with nominal in-plane spatial resolution of 40 μm 
(axial)  80 μm (lateral). M-mode and 2-D parasternal short-axis scans (133 
frames/second) at the level of the papillary muscles were used to assess changes in left 
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ventricle (LV) end-systolic inner diameter (LVIDs), LV end-diastolic inner diameter 
(LVIDd), and fractional shortening (FS%).  
To assess diastolic function, we obtained apical four-chamber views of the left ventricle. 
The pulsed wave Doppler measurements of maximal early (E) and late (A) transmitral 
velocities in diastole were obtained in the apical view with a cursor at mitral valve inflow. 
3.2.4 Delivery of adenoviral vectors into mice 
Mice were anaesthetized with inhaled isofluorane (1-3%). With the guide of 
echocardiography, adenoviral vectors containing human ATP5A1 gene (Ad-ATP5A1, 
2×109 PFU in 100 μL, SignaGen Laboratories, MD, USA) or GFP (Ad-GFP, SignaGen 
Laboratories, MD, USA) were injected into mouse left ventricle.  
3.2.5 Isolation and culture of adult mouse cardiomyocytes 
Adult mouse ventricle cardiomyocytes were isolated and cultured as previously described 
[26].  
3.2.6 Adenoviral infection of cardiomyocytes 
Cardiomyocytes were infected with Ad-ATP5A1, adenoviral vectors containing 
mitochondria-targeted rat calpastatin (Ad-mtCAST, SignaGen Laboratories, MD, USA), 
or beta-gal (Ad-gal, Vector Biolabs, PA, USA) as a control at a multiplicity of infection of 
100 PFU/cell as previously described [27].  
3.2.7 Measurement of mitochondrial superoxide generation 
Superoxide flashes in single mitochondrion were measured to determine mitochondrial 
superoxide generation in living cardiomyocytes as described previously [28]. Briefly, 
cardiomyocytes were infected with an adenoviral vector expressing mt-cpYFP 
(Ad-mt-cpYFP). Ad-mt-cpYFP expresses a circularly permuted yellow fluorescent 
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protein (cpYFP) in the mitochondrial matrix of cells using the cytochrome C oxidase 
subunit IV targeting sequence (mt-cpYFP). Twenty-four hours after infection, confocal 
imaging was recorded using the Olympus FV 1000 laser-scanning microscope equipped 
with a 63x, 1.3NA oil immersion objective and a sampling rate of 0.7s/frame. At least 20 
cardiomyocytes per culture in each group were analyzed.  
3.2.8 Construction of plasmid with mitochondrial targeted capn1 
expression and transfection in H9c2 Cells 
The full coding region of human capn1 cDNA was recovered from pCMV6-XL5 
containing human capn1 (Origene, Rockville, MD, USA) and inserted into 
pCMV/myc/mito, which introduced the mitochondrial signal peptide (Life Technologies 
Inc. Burlington, Ontario, Canada). The resulting plasmid pCMV/myc/mito-capn1 
expresses myc-tagged capn1 selectively in mitochondria.  
Rat cardiomyocyte-like H9c2 cells were transfected with pCMV/myc/mito-capn1 or 
pCMV/myc/mito as a control using the jetPRIMETM DNA transfection reagent (VWR 
International, Mississauga, Ontario, Canada) according to the manufacturer’s 
instructions.  
3.2.9 Calpain activity 
Calpain activity was determined using a fluorescence substrate N-succinyl-LLVY-AMC 
(Cedarlane Laboratories, Burlington, Ontario, Canada) as previously described [27].  
3.2.10 Real-time reverse-transcriptase polymerase chain reaction 
(RT-PCR)  
Total RNA was extracted from heart tissues using the Trizol Reagent (Life Technologies 
Inc. Burlington, Ontario, Canada) and real-time RT-PCR was performed to analyze 
mRNA expression for ANP, β-MHC and GAPDH as previously described [7].  
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3.2.11 Western blot analysis  
The protein levels of capn1, capn2, calpastatin, mitochondrial voltage-dependent anion 
channel (VDAC1), ATP5A1 and beta subunits, and GAPDH were determined by western 
blot analysis using respective specific antibodies (Cell Signaling, Danvers, MA and Santa 
Cruz Biotechnology, Dallas, Texas).  
3.2.12 Measurement of ros generation in freshly isolated 
mitochondria 
Myocellular mitochondria were isolated from the freshly harvested heart as described 
previously [29], with minor modifications as follows. Instead of Nagarse, trypsin (5 mg/g 
wet weight of tissues) was used and after homogenizing and centrifuging, trypsin 
inhibitor (0.5 mg/ml) was added to the supernatant. The isolated mitochondria were 
further purified using Percoll density gradient centrifugation [30]. Mitochondrial ROS 
generation was determined on addition of pyruvate/malate or succinate by using Amplex 
Red and horseradish peroxidise (Invitrogen, USA) according to the manufacturer’s 
instructions.   
3.2.13 Determination of oxidative stress in diabetic hearts 
The formation of ROS in heart tissue lysates was measured by using 
2,7-dichlorodihydro-fluorescein diacetate (DCF-DA, Invitrogen, USA) [6] and Amplex 
Red as indicators according to the manufacturer’s instructions. The protein oxidation in 
heart tissues was assessed by measuring protein carbonyl content using a commercial 
assay kit (Cayman Chemical, USA) following manufacturer’s instructions.  
The anti-oxidant capacity was measured based on reduction of copper (Ⅱ) to copper 
(Ⅰ)using OxiSelectTM Total Antioxidant Capacity Assay Kit (Cell Biolabs, Inc., USA). 
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3.2.14 Immuno-fluorescence staining and confocal microscopy 
Mitochondrial smears were prepared on slides and fixed with freshly prepared 4% 
paraformaldehyde. After incubation with appropriate primary antibodies (capn1 and 
VDAC-1) and secondary antibodies conjugated with differing fluorescence (Alexa Fluor 
488 Donkey anti-mouse IgG and Alexa Fluor 594 Goat anti-rabbit IgG), signals were 
obtained with an Olympus FluoViewTM FV1000 confocal microscope equipped with the 
IX81 motorized inverted system as described [31].  
3.2.15 Co-immunoprecipitation (co-IP) and native gel electrophoresis 
Co-IP and non-denaturing polyacrylamide gel electrophoresis were carried out to analyze 
protein–protein interactions. Briefly, calpain-1 and its interacting proteins were co-precipitated 
using an Immunoprecipitation kit - dynabeads protein G (Life Technologies Inc. Burlington, 
Ontario, Canada), and ATP synthase complex was isolated using ATP synthase immunocapture kit 
(Abcam Inc, Toronto, Ontario, Canada) in isolated mitochondria according to the manufacturer’s 
instructions. Both calpain-1/interacting proteins and ATP synthase complex were subjected to 
non-denaturing polyacrylamide gel electrophoresis for separation, followed by western blot 
analysis.  
3.2.16 ATP synthase activity 
ATP synthase activity was measured using an assay coupled with pyruvate kinase, which 
converts ADP to ATP and produces pyruvate from phosphoenolpyruvate, as described 
previously [32].  
3.2.17 Statistical analysis 
All data were presented as mean ± SD. A one-way or two-way ANOVA followed by 
Newman-Keuls test was performed for multi-group comparisons as appropriate. For 
comparison of 2 groups, unpaired t-test was used. A value of P < 0.05 was considered 
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statistically significant. 
3.3 Results 
3.3.1 Mitochondrial ros generation is increased in diabetic mouse 
hearts and high glucose-stimulated cardiomyocytes 
To determine mitochondrial ROS generation in cardiomyocytes under diabetic conditions, 
we made wild-type mice diabetic by injection of STZ. At 0, 7, 28 and 60 days after STZ 
injection, we isolated mitochondria from mouse hearts and determined mitochondrial 
H2O2 generation. As shown in Figure 3-1A, H2O2 generation in isolated mitochondria 
was increased in a time-dependent manner using pyruvate/malate as substrates. Similarly, 
in cultured adult cardiomyocytes, high glucose (30 mmol/L) incubation increased 
mitochondrial superoxide generation in a time-dependent manner (Figure 3-1B). These 
results confirm that mitochondrial ROS generation is increased in cardiomyocytes under 
diabetic conditions.  
3.3.2 Genetic inhibition of calpain prevents mitochondrial ROS 
generation and reduces oxidative damage in diabetic mouse 
hearts  
We have recently reported that genetic inhibition of calpain reduces diabetic 
cardiomyopathy in mouse models of type-1 diabetes [6, 7]. To understand the underlying 
mechanisms, we determined whether calpain plays a role in mitochondrial ROS 
generation. To this end, we first incubated cultured cardiomyocytes from Tg-CAST and 
wild-type mice with normal or high glucose for 24 hours. Over-expression of calpastatin 
significantly decreased mitochondrial superoxide generation induced by high glucose in 
Tg-CAST cardiomyocytes (Figure 3-1C). This result provides direct evidence that 
inhibition of calpain by over-expressing calpastatin blunts high-glucose stimulated 
superoxide generation in cardiomyocytes. 
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Figure 3-1. Determination of mitochondrial ROS generation  
(A) Adult wild-type mice were injected with streptozotocin (STZ, 50 mg/kg/day, i.p.) for 
5 days. Mice were killed 1 week, 1 month and 2 months after STZ injection. 
Mitochondria were isolated from heart tissues. Mitochondrial H2O2 generation was 
determined using Amplex Red as an indicator after addition of pyruvate/malate. (B and C) 
Adult cardiomyocytes were isolated and cultured for up to 24 hours. (B) Time course of 
mitochondrial superoxide flashes following incubation with high glucose (30 mmol/l) in 
wild-type (WT) cardiomyocytes. (C) Twenty-four hours after incubation with high 
glucose (30 mmol/l, HG) or normal glucose (5 mmol/l, NG), mitochondrial superoxide 
flashes were analyzed in WT and transgenic mice over-expressing calpastatin (Tg-CAST). 
Data are mean ± SD, n = 6 or 3 different cultures. * P < 0.05 versus Sham, 0 hr or NG in 
WT, and # P < 0.05 versus HG in WT. 
144 
We then made Tg-CAST, capn4-ko and their wild-type mice diabetic by injection of STZ. 
Sixty days after STZ injection, calpastatin over-expression or capn4 deletion significantly 
reduced H2O2 generation in mitochondria from STZ-treated Tg-CAST and capn4-ko 
mice, respectively following addition of pyruvate/malate (Figure 3-2A and B) or 
succinate (Figure 3-3A and B). Similarly, H2O2 formation as determined by using 
DCF-DA (Figure 3-2C and D) and Amplex Red (Figure 3-2E and F), and the protein 
carbonyl content (Figure 3-2G and H) were increased in diabetic mouse hearts and 
abrogated in Tg-CAST and capn4-ko mice, respectively. However, total anti-oxidant 
capacity was comparable between wild-type, Tg-CAST and capn4-ko mice after 
induction of diabetes (data not shown). These results suggest that calpain contributes to 
mitochondrial ROS generation and oxidative damage in diabetic hearts. 
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Figure 3-2. Assessment of mitochondrial ROS generation and oxidative stress 
Wild-type (WT), transgenic mice over-expressing calpastatin (Tg-CAST) or 
cardiomyocyte-specific capn4 knockout mice (Capn4-ko) were injected with STZ (50 
mg/kg/day for 5 days, i.p.). Two months after STZ injection, mitochondria were isolated 
from heart tissues. Mitochondrial ROS generation was measured using Amplex Red after 
addition of pyruvate/malate (A and B). ROS formation in heart tissue lysates was 
determined using DCF-DA as an indicator (C and D) or using Amplex Red (E and F). (G 
and H) Oxidative damage was assessed by measuring protein carbonyl contents in heart 
tissue lysates.  Data are mean ± SD, n = 6. * P < 0.05 versus Sham in WT, and # P < 
0.05 versus STZ-treated WT. 
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Figure 3-3. Assessment of mitochondrial ROS generation 
Wild-type (WT), transgenic mice over-expressing calpastatin (Tg-CAST) or 
cardiomyocyte-specific capn4 knockout mice (Capn4-ko) were injected with STZ (50 
mg/kg/day for 5 days, i.p.). Two months after STZ injection, mitochondria were isolated 
from heart tissues. Mitochondrial ROS generation was measured using Amplex Red after 
addition of succinate. Data are mean ± SD, n = 6. * P < 0.05 versus Sham in WT, and # P 
< 0.05 versus STZ in WT.  
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3.3.3 Calpain-1 is increased in mitochondria of stz-induced mouse 
hearts 
Having shown that inhibition of calpain prevented mitochondrial superoxide generation, 
we determined whether the levels of calpains were altered in mitochondria of diabetic 
mouse hearts. In line with the increase in mitochondrial ROS generation, the protein 
levels of capn1 were significantly elevated in mitochondria from diabetic hearts in a 
time-dependent manner (Figure 3-4A). Consistently, diabetes also increased calpain 
activities in mitochondria of diabetic compared with sham animal hearts (Figure 3-5). 
However, diabetes did not change the protein levels of capn2 and calpain-10, an isoform 
well recognised as a mitochondrial calpain [33] (data not shown).  
To provide further evidence in support of calpain-1 accumulation in mitochondria, we 
determined capn1 and VDAC1 proteins in isolated mitochondria of diabetic mouse hearts 
by dual immunofluorescence confocal microscopy. Confocal microscopic analysis 
demonstrated that VDAC1 was detected in mitochondrial membranes (red) and capn1 
was present inside of mitochondria (green), and that percentages of capn1-labelled 
mitochondria were much greater in diabetic versus sham mouse hearts (Figure 3-4B).  
Similarly, the protein levels of capn1 were also increased in hearts of db/db type-2 
diabetic versus db+/- mice (Figure 3-4C). 
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Figure 3-4. Measurement of calpain-1 in mitochondria 
(A) Adult wild-type mice were injected with streptozotocin (STZ, 50 mg/kg/day, i.p.) for 
5 days. Mice were killed 1 week, 1 month and 2 months after STZ injection. 
Mitochondria were isolated from heart tissues and the protein levels of calpain-1 and 
VDAC1 in mitochondria were determined by western blot analysis. Upper panel is the 
representative western blot for capn1 and VDAC1 from 2 out of 6 different hearts in each 
group and lower panel is the quantification of capn1/VDAC1 in all animals. (B) Adult 
wild-type mice were injected with STZ (50 mg/kg/day, i.p.) for 5 days. Two months after 
STZ injection, heart tissues were collected and mitochondria were isolated. After fixation 
on slides, dual immunofluorescent staining for VDAC1 and capn1 was performed using 
their respective antibodies followed by secondary antibodies conjugated with different 
fluorescent dyes. Representative photomicrographs of confocal microscopy for VDAC1 
and capn1 in mitochondria shows membrane staining of VDAC1 (Red) and that capn1 is 
located in mitochondria (Green). (C) Mitochondria were isolated from db/db type-2 
diabetic and db+/- mouse hearts (male and age of 3.5 months). The protein levels of 
capn1 and VDAC1 were determined by western blot analysis. Left panel is a 
representative western blot for capn1 and VDAC1 from 3 out of 6 different hearts in each 
group and right panel is the quantification of capn1 protein normalized to VDAC1. Data 
are mean ± SD from 6 different heart tissues in each group. *P < 0.05 versus Sham.
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Figure 3-5. Measurement of calpain activity in isolated mitochondria 
Wild-type mice were injected with STZ (50 mg/kg/day for 5 days, i.p.) or citrate buffer as 
a sham control. Two months after STZ injection, mitochondria were isolated from heart 
tissues. Calpain activity was determined. Data are mean ± SD, n = 6. * P < 0.05.  
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3.3.4 Mitochondrial calpain-1 contributes to superoxide generation 
and cell death in high glucose-stimulated cardiomyocytes 
To determine whether mitochondrial calpain-1 contributes to superoxide generation in 
cardiomyocytes, we infected cultured cardiomyocytes with an adenoviral vector 
containing mitochondria-targeted calpastatin (Ad-mtCAST) and then incubated them 
with high glucose for 24 hours. Selective over-expression of calpastatin in mitochondria 
prevented mitochondrial superoxide flashes and cell death induced by high glucose 
(Figure 3-6A-D). This result suggests that mitochondrial calpain contributes to 
superoxide generation and cell death in cardiomyocytes induced by high glucose.   
To provide direct evidence to support our hypothesis that the accumulation of calpain-1 in 
mitochondria induces superoxide generation and apoptosis, we introduced 
pCMV/myc/mito-capn1, a plasmid expressing mitochondrial targeted capn1 into 
cardiomyocyte-like H9c2 cells. Twenty-four hours after transfection, mitochondrial and 
cytosolic fractions were isolated from H9c2 cells. Over-expressed capn1 was confirmed 
in mitochondrial but not in cytosolic fractions (Figure 3-7A). Intriguingly, 
mitochondria-targeted over-expression of capn1 significantly increased mitochondrial 
superoxide generation as determined by mitochondrial superoxide flashes (Figure 3-7B) 
and induced apoptosis (Figure 3-7C and D). These results strongly support a causal role 
of mitochondrial calpain-1 in superoxide generation and apoptosis in cardiomyocytes. 
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Figure 3-6. Effects of mitochondria-targeted calpastatin over-expression on 
mitochondrial superoxide flashes and cell death in high glucose-stimulated 
cardiomyocytes 
(A)  H9c2 cells were infected with an adenoviral vector containing 
mitochondria-targeted calpastatin (Ad-mtCAST) or Ad-gal as a control. Twenty-four 
hours later, mitochondrial and cytosolic fractions were prepared, and calpastatin (CAST), 
GAPDH and VDAC1 were detected by western blot analysis. A representative western 
blot confirms myc-tagged CAST is expressed selectively in mitochondria. (B-D) Adult 
cardiomyocytes were isolated from mice. After infection with Ad-mtCAST, 
cardiomyocytes were exposed to normal glucose (NG) or high glucose (HG) for 24 hours, 
mitochondrial superoxide flashes (B), and Annexin V staining for cell death (C and D) 
were determined. Data are mean ± SD from 6 different cultures. *P < 0.05 versus NG + 
Ad-gal, and # P < 0.05 versus HG + Ad-gal. 
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Figure 3-7. Effects of mitochondrial targeted capn1 on ATP5A1 protein, superoxide 
generation and apoptosis in H9c2 cells 
H9c2 cells were transfected with pCMV/myc/mito-capn1 (mt-Capn1) or 
pCMV/myc/mito as a control. Twenty-four hours later, (A) Mitochondrial and cytosolic 
fractions were isolated. Western blot analysis was performed to determine the protein 
levels of capn1, GAPDH and VDAC1. (B) Mitochondrial superoxide flashes were 
assessed. (C and D) Apoptosis was determined by caspase-3 activity and DNA 
fragmentation. (E and F) ATP5A1 and its cleaved fragment were determined by western 
blot analysis. (E) Mitochondrial lysates (100 μg) were incubated with active calpain-1 (5 
μg) for 15 minutes. (F) ATP5A1 immunoblot in H9c2 cells transfected with 
mitochondrial-targeted calpain-1 (mt-capn1). Data are mean ± SD from at least 3 
different experiments. *P < 0.05 versus control. 
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3.3.5 ATP5A1 is a target of calpain-1 in diabetic hearts 
Since studies have shown that the protein levels of ATP5A1 are reduced and ATP 
synthase activity decreases in diabetic hearts [16, 17], our initial effort was focused on 
ATP5A1. After incubation of mitochondrial lysates from the heart with active calpain-1, a 
cleaved fragment of ATP5A1 protein (about 38KD) was detected (Figure 3-7E). 
Interestingly, up-regulation of calpain-1 selectively in mitochondria led to a similar 
cleaved fragment of ATP5A1 protein in H9c2 cells (Figure 3-7F). These results strongly 
indicate that ATP5A1 protein is a direct substrate of calpain-1.     
We further revealed that ATP5A1 was co-immunoprecipitated with capn1 in diabetic 
hearts (Figure 3-8A). Likewise, capn1 was detected in immune-captured ATP synthase 
complex (Figure 3-8B). These results demonstrate a potential interaction between 
calpain-1 and ATP5A1 in mitochondria of diabetic hearts. We also measured the protein 
levels of ATP5A1 in isolated mitochondria of diabetic hearts. Diabetes significantly 
reduced ATP5A1 protein levels in mitochondria (Figure 3-8C), which is consistent with 
previous reports [16, 17], whereas the protein levels of ATP synthase β subunit remain 
unchanged in diabetic hearts (Figure 3-8C). However, the reduction in ATP5A1 protein 
levels was prevented by calpastatin over-expression (Figure 3-8D). In line with a 
reduction in ATP5A1 protein, ATP synthase activity was markedly decreased in 
mitochondria from diabetic hearts and restored in diabetic Tg-CAST mice (Figure 3-8E).  
In cultured cardiomyocytes, over-expression of calpastatin selectively in mitochondria by 
infection with Ad-mtCAST significantly increased ATP synthase activity during high 
glucose stimulation (Figure 3-8F). This result provides further evidence to support that 
calpain activation disrupts ATP synthase activity in diabetic hearts.  
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Figure 3-8. Role of calpain in ATP5A1 expression and ATP synthase disruption in 
diabetic hearts 
(A) Interaction between ATP5A1 and capn1. Capn1 interacting proteins were 
co-immunoprecipitated using capn1 antibody. A representative western blot shows that 
ATP5A1 is detected in capn1 interacting proteins. (B) ATP synthase complex and its 
interacting proteins were captured using ATP synthase immune-capture assay kit. A 
representative western blot shows that capn1 is detected in captured ATP synthase 
complex. (C-E) Myocardial mitochondria were isolated from sham and STZ-injected 
Tg-CAST and their wild-type (WT) mice. (C and D) The upper panels are the 
representative western blot for ATP5A1 protein from 3 out of 6 hearts in each group and 
the lower panels are the quantification of ATP5A1 protein relative to VDAC1 in 
mitochondria. (E) ATP synthase activity was measured in mitochondria. Data are mean ± 
SD, n = 6. *P < 0.05 versus sham or STZ + WT, and #P < 0.05 versus STZ + WT. (F) 
Adult cardiomyocytes were isolated and cultured from wild-type mice. After infection 
with Ad-mtCAST or Ad-gal, the cells were incubated with high glucose (30 mmol/l, HG) 
or normal glucose (5 mmol/l, NG) for 24 hours. ATP synthase activity was determined in 
cell lysates. Data are mean ± SD, n = 6. *P < 0.05 versus NG + Ad-gal, and #P < 0.05 
versus HG + Ad-gal.  
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3.3.6 Over-expression of ATP5A1 reduces mitochondrial superoxide 
generation, cardiac hypertrophy and myocardial dysfunction in 
diabetic mice  
To investigate whether up-regulation of ATP5A1 protects diabetic hearts, we delivered 
Ad-ATP5A1 into mice 72 hours after the last STZ injection. Ad-GFP served as a control. 
Two weeks later, mice received the second dose of Ad-ATP5A1. Two months after STZ 
injection, mice were subjected to various experiments. The efficient delivery of 
adenoviral vectors into the heart was confirmed by GFP signal in heart tissues (Figure 
3-9). As a result, delivery of Ad-ATP5A1 significantly increased ATP5A1 protein and 
ATP synthase activity in diabetic mouse hearts (Figure 3-10A and B), suggesting that 
ectopic expression of ATP5A1 integrates into the complex of ATP synthase. 
Up-regulation of ATP5A1 reduced the formation of H2O2 (Figure 3-10C and D), and 
attenuated cardiac hypertrophy as evidenced by decreased cardiomyocyte sectional area 
(Figure 3-10E) and down-regulation of ANP and β-MHC expression in diabetic mouse 
hearts (Figure 3-10F and G), leading to an improvement of myocardial function in 
diabetic mice as determined by increased fractional shortening and E/A ratio (Figure 
3-10H and I, Table 3-1). However, delivery of Ad-ATP5A1 slightly elevated ATP5A1 
protein levels in sham mouse hearts but did not increase ATP synthase activity.  
To provide further evidence to support the role of ATP5A1, we infected adult 
cardiomyocytes with Ad-ATP5A1 or Ad-gal as a control, and then incubated them with 
high glucose for 24 hours. Up-regulation of ATP5A1 increased ATP synthase activity in 
high glucose- but not normal glucose-stimulated cardiomyocytes (Figure 3-11A), reduced 
mitochondrial superoxide generation (Figure 3-11B) and prevented cell death induced by 
high glucose (Figure 3-11C and D).
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Figure 3-9. GFP signal in heart tissues after delivery of Ad-GFP 
Adult mice were injected with Ad-GFP via tail vein. Five days later, heart tissues were 
collected and cryosections were prepared. The sections were stained with Hoechst 33342 
for nuclei. The signals for GFP (green color) and Hoechst 33342 (blue) were captured.   
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Figure 3-10. Effects of ATP5A1 over-expression in diabetic cardiomyopathy  
Adult mice were injected with Ad-ATP5A1 or Ad-GFP and then treated with STZ. (A) 
Up-regulation of ATP5A1 protein was confirmed by western blot analysis. Upper panel is 
a representative western blot from 2 out of 6 different hearts for ATP5A1 and VDAC1, 
and lower panel is quantification of ATP5A1/GAPDH ratio for all hearts. (B) ATP 
synthase activity. (C and D) H2O2 formation was determined in heart tissue lysates using 
Amplex Red (C) and DCF-DA as indicators (D). (E) Cardiomyocyte size in heart sections. 
(F) The mRNA levels of beta-MHC. (G) The mRNA levels of ANP. (H and I) 
Echocardiographic analysis was performed to assess myocardial function. Data are mean 
± SD, n = 6-8. *P < 0.05 versus sham + Ad-GFP, and #P < 0.05 versus STZ + Ad-GFP. 
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Table 3-1. General information in mice after receiving Ad-GFP or Ad-ATP5A1 
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Figure 3-11. Role of ATP5A1 in ATP synthase activity, mitochondrial superoxide 
generation and cell death in cardiomyocytes 
Adult mouse cardiomyocytes were isolated from wild-type mice. After cell attachment to 
the culture dish, they were infected with Ad-ATP5A1 or Ad-gal. Twenty-four hours later, 
cells were incubated with normal glucose (NG) or high glucose (HG) for 24 hours. (A) 
ATP synthase activity. (B) Mitochondrial superoxide generation. (C) Representative 
pictures for annexin V staining positive cells as an indicator of cell death (green color). 
(D) Quantification of annexin V staining positive cells. Data are mean ± SD from at least 
3 different experiments. *P < 0.05 versus Ad-gal + NG, and #P < 0.05 versus Ad-gal + 
HG. 
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3.4 Discussion 
The major findings of this study are that genetic inhibition of calpain increases the 
protein levels of ATP5A1 and ATP synthase activity, and decreases mitochondrial ROS 
generation and oxidative damage in diabetic hearts. Both type-1 and type-2 diabetes 
induce calpain-1 accumulation in mitochondria of the heart. Selective inhibition of 
mitochondrial calpain attenuates ATP synthase disruption, reduces mitochondrial 
superoxide generation and prevents apoptosis in cardiomyocytes under diabetic 
conditions, whereas targeted up-regulation of calpain-1 specifically in mitochondria 
induces the cleavage of ATP5A1, superoxide generation and apoptosis in cardiomyocytes. 
In a mouse model of T1D, up-regulation of ATP5A1 restores ATP synthase activity and 
decreases mitochondrial ROS generation in diabetic hearts, and reduces diabetic 
cardiomyopathy. Thus, ATP synthase disruption and mitochondrial ROS generation are 
important mechanisms by which calpain activation promotes diabetic cardiomyopathy. 
Accumulating evidence indicates that mitochondrial ROS production is increased and 
oxidative stress occurs in type-1 and type-2 diabetic hearts [17-20]. Although some 
type-1 diabetic animals did not exhibit increased mitochondrial superoxide generation in 
the heart [21, 22], selective inhibition of mitochondrial ROS production reduces adverse 
cardiac changes in T1D models [23, 24], supporting a critical role of mitochondrial ROS. 
The present study provides further evidence that demonstrates that diabetic conditions 
induce mitochondrial superoxide generation in cultured cardiomyocytes and hearts in 
vivo. ROS produced by mitochondria not only directly contributes to mitochondrial 
dysfunction [34], cell death and hypertrophy in cardiomyocytes and hearts under stress 
[35, 36], but also serves as “second messengers” in cellular signalling pathways [37]. 
Thus, targeted inhibition of mitochondrial ROS by transgenic over-expression of 
superoxide dismutase-2 (SOD2) and mitochondrial catalase reduces cardiac hypertrophy, 
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preserves cardiac structures and improves function in a mouse model of type-1 diabetes 
[23] and in insulin-resistant and obese Ay mice [24], respectively. We further show that 
genetic inhibition of calpain significantly attenuates mitochondrial superoxide generation 
and subsequent oxidative damage in diabetic mouse hearts, which are associated with 
reduced myocardial injury and improved myocardial function in diabetic mice. Thus, our 
data suggest an important role of calpain in mitochondrial ROS generation in 
development of diabetic cardiomyopathy.  
It is well-known that mitochondria generate superoxide, the primary ROS as by-products, 
when single electrons leak to react with molecular oxygen [38]. While many 
mitochondrial enzymes have been reported to produce ROS, the respiratory chain is the 
major source of ROS in mitochondria. Within the respiratory chain, Complexes Ⅰand 
Ⅲ have been identified as major ROS generators. On the other hand, mitochondrial ROS 
are eliminated by antioxidant defence systems. Superoxide anion dismutates to H2O2 
spontaneously, or by SOD2 in mitochondria. H2O2 can be readily converted to water by 
catalase and glutathione peroxidase. In addition to these antioxidant enzymes, 
mitochondria possess several low-molecular-weight antioxidants, including α-tocopherol 
and ubiquinol, etc. An increase in superoxide generation and/or a decrease in antioxidant 
capacity will lead to oxidative stress in mitochondria [39]. In this regard, our data suggest 
that calpain may promote oxidative damage through increased mitochondrial superoxide 
generation rather than decreased antioxidant capacity because inhibition of calpain does 
not affect the anti-oxidant capacity in diabetic hearts. 
Multiple mechanisms have been suggested to mediate mitochondrial ROS generation in 
diabetic hearts. It was reported that high glucose concentrations result in increased 
metabolic input into mitochondria, which overwhelms the respiratory chain causing 
mitochondrial hyperpolarization, leading to electron backup within the respiratory chain 
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and ROS overproduction [38]. In addition, elevated circulating lipids and 
hyperinsulinemia together increase fatty acid delivery to cardiomyocytes, which rapidly 
adapt by promoting fatty acid utilization. High rates of fatty acid oxidation increase 
mitochondrial membrane potential, leading to the production of ROS in mitochondria [40, 
41]. In the present study, we show that diabetes increases calpain-1 in mitochondria and 
calpain-1 accumulation in mitochondria correlates with ROS generation in diabetic 
mouse hearts. Importantly, selective inhibition of mitochondrial calpain reduces 
superoxide generation in cardiomyocytes under diabetic conditions whereas targeted 
over-expression of capn1 in mitochondria sufficiently induces superoxide generation in 
cardiomyocytes. Thus, mitochondrial calpain-1 may represent a novel mechanism 
underlying mitochondrial ROS generation in cardiomyocytes under diabetic conditions. 
 Another important finding is that mitochondrial calpain-1 negatively regulates ATP5A1 
protein, leading to ATP synthase disruption in diabetic hearts. ATP synthase, also called 
Complex V, is an enzyme that uses the energy created by the proton electrochemical 
gradient to synthesize ATP from ADP [42]. It is located within the mitochondria. ATP 
synthase consist of 2 regions: the Fo portion and F1 portion. The Fo region of ATP 
synthase is a proton pore located within the inner membrane of mitochondria, which 
transfers the energy created by the proton electrochemical gradient to F1, where ADP is 
phosphorylated to ATP. The F1 region of ATP synthase comprises five different subunits 
(α, β, γ, , and ) in the matrix of the mitochondria. Down-regulation of ATP synthase has 
been shown in both type-1 and type-2 diabetic hearts [16, 17]. Similarly, we show a 
significant reduction of ATP5A1 protein and of its activity in mitochondria from diabetic 
mouse hearts. Importantly, diabetes-induced down-regulation of ATP5A1 and ATP 
synthase activity are prevented by both calpastatin over-expression and capn4 deletion. 
Thus, our observations are consistent with a model whereby calpain-1 accumulation in 
mitochondria compromises ATP synthase through the proteolysis of ATP5A1 protein in 
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diabetic mouse hearts. In fact, selective up-regulation of calpain-1 in mitochondria 
induces the cleavage of ATP5A1 protein, mitochondrial superoxide generation and 
apoptosis in cultured cardiomyocytes. Although we could not detect Opa-1 and NCX1 
protein in calpain-1 immunoprecipitates (data not shown), it is worthwhile to mention 
that calpain-1 may also target other substrates in mitochondria. For example, calpain-1 
has been reported to cleave apoptosis inducing factor, leading to apoptosis during 
ischemia/reperfusion injury in the heart [14]. Thus, it is possible that there may be 
multiple targets of calpain-1 in mitochondria of diabetic hearts, which merits further 
investigation. 
Disruption of ATP synthase within Complex V results in excess electron “backup” in the 
individual electron transfer complexes [34], in particular Complex I and III, promoting 
mitochondrial superoxide generation. Indeed, an increase in reverse electron flow and 
electrons leaking from Complex I and III of the respiratory chain has been suggested to 
be main mechanisms promoting mitochondrial ROS generation in diabetes [40, 41]. 
Disruption of ATP synthase also induces insufficient ATP production, which directly 
contributes to myocardial dysfunction. In support of this view, we show that 
up-regulation of ATP5A1 increases ATP synthase activity, decreases mitochondrial ROS 
generation and mitigates diabetic cardiomyopathy. Taken together, our observation argues 
that calpain-1 mediates mitochondrial superoxide generation, at least partly by 
down-regulation of ATP5A1 and disruption of ATP synthase, leading to cardiomyopathic 
changes in diabetic mice. It is important to mention that over-expression of ATP5A1 per 
se is not sufficient to increase ATP synthase activity but it prevents 
diabetes/hyperglycemia-induced decrease in its activity in cardiomyocytes. 
In the present study, STZ was given in multiple low doses to induce T1D in mice. In this 
model, an inflammatory response occurs in the β-cells, leading to lymphocytic infiltrates 
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and cell death [43], which effectively models the autoimmune T cell-mediated destruction 
and hypoinsulinemia observed in human T1D [44]. Since mitochondrial capn1 protein is 
also elevated in db/db type-2 diabetic mouse hearts, similar mechanisms may be 
operating in type-2 diabetic cardiomyopathy, which requires further study for 
clarification. Future study is also needed to determine whether mitochondrial calpain is 
increased and contributes to diabetic cardiomyopathy in humans. 
Although the present study focuses on mitochondrial calpain-1 and ROS generation, 
other mechanisms may be also involved in calpain-mediated diabetic cardiomyopathy. In 
particular, calpain activation may induce the cleavages of important cytosolic proteins 
including signaling molecules (PKC and NF-κB) [45, 46], calcium regulatory proteins 
[47, 48] and myofibril proteins [49, 50], which may contribute to myocardial dysfunction 
in diabetes.  
In summary, we have provided evidence to demonstrate that mitochondrial calpain-1 
stimulates mitochondrial ROS generation through down-regulation of ATP5A1 and 
disruption of ATP synthase, which promotes diabetic cardiomyopathy. These findings 
uncover a novel mechanism underlying diabetic cardiomyopathy, which may have 
significant implications in diabetic cardiac complications. 
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Chapter 4 
4 Therapeutic inhibition of mitochondrial reactive oxygen 
species with mito-TEMPO reduces diabetic 
cardiomyopathy4 
 
 
 
 
 
 
 
 
 
 
 
                           
4 This chapter has been published in the following manuscript: 
 Ni R, Cao T, Xiong S, Ma J, Fan GC, Lacefield JC, Lu Y, Le Tissier S, and Peng T. (2016) 
Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces 
diabetic cardiomyopathy, Free Radic Biol Med 90, 12-23. 
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4.1 Introduction 
Globally, the number of adults affected with diabetes is rapidly growing and it is 
estimated to increase to nearly 400 million by 2030 [1]. Both type-1 and type-2 diabetes 
induce complications including visual impairments and blindness, nerve and kidney 
damage [2]. However, the greatest challenges lie in cardiovascular complications, 
accounting for up to 80% diabetes-related morbidity and mortality [3]. Diabetes can 
directly affect the heart, a condition described as diabetic cardiomyopathy. Diabetic 
cardiomyopathy has been defined as ventricular dysfunction that occurs in the absence of 
changes in blood pressure and coronary artery disease [4]. So far, there is no specific 
therapy available for this disease.  
Oxidative damage induced by reactive oxygen species (ROS) has been implicated in the 
pathogenesis of diabetic cardiomyopathy [5-7]. ROS is mainly produced by mitochondria, 
NADPH oxidase and xanthine oxidase in the heart [8, 9]. Inhibition of xanthine oxidase 
or NADPH oxidase reduces diabetic cardiomyopathy [10-12]. There is convincing 
evidence that mitochondrial ROS production is increased in type-1 and type-2 diabetic 
hearts [13-17]. Transgenic over-expression of manganese superoxide dismutase (MnSOD) 
and mitochondrial catalase inhibit mitochondrial ROS and reduce cardiac hypertrophy, 
preserves cardiac structures and improves function in a mouse model of type-1 diabetes 
and in insulin-resistant and obese Ay mice, respectively [18, 19]. These studies suggest a 
critical role of mitochondrial ROS in diabetic cardiomyopathy. Given the fact that 
commonly employed antioxidants have proven ineffective in clinical trials, it is possible 
that these agents may not be adequately delivered to the sub-cellular sites of ROS 
production. Because the mitochondria are important sources of ROS, we hypothesized 
that therapeutic inhibition of mitochondrial ROS by a mitochondrial targeted antioxidant 
(2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium 
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chloride, monohydrate (mito-TEMPO) might be beneficial in the setting of diabetic 
cardiomyopathy. 
Mito-TEMPO is a physicochemical compound as one of SOD mimics. It has an ability to 
pass through lipid bilayers easily and accumulate selectively in mitochondria [20]. Both 
in vitro and in vivo studies have confirmed that mito-TEMPO is a mitochondria-targeted 
antioxidant with superoxide and alkyl radical scavenging properties [20-22]. In vitro 
study showed that incubation with mito-TEMPO prevented cell death in adult 
cardiomyocytes induced by a pharmacological MnSOD inhibitor [23]. In vivo studies 
revealed that administration of mito-TEMPO improved cardiac function in a mouse 
model of pressure over-load heart failure [24], and reduced diabetes-attributable cardiac 
injury and mortality after myocardial infarction [25]. In this study, we demonstrated that 
therapeutic inhibition of mitochondrial ROS using mito-TEMPO prevented oxidative 
stress and reduced cardiomyopathic changes in mouse models of type-1 and type-2 
diabetes. Our data strongly indicate that mitochondria-targeted antioxidants have 
therapeutic effects on diabetic cardiac complications.  
4.2 Material and methods 
4.2.1 Animals and cardiomyocytes culture 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). 
All experimental protocols were approved by the Animal Use Subcommittee at the 
University of Western Ontario, Canada (2008-079). Breeding pairs of C57BL/6 mice and 
db+/- mice were purchased from the Jackson Laboratory. Transgenic mice 
over-expressing a circularly permuted yellow fluorescent protein in the mitochondrial 
matrix of cells (Tg-mtcpYFP) were kindly provided by Dr. Wang Wang (University of 
Washington, Seattle) [26]. A breeding program for mice was implemented at our animal 
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care facilities. 
Adult mouse ventricle cardiomyocytes were isolated from C57BL/6 mice, and cultured as 
described in our recent studies [27]. 
4.2.2 Experimental protocol 
Type-1 diabetes was induced in adult male mice (2-month old) by consecutive 
intraperitoneal injection of streptozotocin (STZ, 50 mg/kg/day) for 5 days [11]. 
Seventy-two hours after the last injection of STZ, random blood glucose levels were 
measured using the OneTouch Ultra 2 blood glucose monitoring system (Life Scan, Inc. 
CA, USA). Mice were considered diabetic and used for the study only if they had 
hyperglycemia ( 15 mM) 72 h after STZ injection. Citrate buffer-treated mice were used 
as non-diabetic control (blood glucose < 12 mM). Thirty days after diagnosis, diabetic 
mice (6-8 in each group) received daily injection of mito-TEMPO (0.7 mg/kg/day, i.p., 
Enzo Life Sciences, Inc., the product number: ALX-430-150) [28] or vehicle for 30 days.  
Type-2 diabetic db/db mice were produced by breeding db+/- mice. Male db/db mice and 
their littermate db+/- mice received daily injection of mito-TEMPO (0.7 mg/kg/day, i.p.) 
starting at age of 2.5 months for 30 days.        
4.2.3 Echocardiography 
Animals were lightly anaesthetized with inhalant isoflurane (1%) and imaged using a 
40-MHz linear array transducer attached to a preclinical ultrasound system (Vevo 2100, 
FIJIFILM VisualSonics, Canada) with nominal in-plane spatial resolution of 40 μm (axial) 
 80 μm (lateral). M-mode and 2-D parasternal short-axis scans (133 frames/second) at 
the level of the papillary muscles were used to assess changes in left ventricle (LV) 
end-systolic inner diameter, LV end-diastolic inner diameter, LV posterior wall thickness 
in end-diastole and end-systole, fractional shortening (FS%) and ejection fraction (EF%). 
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An apical four chamber view of the left ventricle was obtained and the pulsed wave 
Doppler measurements were performed in the apical view with a cursor at mitral valve 
inflow: maximal early (E) and late (A) transmitral velocities in diastole. The diastolic 
function was determined by the ratio of E to A peak. 
4.2.4 Histological analyses  
For cardiomyocyte cross-sectional area, several sections of the heart (5 μm thick) were 
prepared and stained for membranes with fluorescein isothiocyanate–conjugated wheat 
germ agglutinin (Invitrogen) and for nuclei with Hochest. A single cardiomyocyte was 
measured by using an image quantitative digital analysis system (NIH Image version 1.6) 
as described [11]. The outline of at least 200 cardiomyocytes was traced in each section.  
4.2.5 Measurement of ROS generation in isolated mitochondria 
Interfibrillar mitochondria were isolated from freshly harvested hearts as described 
previously [29]. The isolated mitochondria were further purified using Percoll density 
gradient centrifugation. The freshly isolated mitochondria (10 µg) was incubated with 
pyruvate/malate (5/5 mmol/l) in a reaction buffer containing Amplex Red (0.05 mmol/l, 
Life Technologies Inc. Burlington, Ontario, Canada) and horseradish peroxidase (0.1 
units/ml) at 37ºC. The fluorescent signals were monitored by spectrofluorometer at the 
520/580 nm in every 10 minutes. 
4.2.6 Determination of oxidative stress levels in diabetic hearts 
The oxidative stress levels in heart tissue lysates were measured by using 
2,7-dichlorodihydro-fluorescein diacetate (DCF-DA, Invitrogen, USA) as an indicator 
[11]. Briefly, fresh heart tissues were homogenized in an assay buffer. The homogenates 
(50 μg protein) were incubated with DCF-DA at 37ºC for 3 hours. The fluorescent 
product formed was quantified by spectrofluorometer at the 485/525 nm. Changes in 
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fluorescence were expressed as arbitrary unit.  
The protein oxidation in heart tissue lysates was assessed by measuring protein carbonyl 
content using a commercial assay kit (Cayman Chemical, USA) following manufacturer’s 
instructions.  
4.2.7 Measurement of mitochondrial superoxide generation in 
cardiomyocytes 
Superoxide flashes in single mitochondrion were measured to determine mitochondrial 
superoxide generation in living cardiomyocytes as described [30]. Briefly, 
cardiomyocytes were infected with an adenoviral vector expressing mt-cpYFP 
(Ad-mt-cpYFP, kindly provided by Dr. Wang Wang from the University of Washington, 
Seattle, USA). Ad-mt-cpYFP expresses a circularly permuted yellow fluorescent protein 
(cpYFP) in the mitochondrial matrix of cells using the cytochrome C oxidase subunit IV 
targeting sequence (mt-cpYFP). Twenty-four hours after infection, confocal imaging was 
recorded using the Olympus FV 1000 laser-scanning microscope equipped with a 63x, 
1.3NA oil immersion objective and a sampling rate of 0.7s/frame. At least 20 
cardiomyocytes per culture in each group were analyzed. 
Mitochondrial superoxide generation was also assessed in living cardiomyocytes from 
Tg-mtcpYFP mice by using the MitoSOXTM Red mitochondrial superoxide indicator 
(Molecular Probes) and oxidant levels measured by using Dihydroethidium (DHE, 
Molecular Probes). The cpYFP signals were used to identify mitochondrial MitoSOXTM 
Red and DHE staining in cardiomyocytes. 
4.2.8 Determination of apoptotic cell death 
Caspase-3 activity in myocardial tissues and cardiomyocytes was measured by using a 
caspase-3 fluorescent assay kit (BIOMOL Research Laboratories). 
180 
Cell death was also determined in cardiomyocytes by annexin V/ Hochest staining as 
described [31].  
4.2.9 Real-time RT-PCR 
Total RNA was extracted from heart tissues using the Trizol Reagent (Life Technologies 
Inc. Burlington, Ontario, Canada). Real-time RT-PCR was performed to analyze mRNA 
expression for β-myosin heavy chain (β-MHC), atrial natriuretic peptide (ANP), gp91phox, 
p47phox and GAPDH as previously described [11]. 
4.2.10 Western blot analysis 
The protein levels of Bcl-2, phosphorylated and total extracellular signal-regulated 
kinase-1/2 (ERK1/2), c-Jun NH2-terminal kinase-1/2 (JNK1/2), p38 kinase, and GAPDH 
were determined by western blot analysis using their specific antibodies (Cell Signaling, 
Danvers, MA). 
4.2.11 Statistical analysis 
All data were given as means ± SD. Differences between two groups were compared by 
unpaired Student's t test. For multi-group comparisons, ANOVA followed by 
Newman-Keuls test was performed. A value of P < 0.05 was considered statistically 
significant. 
4.3 Results 
4.3.1 Mito-TEMPO inhibited high glucose-induced mitochondrial 
superoxide generation and cell death in cardiomyocytes 
To determine the effects of mito-TEMPO on mitochondrial superoxide generation and 
cell death, we incubated adult cardiomyocytes with normal glucose (5 mmol/l) or high 
glucose (30 mmol/l) in the presence of mito-TEMPO (25 nmol/l) or vehicle for 24 hours. 
This dose of mito-TEMPO was chosen because it has been shown to increase 
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mitochondrial superoxide dismutation by 3-fold while not affecting cytoplasmic 
dismutation in cultured cells [20]. As shown in Figure 4-1A, high glucose increased 
mitochondrial flashes in cardiomyocytes, which were abrogated by mito-TEMPO, 
indicating an increase in mitochondrial superoxide generation. This was further 
confirmed by the MitoSOXTM Red or DHE staining in living cardiomyocytes during high 
glucose stimulation (Figure 4-1B and C).  
High glucose induced cardiomyocyte death as determined by annexin-V/Hochest staining. 
Co-incubation with mito-TEMPO prevented high glucose-induced cell death in 
cardiomyocytes (Figure 4-1D and E). These results demonstrate that inhibition of 
mitochondrial superoxide generation prevents high glucose-induced cardiomyocyte 
death. 
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Figure 4-1. Effects of mito-TEMPO (M-TEMPO) on mitochondrial superoxide 
generation and cell death in cardiomyocytes  
Adult mouse cardiomyocytes were incubated with normal glucose (NG) or high glucose 
(HG) for 24 h in the presence of M-TEMPO or vehicle. (A) Single mitochondrial 
superoxide flashes were determined. (B) Representative microphotographs from 5 
different cultures for the MitoSOX staining, cpYFP signals and nuclei (Hoechst staining) 
show overlap of MitoSOX staining and cpYFP signals in cardiomyocytes. (F) 
Representative microphotographs from 5 different cultures for the DHE staining, cpYFP 
signals and nuclei (Hoechst staining) show overlap of DHE staining and cpYFP signals in 
cardiomyocytes. (D) A representative staining for annexin V (green color) and nuclei 
(blue color) and (E) Quantification of death cells (%). Data are mean ± SD from 5 
different cell cultures. *P < 0.05 versus vehicle + NG and †P < 0.05 versus vehicle + HG. 
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4.3.2 Administration of mito-TEMPO abolished mitochondrial ROS 
generation and oxidative stress in hearts of diabetic mice 
Injection of mito-TEMPO did not affect the blood glucose levels, heart weight and body 
weight in both sham and diabetic mice (Tables 4-1 and 2). Neither abnormal behaviors or 
health problems including myocardial function and death nor changed intake of food and 
water was observed due to the use of mito-TMEPO in sham mice (Tables 4-3), 
suggesting there might be no obvious toxic side-effects of mito-TEMPO. 
Mitochondrial ROS generation was significantly increased in both db/db and 
STZ-induced mouse hearts. Administration of mito-TEMPO abolished mitochondrial 
ROS generation in diabetic mouse hearts (Figure 4-2A and B). 
To assess oxidative stress in diabetic hearts, we first measured oxidative stress levels in 
heart tissue lysates. The oxidative stress levels were increased in db/db and STZ-induced 
mouse hearts, which was inhibited by mito-TEMPO (Figure 4-2C and D). The total 
antioxidant capacity (including small molecule and protein antioxidants) was also 
increased in diabetic hearts (Figure 4-3). We then determined the oxidative damage in 
diabetic mice hearts by measuring the protein carbonyl content. The protein carbonyl 
content was elevated in db/db and STZ-induced mouse hearts. However, injection with 
mito-TEMPO abrogated diabetes-induced protein carbonyl content (Figure 4-2E and F). 
These results suggest that mito-TEMPO effectively blocks mitochondrial ROS 
production and prevents oxidative stress in diabetic mouse hearts.  
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Table 4-1. General information in db/db and db+/- mice receiving mito-TEMPO 
 
 
Table 4-2. General information in STZ-injected mice receiving mito-TEMPO 
 
 
Table 4-3. Intake of food and water in mice receiving mito-TEMPO 
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Figure 4-2. Effects of mito-TEMPO (M-TEMPO) on mitochondrial ROS generation 
and oxidative stress 
Mitochondrial oxidant levels were assessed using Amplex Red in db+/- and db/db hearts 
(A) or sham and STZ-treated hearts (B). Oxidative stress levels were determined using 
DCF-DA in db+/- and db/db hearts (C) or sham and STZ-treated hearts (D). Protein 
carbonyl content was measured in db+/- and db/db hearts (E) or sham and STZ-treated 
hearts (F). Data are mean ± SD; n = 6-8. *P < 0.05 versus vehicle in db+/- or sham and 
†P < 0.05 versus vehicle in db/db or STZ. 
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Figure 4-3. Effect of mito-TEMPO on total antioxidant capacity in db/db mice and 
STZ-injected mice  
The total antioxidant capacity was increased in db/db (A) and STZ-treated mouse hearts 
(B), but was reduced by mito-TEMPO (M-TEMPO). Data are means ± SD; n = 6-8. *P < 
0.05 versus vehicle in db+/- or sham and †P < 0.05 versus vehicle in db/db or STZ. 
188 
Since NADPH oxidase is another important source of ROS in the heart, we measured 
NADPH oxidase expression. Real-time PCR revealed that the mRNA levels of gp91phox 
and p47phox were significantly increased in STZ-induced type-1 diabetic hearts but not in 
db/db mouse hearts. Administration of mito-TEMPO decreased the mRNA levels of 
gp91phox and p47phox in STZ-induced mouse hearts whereas it did not have significant 
impact on their expression in db/db mouse hearts (Figure 4-A-D). 
To examine whether mitochondrial superoxide interacts with gp91phox-containing 
NADHP oxidase (Nox2) activation, we used gp91ds-tat peptide to inhibit Nox2 
activation in cardiomyocytes [32]. Cardiomyocytes were incubated with normal or high 
glucose in the presence of gp91ds-tat (10 µmol/l, AnaSpec, Inc., Fremont, CA, USA), 
mito-TEMPO (25 nmol/l) and vehicle, either alone or in combination for 24 hours. 
Gp91ds-tat and mito-TEMPO alone or in combination prevented mitochondrial 
superoxide production and oxidant levels induced by high glucose as determined by the 
MitoSOX Red and DHE staining, respectively (Figure 4-E and F). Similarly, high 
glucose-induced cell death was inhibited by gp91ds-tat or mito-TEMPO; however, a 
combination of gp91ds-tat and mito-TEMPO did not provide further protection in 
cardiomyocytes (Figure 4-5), suggesting a potential interaction between mitochondrial 
superoxide and Nox2 activation. 
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Figure 4-4. (A-D) Effects of mito-TEMPO (M-TEMPO) on NADPH oxidase 
expression in diabetic mice 
The mRNA levels of gp91phox and p47phox mRNA in db+/- and db/db mouse hearts (A and 
B) or sham and STZ-treated mouse hearts (C and D) were determined by real-time 
RT-PCR. Data are mean ± SD; n = 6-8. *P < 0.05 versus sham and †P < 0.05 versus 
vehicle + STZ. 
(E and F) Effects of gp91ds-tat and mito-TEMPO (M-TEMPO) on mitochondrial 
superoxide production in cardiomyocytes 
Cultured cardiomyocytes isolated from Tg-mtcpYFP mice were incubated with normal 
(NG) or high glucose (HG) in the presence of gp91ds-tat, M-TEMPO or vehicle, either 
alone or in combination for 24 hours. Mitochondrial superoxide production was then 
determined. (E) Representative microphotographs for the MitoSOX staining, cpYFP 
signals and nuclei (Hoechst staining) show overlap of MitoSOX staining and cpYFP 
signals in cardiomyocytes. (F) Representative microphotographs for the DHE staining, 
cpYFP signals and nuclei (Hoechst staining) show overlap of DHE staining and cpYFP 
signals in cardiomyocytes. Data are from 5 different cultures. 
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Figure 4-5. Effects of gp91ds-tat and mito-TEMPO (M-TEMPO) on cell death 
Cultured cardiomyocytes isolated from Tg-mtcpYFP mice were incubated with normal 
(NG) or high glucose (HG) in the presence of gp91ds-tat, M-TEMPO or vehicle, either 
alone or in combination for 24 hours. Cell death was determined by annexin V staining. 
(A) Representative staining for annexin V (green color) and nuclei (blue color). (B) 
Quantification of death cells (%). Data are mean ± SD from 5 different cultures. *P < 
0.05 versus vehicle+control+NG and †P < 0.05 versus vehicle+control+HG. 
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4.3.3 Mito-TEMPO reduced cardiomyopathic changes in type-2 
diabetic db/db mice 
Histological analysis of cardiomyocyte cross-sectional areas showed an increase in 
cardiomyocyte size from db/db mouse hearts. However, administration of mito-TEMPO 
did not affect cardiomyocyte size in sham animals but reduced cardiomyocyte size in 
db/db mice hearts (Figure 4-6A). Similarly, the mRNA levels of ANP and β-MHC were 
elevated in diabetic db/db mouse hearts and significantly reduced in db/db mice receiving 
mito-TEMPO (Figure 4-6B and C). These results demonstrate that mito-TEMPO prevents 
myocardial hypertrophy in type-2 diabetic db/db mice. 
Apoptosis plays an important role in development of diabetic cardiomyopathy. We 
examined the effects of mito-TEMPO on apoptosis in db/db mouse hearts. Diabetes 
increased caspase-3 activity, an indicator of apoptosis, and decreased the protein levels of 
BCL-2, an important anti-apoptotic factor in db/db mouse hearts. Administration of 
mito-TEMPO prevented caspase-3 activity and increased BCL-2 protein expression in 
db/db mouse hearts (Figure 4-6D and E). These results suggest that inhibition of 
mitochondrial ROS protects the heart against apoptosis in diabetic mice. 
Echocardiographic analysis revealed a decline of E/A ratio in db/db mice (Figure 4-6F), 
indicating myocardial diastolic dysfunction, while myocardial systolic function was 
preserved in db/db mice as determined by FS% and EF% (Figure 4-6G and H, and Table 
4-4). Injection of mito-TEMPO significantly increased the E/A ratio in db/db mice 
(Figure 4-6F). Taken together, administration of mito-TEMPO reduces cardiomyopathy 
in type-2 diabetic db/db mice. 
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Figure 4-6. Effects of mito-TEMPO (M-TEMPO) on cardiomyopathic changes in 
db/db mice 
(A) Cardiomyocyte cross-sectional areas. (B and C) the mRNA levels of ANP and 
β-MHC in db/db mouse hearts. (D) Caspase-3 activity in db/db hearts. (E) The upper 
panel is a representative western blot for BCL-2 in myocardial tissues, and the lower 
panel is the quantitative data from western blot analysis for BCL-2/GAPDH. (F) 
Myocardial diastolic function (E/A). (G) Myocardial systolic function (FS%). (H) Left 
ventricular ejection fraction (EF%). Data are mean ± SD; n = 6-8. *P < 0.05 versus 
vehicle in db+/- and †P < 0.05 versus vehicle in db/db.  
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Table 4-4. Parameters of echocardiographic analysis in db/db and db+/- mice 
receiving mito-TEMPO 
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4.3.4 Mito-TEMPO mitigated diabetic cardiomyopathy in 
STZ-induced mice 
We also examined the effects of mito-TEMPO on diabetic cardiomyopathy in 
STZ-induced mice. Consistently, cardiomyocyte cross-sectional areas and gene 
expression of ANP and β-MHC were significantly increased in STZ-induced type-1 
diabetic hearts (Figure 4-7A-C). These hypertrophic changes were attenuated by 
mito-TEMPO (Figure 4-7A-C). Injection of STZ increased caspase-3 activity (Figure 
4-7D) and reduced anti-apoptotic protein BCL-2 in the heart (Figure 4-7E), which were 
prevented by mito-TEMPO (Figure 4-7D and E). Finally, myocardial diastolic and 
systolic functions were decreased in STZ-induced mice as determined by the E/A ratio 
(Figure 4-7F), FS% and EF% (Figure 4-7G and H, and Table 4-5), respectively. However, 
administration of mito-TEMPO restored both myocardial diastolic and systolic functions 
in STZ-induced type-1 diabetic mice (Figure 4-7F-H and Table 4-4). 
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Figure 4-7. Effects of mito-TEMPO (M-TEMPO) on cardiomyopathic changes in 
STZ-injected mice 
(A-D) Cardiomyocyte cross-sectional areas (A), the mRNA levels of ANP (B) and 
β-MHC (C) and caspase-3 activity (D) were determined in STZ-treated hearts. (E) The 
upper panel is a representative western blot for BCL-2, and the lower panel is the 
quantification of BCL-2 protein levels relative to GAPDH. (F) Echocardiographic 
analysis (E/A). (G) Myocardial systolic function (FS%). (H) Left ventricular ejection 
fraction (EF%). Data are mean ± SD; n = 6-8. *P < 0.05 versus sham and †P < 0.05 
versus vehicle + STZ. 
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Table 4-5. Parameters of echocardiographic analysis in STZ-injected mice receiving 
mito-TEMPO 
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4.3.5 Mito-TEMPO attenuated ERK1/2 activation in diabetic mouse 
hearts and high glucose-stimulated cardiomyocytes 
Since activation of mitogen-activated protein kinase has been implicated in diabetic 
cardiomyopathy and they are sensitive to oxidative stress, we therefore examined the 
phosphorylation of its three family members: ERK1/2, JNK1/2 and p38. Western blot 
analysis showed that phosphorylated ERK1/2 was increased in both diabetic mouse 
hearts (Figure 4-8A and B) while no change in phosphorylated JNK1/2 and p38 was 
observed (data not shown). Mito-TEMPO significantly reduced ERK1/2 phosphorylation 
in db/db and STZ-induced mouse hearts (Figure 4-8A and B). 
To further address the involvement of ERK1/2, we incubated adult cardiomyocytes with 
normal (5 mmol/l) or high glucose (30 mmol/l) in the presence of mito-TEMPO (25 
nmol/l) or vehicle for 24 hours. High glucose increased phosphorylated ERK1/2, which 
was abolished by mito-TEMPO (Figure 4-8C). In addition, co-incubation with ERK1/2 
inhibitor PD98059 (10 μmol/l) prevented high glucose-induced cell death (Figure 4-8D). 
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Figure 4-8. Effects of mito-TEMPO(M-TEMPO) on ERK1/2 phosphorylation in 
hearts and cardiomyocytes  
Upper panels are representative western blots for phosphorylated ERK1/2 (p-ERK) and 
total ERK1/2 (T-ERK), and lower panels are quantitative data of p-ERK/T-ERK ratio in 
db+/- and db/db hearts (A), sham and STZ-treated hearts (B) or high glucose-stimulated 
cardiomyocytes (C). (D) Cell death was determined by annexin V staining. Upper panel 
is a representative staining for annexin V (green color) and nuclei (blue color) and lower 
panels are the quantification of death cells (%). Data are mean ± SD; n = 6-8 or 5 
different cultures. *P < 0.05 versus vehicle in db+/-, sham or normal glucose and †P < 
0.05 versus vehicle in db/db, STZ or high glucose. 
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4.4 Discussion 
The present study provides the first evidence that therapeutic inhibition of mitochondrial 
ROS by mito-TEMPO reduces cardiomyopathic changes and improves myocardial 
function in type-1 and type-2 diabetic mice. Our study also provides direct evidence that 
high glucose induces mitochondrial superoxide generation, which is prevented by 
mito-TEMPO. We further suggest that ROS amplified in mitochondria subsequently 
activates downstream ROS-sensitive signaling pathways (e.g. ERK1/2) implicated in 
pathological cardiac changes in diabetes (Figure 4-9). 
 This study demonstrates that both type-1 and type-2 diabetes promoted 
mitochondrial ROS generation, increased intracellular oxidative stress levels and induced 
oxidative damage in the heart, which are consistent with previous reports [13-17]. The 
total antioxidant capacity was also increased in diabetic hearts as well. Furthermore, our 
in vitro study provides direct evidence that high glucose induced mitochondrial 
superoxide generation in cultured cardiomyocytes. Thus, the elevation of oxidative stress 
levels and oxidative damage may be caused by increased ROS generation rather than 
decreased antioxidant capacity. Whereas we used cpYFP as a probe to measure 
mitochondrial superoxide flashes in cardiomyocytes, we are aware there has been a 
controversy concerning the use of the cpYFP as a superoxide probe [33, 34]. To validate 
mitochondrial superoxide generation in cardiomyocytes, we also assessed mitochondrial 
superoxide production by using the MitoSOXTM Red mitochondrial superoxide indicator. 
In addition, DHE was employed to measure oxidant levels in cardiomyocytes. Both 
MitoSOXTM Red and DHE staining showed an increase in mitochondrial oxidant levels 
during high glucose stimulation, which was inhibited by mitochondrial-targeted 
antioxidant mito-TEMPO, similar to the changes in mitochondrial flashes. 
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Figure 4-9. Diagrammatic illustration of the proposed mechanisms of mito-TEMPO 
protection in type-1 and type-2 diabetic cardiomyopathy 
Diabetes induces mitochondrial ROS generation. ROS-induced oxidative damage and 
ROS-mediated activation of signaling contribute to cardiac apoptosis, hypertrophy and 
dysfunction. 
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It is well known that excessive mitochondrial ROS causes mitochondrial dysfunction in 
cardiomyocytes [35], compromising ATP production and inducing cell death [36], both of 
which directly contribute to myocardial dysfunction [37]. In fact, ATP product is reduced 
and apoptosis is induced in diabetic hearts [38, 39]. Mitochondrial ROS over-production 
also promotes adverse myocardial hypertrophy, an important cellular hallmark of diabetic 
cardiomyopathy [40, 41]. Thus, targeted inhibition of mitochondrial ROS by transgenic 
over-expression of SOD2 and mitochondrial catalase prevents cardiac adverse changes 
and dysfunction in a mouse model of type-1 diabetes and in insulin-resistant and obese 
Ay mice, respectively [18, 19]. The present study extends these previous findings to 
investigate the therapeutic potentials of targeted inhibition of mitochondrial ROS in both 
type-1 and type-2 diabetic mice. We show that incubation with mito-TEMPO efficiently 
inhibited mitochondrial superoxide generation in high glucose-stimulated cardiomyocytes 
and treatment of mito-TEMPO after diabetes onset abolished diabetes-induced 
mitochondrial ROS production and oxidative damage in hearts. Consequently, 
administration of mito-TEMPO prevented hypertrophy and attenuated myocardial 
dysfunction in both type-1 and type-2 diabetic mice. Thus, antioxidant strategies 
specifically targeting mitochondria may have therapeutic benefit in diabetic cardiac 
complications.  
Gp91phox-containing NADPH oxidase is another important source of ROS in 
cardiomyocytes [42]. It consists of cytosolic subunits (p67phox, p47phox, p40phox and Rac1) 
and membrane subunits (gp91phox and p22phox). We have recently demonstrated that 
gp91phox containing NADPH oxidase significantly contributes to diabetic cardiomyopathy 
[11, 31]. The present study shows that gp91phox and p47phox were up-regulated in 
STZ-induced mouse hearts, which is consistent with our recent report [11]. In contrast, 
NADPH oxidase expression was not altered in type-2 diabetic db/db mice, suggesting a 
differential expression of NADPH oxidase in type-1 and type-2 diabetes. Inhibition of 
mitochondrial ROS by mito-TEMPO prevented up-regulation of NADPH oxidase 
expression in type-1 diabetic hearts. This suggests that mitochondrial ROS signaling may 
promote NADPH oxidase expression in type-1 diabetic hearts. In fact, this has been 
recognized that mitochondrial ROS positively regulates NADPH oxidase subunits 
expression and activation under pathological conditions including diabetes [43]. On the 
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other hand, we have recently reported that deletion of Rac1 or pharmacological inhibition 
of NADPH oxidase activation reduces mitochondrial ROS generation in diabetic hearts, 
suggesting that NADPH oxidase promotes mitochondrial ROS generation [31]. Thus, it is 
most likely that cross-talks between mitochondria and NADPH oxidase form a positive 
feedback loop in favor of ROS production and oxidative damage in type-1 diabetic hearts, 
and disruption of this feedback loop by inhibiting either of them provides beneficial 
effects in diabetes. This is indeed supported by our findings that inhibition of either 
mitochondrial superoxide or gp91phox-containing NADPH oxidase prevents mitochondrial 
superoxide production and attenuates apoptosis in high glucose-stimulated 
cardiomyocytes.  
Apoptosis has been implicated in the pathogenesis of diabetic cardiomyopathy [4, 39, 44]. 
Cardiomyocyte apoptosis has been reported to occur in diabetic animal models and 
patients [44]. Apoptotic cell death in the heart causes a loss of contractile tissue which 
initiates cardiac remodeling. The loss of cardiomyocytes and hypertrophy of the 
remaining viable cardiomyocytes characterize the diabetic cardiomyopathy. As such, 
inhibition of cardiomyocyte apoptosis has been shown to prevent the development of 
diabetic heart diseases [45]. In the present study, administration of mito-TEMPO 
prevented caspase-3 activation in type-1 and type-2 diabetic mouse hearts. This effect of 
mito-TEMPO was associated with up-regulation of BCL-2 protein in diabetes. In cultured 
cardiomyocytes, we provide direct evidence in support of our hypothesis that inhibition 
of mitochondrial superoxide generation protects cardiomyocytes under diabetic 
conditions. Thus, inhibition of apoptotic cell death may be one of important mechanisms 
by which mito-TEMPO reduces diabetic cardiomyopathy. 
ROS production and subsequent oxidative damage have been demonstrated to activate a 
variety of signaling pathways, among which ERK1/2, p38 and JNK1/2 have been 
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implicated in apoptosis and hypertrophy in the heart [46, 47]. Studies have shown that 
ERK1/2 is activated in diabetic hearts whereas p38 and JNK1/2 activities are either 
increased or decreased in diabetes [48, 49]. Activation of ERK1/2 and p38 contributes to 
apoptosis and hypertrophy in cardiomyocytes under diabetic conditions [50, 51]. The 
present study shows that the levels of phosphorylated ERK1/2 were increased in type-1 
and type-2 diabetic hearts; however, phosphorylation of p38 and JNK1/2 remained 
unaltered. Importantly, administration of mito-TEMPO prevented ERK1/2 activation in 
diabetic hearts and cardiomyocytes under diabetic conditions, and inhibition of ERK1/2 
prevented cell death in high glucose-stimulated cardiomyocytes. Thus, blocking ERK1/2 
signaling may represent a potential mechanism underlying the cardiac protection of 
mito-TEMPO in diabetes. 
Although mito-TEMPO is a mitochondria-targeted antioxidant with superoxide and alkyl 
radical scavenging properties [20], it is currently unknown whether there are any 
off-target effects of mito-TEMPO when it is accumulated in mitochondria, and it is also 
unclear how much of mito-TEMPO has actually gone to the heart. The present study 
shows that administration of mito-TEMPO did not display any effects on blood glucose, 
body weight, activity and dietary ingestion in both sham and diabetic mice, suggesting no 
significant side-effects of this reagent. In addition, systemic administration of 
mito-TEMPO may provide protective effects on other organs in diabetes, which may 
benefit the heart. 
4.5 Conclusions 
Administration of mitochondria-targeted antioxidants may be an effective therapy for 
diabetic cardiac complications.  
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Chapter 5 
5 General discussion, limitations and future directions 
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5.1 General Discussion 
Calpains have been implicated in a variety of cardiac diseases and may represent an 
important target for therapy [1]. However, the mechanisms by which calpains play a role 
in the pathogenesis of cardiac diseases remain incompletely understood. The major 
findings of this thesis are that calpain-1 is increased in mitochondria of the hearts under 
septic (Chapter 2) and diabetic conditions (Chapter 3), and that increased mitochondrial 
calpain-1 correlates with mitochondrial ROS generation, myocardial pathological 
changes and myocardial dysfunction. Targeted inhibition of mitochondrial ROS prevents 
apoptosis in cardiomyocytes and reduces cardiomyopathic changes in both type-1 and 
type-2 diabetes (Chapter 4). Importantly, we demonstrate for the first time that 
mitochondrial calpain-1 targets and cleaves ATP5A1 subunit, leading to a reduction in 
ATP synthase activity, and that disruption of ATP synthase promotes mitochondrial ROS 
generation in cardiomyocytes and hearts under septic and diabetic conditions. These 
findings reveal a novel role of calpain-1 in septic and diabetic cardiomyopathy, identify 
ATP5A1 as a new target of calpain-1 in mitochondria and provide a new mechanism 
underlying calpain-mediated cardiac diseases, specifically mitochondrial ROS generation. 
Thus, this study significantly increases our understanding of the role of calpain in 
cardiovascular diseases. 
Calpains have been considered as a cytoplasmic enzyme [2, 3]. However, it has been 
shown that calpains are trans-located from the cytosol to sarcolemma following 
myocardial ischemia/reperfusion (I/R) [4]. Translocation of calpain-2 to nuclei of 
cardiomyocytes was also observed in tail-suspended rats [5]. Some isoforms including 
calpain-1, calpain-2 and calpain-10 have been demonstrated to be also present in 
mitochondria [6-15]. An important finding of this thesis is that both septic and diabetic 
conditions significantly increase the protein levels and activities of calpain-1 in 
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mitochondria of mouse hearts, whereas the protein levels of calpain-2 are slightly 
elevated in both conditions. In contrast, the protein levels of calpain-10 are not changed 
in septic and diabetic hearts. Our present data further show that the majority of 
mitochondrial calpain-1 is located in mitochondrial matrix as well as the intermembrane 
space of septic hearts. An early study reported that I/R condition increases calpain-1 in 
mitochondrial intermembrane space in cardiomyocytes [16]. More recent studies from 
two independent laboratories demonstrated that both calpain-1 and calpain-2 are 
increased in mitochondrial matrix from heart tissues following I/R [17, 18]. Thus, 
increased calpains in mitochondria may be a common phenomenon in the heart under 
stress. However, it is currently unknown how calpains are elevated in mitochondria of the 
heart under stress. Our data indicate that increased calpains in mitochondria may be due 
to translocation from the cytosol because (1) the protein levels of total intercellular 
calpains are comparable between normal and diseased hearts (including sepsis and 
diabetes), and (2) inhibition of calpain activity prevents the accumulation of calpain-1 in 
mitochondria of septic hearts. The latter also suggests that calpain activation is necessary 
for its translocation into mitochondria. Further evidence in support of the mitochondrial 
translocation is that the N-terminus of calpain-1 contains a mitochondrial targeting 
sequence [19]. Nevertheless, it is still unclear how calpains relocate to mitochondria after 
activation in diseased hearts. A recent study revealed that Ca2+ overload induced 
translocation of calpain to sarcolemma through reverse mode of Na+/Ca2+ exchanger in 
the heart during ischemia. They showed that inhibition of Na+/Ca2+ exchanger markedly 
attenuated calpain-1 translocation, suggesting that Na+/Ca2+ exchanger may be important 
for calpain translocation [20]. Interestingly, similar Na+/Ca2+ exchanger exists on 
mitochondrial membrane [21]. It is possible that Na+/Ca2+ exchanger may mediate 
relocation of calpains from the cytosol to mitochondria in cardiac disease, which merits 
future investigation. 
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Increased calpains in mitochondria was reported to be associated with cardiac apoptosis. 
Following I/R, mitochondrial calpain-1 increased in the intermembrane space and 
induced cleavage of apoptosis inducible factor (AIF), leading to apoptosis in 
cardiomyocytes [16]. Our data demonstrate for the first time that calpain-1 increases in 
mitochondrial matrix and cleaves ATP5A1, leading to disruption of ATP synthase in both 
septic and diabetic hearts. Disruption of ATP synthase results in a reduction in ATP 
production, which directly contributes to myocardial dysfunction. Furthermore, 
compromised ATP synthase within mitochondrial complex V results in “back-up” of 
electrons and thus promotes electron leak from the individual complexes on the 
respiratory chain, especially complexes I and III, leading to mitochondrial superoxide 
generation. In fact, inhibition of calpain or restoration of ATP synthase by up-regulation 
of ATP5A1 prevents mitochondrial ROS generation in cardiomyocytes and hearts under 
septic and diabetic conditions. Furthermore, selective up-regulation of calpain-1 in 
mitochondria sufficiently induces mitochondrial ROS generation in cardiomyocytes. 
Thus, our data provide a novel mechanism that mitochondrial calpain-1 induces 
mitochondrial superoxide generation by disruption of ATP synthase through proteolysis 
of ATP5A1 in cardiomyocytes under septic and diabetic conditions. Increased calpains in 
mitochondrial matrix were also reported to cleave and compromise complex 1 activity in 
ischemic hearts, leading to defect in ATP production, which directly contributes to 
myocardial dysfunction and may also promote superoxide generation [17]. It is important 
to mention that mitochondrial complex-Ⅰ activity was also compromised in diabetic and 
septic hearts [22, 23]. Thus, it is likely that increased calpains in mitochondrial matrix 
may disrupt the respiratory chain by targeting both ATP synthase and complex-Ⅰ, and 
may represent a new mechanism underlying calpain-mediated mitochondrial ROS 
generation in cardiac diseases. However, it remains to be determined whether calpains 
have any other targets in mitochondrial matrix in diseased hearts. Taken together, 
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calpains in mitochondrial intermembrane space cleaves AIF, leading to apoptosis and 
calpains in mitochondrial matrix disrupts energetic metabolism and promotes 
mitochondrial ROS generation in diseased hearts, which contribute to myocardial 
dysfunction and pathological changes as discussed below. 
It is well-known that excessive mitochondrial ROS have been implicated in cardiac 
pathophysiological processes [24]. First, mitochondrial ROS impairs mitochondria which 
may induce more ROS generation in mitochondria and further mitochondrial dysfunction, 
causing a vicious circle [25]. Second, mitochondrial ROS also promotes cell death in the 
heart [26]. Third, mitochondrial ROS act as a “second messenger” in cellular signaling 
pathways, leading to pro-inflammatory response and hypertrophy in cardiomyocytes [27]. 
Thus, selective inhibition of mitochondrial ROS has been protective in a variety of 
cardiac diseases. For example, pressure-overload induced heart failure was significantly 
ameliorated by treatment of mitochondrial-targeted antioxidant peptide, Szeto-Schiller 
(SS) 31 in a mouse model of transverse aortic constriction [28]. Transgenic 
over-expression of mitochondrial catalase and superoxide dismutase-2 (SOD2) attenuated 
cardiac hypertrophy, protected cardiac structures and improved myocardial function in 
angiotension-II induced hearts and type-1 diabetic mice [26, 29, 30]. In this work, we 
extend these previous findings to investigate the therapeutic effects of 
mitochondria-targeted antioxidant mito-TEMPO on diabetic cardiomyopathy in both 
type-1 and type-2 diabetic mice. We show that injection of mito-TEMPO efficiently 
inhibits mitochondrial superoxide generation, reduces hypertrophy and attenuates cardiac 
dysfunction in type-1 and type-2 diabetic mice. Given the evidence that mitochondrial 
calpain-1 induces mitochondrial ROS generation in diseased hearts, excessive 
mitochondrial ROS production may be an important mechanism by which calpain-1 
mediates cardiac diseases (Figure 5-1). 
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In summary, this thesis study has provided evidence in support that accumulation of 
calpain-1 in mitochondria disrupts ATP synthase through the proteolysis of ATP5A1, 
leading to a reduction in ATP production and promoting mitochondrial ROS generation. 
Mitochondrial ROS not only induces apoptosis, hypertrophy and pro-inflammatory 
response, but also promotes mitochondrial dysfunction, leading to ATP depletion, all of 
which directly contribute to septic cardiomyopathy and diabetic cardiomyopathy. 
Considering that calpains are also increased in ischemic heart diseases, where 
mitochondrial ROS production are increased, it is most likely that increased calpains in 
mitochondria and subsequent mitochondrial ROS generation may be a common 
mechanism contributing to cardiac diseases (Figure 5-1). Thus, targeted inhibition of 
mitochondrial calpains may represent a novel therapeutic approach for cardiac diseases.  
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Figure 5-1. Illustration of the proposed mechanism for increased mitochondrial 
calpain 1-induced ROS generation in cardiac disease 
The proposed mechanism in present study is summarized: increased mitochondrial 
calpain 1 disrupts ATP synthase via cleavage of ATP5A1 leading to excessive 
mitochondrial ROS generation, which contributes to the development of cardiac disease. 
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5.2 Limitations 
This study is mainly focused on the role of mitochondrial calpain-1; however, 
mitochondrial calpain-2 may also play a role in septic and diabetic cardiomyopathy as 
increased calpain-2 in mitochondria was reported to compromise complex-Ⅰ activity in 
ischemic hearts [18]. Although our data indicate that increased mitochondrial calpain-1 is 
closely associated with mitochondrial ROS generation in septic and diabetic hearts, direct 
evidence from in vivo hearts is lacking. It is also unknown whether targeted inhibition of 
mitochondrial calpains provides beneficial effects in diseased hearts. 
As for the substrates of calpains in mitochondrial matrix, other proteins may be also 
targeted by calpain-1 and calpain-2 in diseased hearts. This thesis study did not examine 
the role of increased calpains in mitochondrial intermembrane space whereas they may 
play a role in cardiac diseases. 
So far, all data regarding the role of mitochondrial calpains in cardiac diseases were 
obtained from cultured cardiomyocytes and animal models. Studies are needed to 
determine whether calpains are also increased in mitochondria of human diseased hearts. 
If yes, whether increased calpains in mitochondria are associated with compromised ATP 
synthase and complex-Ⅰ activities, as well as mitochondrial ROS generation in human 
diseased hearts. 
5.3 Future directions 
Future directions should include the following items: 
First, to provide direct in vivo evidence to support the role of increased mitochondrial 
calpains in mitochondrial ROS generation and myocardial injury, we are investigating 
whether forced up-regulation of calpain-1 and calpain-2 restricted to cardiomyocyte 
221 
mitochondria induces mitochondrial ROS generation, ATP synthase activity, complex-Ⅰ 
activity, cardiac structural and morphological changes, and myocardial function by 
generating transgenic mice with cardiac-specific and mitochondrial-targeted 
up-regulation of calpain-1 and calpain-2.  
Second, we will generate transgenic mice with cardiac-specific and 
mitochondrial-targeted over-expression of calpastatin, an endogenous inhibitor of 
calpain-1 and calpain-2, and investigate whether selective inhibition of mitochondrial 
calpain-1 and calpain-2 prevents mitochondrial ROS generation and reduces myocardial 
injury under pathological conditions including ischemia/reperfusion, diabetes and sepsis.  
Third, we will investigate additional targets of calpains in mitochondria. To do this, we 
will use proteomic approaches (including 2D gel and MASS) to identify potential 
substrates of calpains in mitochondria of diseased hearts. 
Finally, it is important to determine whether calpain-1 and calpain-2 in mitochondrial are 
increased in human diseased hearts and whether these changes correlate with cleavages of 
calpain targets in mitochondria. We will plan to compare the protein levels of calpains in 
mitochondria between human diseased hearts (e.g. transplanted diseased hearts) and 
healthy hearts (brain trauma).   
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